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1	Introduction	
	 1	
1	Introduction	
1.1 The	obesity	pandemic		Over	the	last	decades,	obesity	has	become	a	major	public	health	concern	with	1.9	billion	adults	 classified	 as	 overweight	 and	 650	million	 as	 obese	 in	 20161.	 The	World	 Health	Organisation	 (WHO)	 defines	 overweight	 and	 obesity	 as	 abnormal	 or	 excessive	 fat	accumulation	that	may	impair	an	individual´s	health1.		Although	 now	 recommended	 only	 as	 an	 approximate	measure,	 the	 body	mass	index	 (BMI)	 is	 utilised	 to	 classify	 overweight	 and	 obesity.	 BMI	 is	 a	 simple	 index	 of	weight-for-height	defined	as	a	person´s	weight	in	kilograms	divided	by	the	square	of	his	or	 her	 height	 in	 meters	 (kg/m2)1.	 A	 BMI	 greater	 or	 equal	 to	 25	 is	 referred	 to	 as	overweight,	whereas	a	BMI	greater	or	equal	to	30	is	defined	as	obesity.	The	number	of	obesity	incidences	are	steadily	increasing	with	studies	showing	that,	 if	trends	continue	as	expected,	2.16	billion	of	the	world´s	adult	population	will	be	classified	as	overweight	and	1.12	billion	as	obese	by	20302.	This	prognosis	is	supported	by	an	alarming	number	of	children	and	adolescents	that	are	strongly	affected	by	obesity	and	overweight	with	an	estimated	41	million	under	the	age	of	5	years	and	340	million	aged	5-19	years	in	20161.		Obesity	 results	 from	 a	 steady	 and	 complex	 synergism	 between	 predisposing	genes	 and	 environmental	 stimuli3.	 Interestingly,	 the	 predisposition	 to	 obesity	 might	already	 develop	 in	 offspring	 in	 early	 stages	 of	 life	 as	 rodent	 studies	 indicate	 that	offspring	 had	 a	 higher	 risk	 for	 the	 development	 of	 obesity	 and	 impaired	 glucose	homeostasis	when	 the	mother	 consumed	 a	 high-fat	 diet	 (HFD)	 during	 lactation4.	 This	result	 demonstrates	 the	 severe	 impact	 nutrition	 might	 have	 on	 an	 individual´s	physiology	 and	 draws	 attention	 to	 the	 alarming	 reach	 of	 the	 metabolic	 syndrome.	 If	untreated,	 obesity	 can	 result	 in	 severe	 diseases	 such	 as	 type	 2	 diabetes	 mellitus	(T2DM)5,	 artherosclerosis6,	 cardiovascular	 disease5,	 different	 types	 of	 cancer7,	 liver	manifestations	of	metabolic	disease8,	or	even	mortality9.	The	obesity	pandemic	has	reached	such	a	severe	impact	worldwide	that	we	have	transitioned	 to	 a	world	 in	which	 suffering	 due	 to	 over-nutrition	 outpaces	 that	 due	 to	under-nutrition10,11	 leading	 to	 a	massive	 burden	 on	 health	 systems	 around	 the	 globe.	Attempts	to	manage	and	prevent	obesity	have	had	limited	success	so	far.	Thus,	a	better	
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understanding	of	the	adipocyte	itself	and	the	etiology	of	obesity	is	necessary	to	develop	more	successful	and	personalized	prevention	and	treatment	possibilities.		
1.1.1	Obesity,	type	2	diabetes	mellitus,	and	other	obesity-associated	diseases		Diabetes	 mellitus	 (DM)	 is	 characterized	 by	 high	 blood	 sugar	 levels	 over	 a	 prolonged	period	 and,	 therefore,	 is	 classified	 as	 metabolic	 disorder.	 In	 2016,	 DM	 was	 listed	 as	number	7	of	the	top	10	causes	of	deaths	worldwide12.	One	year	later,	the	International	Diabetes	 Federation	 (IDF)	 estimated	 the	 total	 number	 of	 adults	 (20-79	 years	 of	 age)	with	DM	to	be	425	million	worldwide13.	DM	is	classified	into	two	different	forms:	Type	1	diabetes	mellitus	(T1DM)	and	type	2	diabetes	mellitus	(T2DM).			 T1DM	is	defined	as	an	autoimmune	disease	in	which	insulin-producing	b-cells	of	the	 pancreas	 are	 defective,	 resulting	 in	 a	 complete	 loss	 or	 highly	 impaired	 insulin	production14.	 Symptoms	 include	 chronic	 hyperglycemia,	 polyuria,	 polydipsia,	 weight	loss,	constant	hunger,	and	fatigue14.		Patients	 diagnosed	 with	 T2DM	 use	 the	 insulin	 their	 (initially	 functional)	pancreatic	 b-cells	 secrete	 ineffectively.	 The	 disorder	 is	 characterized	 by	 chronic	hyperglycemia	 caused	 by	 the	 development	 of	 insulin	 resistance	 in	 peripheral	 organs,	such	 as	 the	 white	 adipose	 tissue	 (WAT),	 the	 liver	 or	 the	 skeletal	 muscle15.	 Insulin	resistance	develops	due	to	a	progressive	loss	of	the	insulin-induced	inhibitory	effect	on	glycogenolysis	and	gluconeogenesis.	Furthermore,	under	 these	conditions,	 insulin	 fails	to	efficiently	stimulate	glucose	and	triglyceride	uptake	into	fat	and	muscle	as	well	as	to	suppress	hepatic	glucose	production	resulting	in	increased	blood	glucose	levels.		In	a	healthy	state,	 insulin	binds	 to	 the	 insulin	receptor	and	 induces	a	signalling	pathway	 including	 the	phosphatidyl	 inositol	3-kinase	 (PI3K)	pathway16.	 Subsequently,	AKT	is	phosphorylated	and	activated	leading	to	the	expression	of	many	targets	involved	in	metabo-regulatory	pathways16.	In	the	beginning,	the	hyperactivation	of	pancreatic	b-cells	 is	able	 to	compensate	 for	 the	 insulin	resistance.	However,	 chronic	hyperglycemia	eventually	 leads	 to	progressive	deterioration	of	 pancreatic	b-cell	 function	 culminating	first	 in	 exhaustion	 and	 loss	 of	 these	 cells	 ultimately	 resulting	 in	 relative	 insulin	deficiency	in	T2DM	patients17.		The	 symptoms	 of	 T2DM	 are	 similar	 to	 that	 of	 T1DM	 but	 are	 less	 distinct.	Misinterpretation	of	symptoms	can	result	in	a	delayed	diagnosis,	sometimes	even	years	after	 onset,	 a	 situation	 where	 complications	 are	 inevitable.	 Hyperglycemia	 resulting	
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from	uncompensated	T2DM	increases	the	risk	for	microvascular	damage	and	can	result	in	 complications	 like	 retinopathy,	 nephropathy	 and	 neuropathy18.	 As	 such,	 T2DM	 can	have	massive	effects	on	the	function	of	several	organs18.	Moreover,	T2DM	can	result	in	macrovascular	complications	which,	if	left	untreated,	can	result	in	strokes,	heart	attacks,	and	insufficiency	in	blood	flow	to	legs,	potentially	leading	to	amputation18.		Despite	 the	 growing	 knowledge	 about	 molecular	 and	 cellular	 alterations	associated	 with	 the	 disease,	 the	 steadily	 increase	 of	 T2DM	 diagnoses	 strengthen	 the	need	 to	 understand	 the	 underlying	 aspects	 contributing	 to	 the	 development	 and	progression	of	T2DM	and	other	obesity-associated	diseases.			
1.2	 Regulation	 of	 energy	 metabolism	 by	 adipose	 tissue	 thermogenesis	 in	
mice		
	Prior	 research	 has	 thoroughly	 investigated	 how	 the	 central	 nervous	 system	 (CNS),	 in	particular	the	hypothalamic	area	of	the	brain,	regulates	body	weight19.	Different	nuclei	of	the	hypothalamus	have	been	identified	and	characterized	regarding	their	function	in	the	regulation	of	energy	homeostasis19.	Moreover,	previous	studies	have	shown	that	a	fine-tuned	system	involving	hormonal	and	neuronal	mechanisms	is	in	place	to	respond	to	 feeding	 behaviour	 with	 neuropeptides	 produced	 by	 the	 brain20.	 Nevertheless,	 to	ensure	 proper	 energy	 homeostasis	 in	 the	 body	 the	 bidirectional	 communication	between	peripheral	tissues	and	the	brain	is	important20.		One	 peripheral	 organ	 that	 is	 strongly	 involved	 in	 the	 regulation	 of	 energy	 and	glucose	homeostasis	in	the	body	is	the	adipose	tissue	(AT).	Next	to	its	more	mechanistic	function	of	cushioning	and	insulating	the	body,	the	AT	stores	energy	in	the	form	of	lipids	(lipogenesis)	 after	 feeding	 and	 ensures	 lipid	 mobilisation	 and	 distribution	 (lipolysis)	within	the	body	after	fasting.	During	lipogenesis	excess	carbohydrates	are	converted	to	fatty	 acids,	 which	 are	 subsequently	 esterified	 and	 stored	 as	 triglycerides	 (TGs)21.	Lipolysis,	 on	 the	 other	 hand,	 involves	 the	 release	 of	 fatty	 acids	 into	 the	 circulation	 to	provide	fuel	for	b-oxidation.	Moreover,	the	AT	functions	as	a	paracrine	and	an	endocrine	organ.	As	an	endocrine	organ,	it	is	responsible	for	the	release	of	different	hormones,	in	particular	adipokines22	 that	affect	various	conditions	such	as	appetite,	energy	balance,	insulin	 sensitivity,	 lipid	 metabolism	 and	 lipid	 homeostasis	 by	 interacting	 with	 other	tissues,	the	sympathetic	nervous	system	and	the	brain23.	
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In	 mammals,	 three	 different	 classes	 of	 adipocytes	 have	 been	 identified:	 WAT,	mainly	located	in	the	intra-abdominal	and	subcutaneous	regions,	brown	adipose	tissue	(BAT),	primarily	found	in	the	interscapular	region	in	rodents,	and	beige/’brite’	(brown	in	white)	AT,	 an	 adrenergically	 inducible	 form	of	 fat	 that	 is	 dispersed	 throughout	 the	AT24.	 All	 three	 ATs	 stem	 from	 a	 mesodermal	 origin	 and	 pre-adipocytes	 express	 the	
preadipocyte	 factor-1	 (Pref1),	 which	 represses	 the	 differentiation	 of	 adipocytes25.	However,	 as	 soon	as	 cells	undergo	growth	arrest,	Pref1	 expression	 is	down-regulated,	activating	a	signalling	cascade	 that	 results	 in	adipogenic	differentiation.	Factors	which	contribute	to	this	process	are	the	transcription	factors	proliferator-activated	receptor	g	(PPARg)	and	CCAAT/enhancer-binding	proteins	(C/EBP	a,	b	and	g)26.		While	white	adipocytes	are	involved	in	the	storage	and	release	of	energy	in	form	of	 fatty	 acids	 in	 response	 to	 systemic	 demands,	 brown	 and	 beige	 adipocytes	 convert	dietary	and	stored	nutrients	such	as	fatty	acids	and	glucose	directly	for	the	generation	of	heat	 in	 a	 process	 called	 non-shivering	 thermogenesis	 (NST).	 With	 this,	 euthermia	 is	maintained	 by	 uncoupling	 electrochemical	 energy	 stored	 within	 proton	 gradients	 in	mitochondria24.	 These	 processes	 propelled	 brown	 and	 beige	 ATs	 into	 the	 focus	 of	attention	as	a	potential	new	way	to	counteract	obesity	and	obesity-associated	diseases	by	increasing	whole-body	energy	expenditure	(EE)	and,	therefore,	positively	influencing	adiposity.		In	 1983	 it	 was	 calculated	 by	 Rothwell	 and	 Stock	 that	 40-50g	 of	 additional	maximally	 stimulated	 BAT	 would	 be	 sufficient	 to	 combust	 20%	 of	 calories	 more	ingested	per	day	in	humans28.	Critically	to	this	project,	dysfunction	in	the	regulation	and	thermogenic	 activation	 of	AT	 results	 in	 the	 development	 of	 obesity	 and	 its	 associated	disorders	 such	 as	 insulin	 resistance,	 diabetes,	 depression,	 cardiovascular	 disease	 and	cancer29.	Thus,	there	is	an	urgent	need	to	better	understand	the	molecular	mechanisms	in	brown	and	beige	adipocytes	as	the	manipulation	of	adipocyte	biology	represents	an	attractive	therapeutic	strategy	to	combat	metabolic	disease.		
1.2.1	White	adipose	tissue		Adipose	tissue	is	a	 loose	connective	tissue	which	is	composed	of	mature	adipocytes	as	well	 as	 the	 stromal	 vascular	 fraction	 (SVF)	 composed	 of	 a	 heterogeneous	 cellular	ensemble,	 consisting	 of	 preadipocytes,	 fibroblasts,	 vascular	 endothelial	 cells,	 various	inflammatory	 cells	 (macrophages),	 and	 immune	 cells.	 It	 develops	 in	 distinct	 locations	
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throughout	the	body	and	larger	accumulations	are	defined	as	adipose	depots.	WAT	can	be	divided	into	several	depots	of	which	the	most	common	depots	represent	visceral	fat	(located	 around	 internal	 organs)	 and	 subcutaneous	 fat	 (located	 beneath	 the	 skin).	Additionally,	 WAT	 can	 be	 found	 in	 other	 parts	 of	 the	 body	 such	 as	 bone	 marrow,	intermuscular	or	in	breast	tissue.		Visceral	white	adipose	tissue	(vWAT),	also	called	abdominal	 fat,	 is	composed	of	several	adipose	depots,	 including	mesenteric,	epididymal	white	adipose	tissue	(eWAT)	and	 perirenal	 depots.	 It	 is	 mainly	 located	 inside	 the	 abdominal	 cavity	 surrounding	organs	such	as	the	stomach,	liver,	intestines,	or	kidneys	and	drains	directly	through	the	portal	circulation	to	the	 liver23.	Here	vWAT	provides	direct	hepatic	access	to	free	fatty	acids	 (FFAs)	 and	 adipokines	 which	 are	 secreted	 by	 visceral	 adipocytes23.	 vWAT	 is	mostly	 composed	of	 large	 adipocytes	due	 to	 its	 reduced	 capacity	 for	preadipocytes	 to	differentiate23.	 Women	 and	 men	 possess	 different	 amounts	 of	 vWAT.	 Whereas	 in	females	 vWAT	 accounts	 for	 5-8%	 of	 body	mass,	 for	males	 its	 10-20%30.	 However,	 in	both	 genders,	 the	 amount	 of	 visceral	 fat	 increases	with	 age30.	 One	 study	 showed	 that	patients	with	a	higher	amount	of	visceral	abdominal	obesity	had	difficulties	in	disposing	and	 oxidizing	 glucose	 and,	 therefore,	 greater	 lipid	 oxidation	 compared	 to	 people	with	peripheral	obesity23.		In	humans	scWAT	 is	mainly	 located	 in	 the	 femerogluteal	 regions,	 the	back,	and	anterior	abdominal	wall	and	accounts	for	80%	of	all	body	fat30,31.	Normally,	lipid	release	and	uptake	in	white	adipocytes	are	well	balanced.	However,	due	to	the	constant	change	in	 food	availability,	white	 adipocytes	 are	more	dynamic	 and	possess	 the	possibility	 to	change	 in	 size32.	 Typically,	 white	 adipocytes	 contain	 a	 unilocular	 lipid	 droplet	 which	requires	90%	of	the	adipocyte	mass	and	give	the	cells	their	spherical	shape24.	In	case	of	excess	energy	intake	and	limited	EE	cells	either	increase	in	number	(hyperplasia)	or	in	size	 (hypertrophy)	 to	 provide	 a	 storage	 side	 for	 fatty	 acids32.	 The	deposition	 of	 lipids	within	these	adipose	depots	happens	in	a	hierarchical	manner.	First,	fat	accumulation	in	subcutaneous	depots	represents	the	normal	physiological	buffer	as	it	can	store	FFAs	and	glycerol	as	TGs33.	 Second,	as	 soon	as	 lipid	storage	capacity	 is	 saturated,	excess	energy	will	be	stored	in	vWAT32.	When	the	capacity	to	store	excess	TGs	in	WAT	is	exceeded	or	the	possibility	to	generate	new	adipocytes	is	impaired,	due	to	genetic	predisposition	or	stress,	fat	starts	to	accumulate	in	areas	outside	the	adipose	tissues23.	Comparing	 both	 types	 of	 ATs	 with	 each	 other	 in	 terms	 of	 their	 role	 during	adiposity,	 scWAT	 has	 been	 shown	 to	 inversely	 correlate	 with	 disease	 risk	 whereas	
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vWAT	is	often	associated	with	metabolic	disease34.	In	a	study	by	Tran	and	Kahn	(2010),	transplantation	 experiments	 showed	 that	 placing	 vWAT	 into	 a	 subcutaneous	 position	had	 only	 little	 positive	 effect	 whereas	 the	 transplantation	 of	 scWAT	 into	 visceral	compartments	 resulted	 in	 reduced	 adiposity	 and	 improvements	 in	 glucose	homeostasis35.	 One	 contributing	 factor	 to	 the	 beneficial	 effects	 on	 metabolism	 is	 the	property	of	scWAT	cells	to	undergo	browning,	a	process	that	is	activated	in	response	to	different	stimuli	that	lead	to	the	expression	of	the	thermogenic	gene	program,	normally	associated	with	BAT	(see	1.2.2).	As	a	consequence,	the	arising	beige	cells	contribute	to	EE	by	reducing	the	amount	of	lipids	stored	within	the	WAT36.		As	 described	 in	 this	 section,	WAT	 depots	 are	 distinct	 from	 each	 other	 as	 they	possess	 specific	 differences	 that	 comprise	 among	 others	 cellular,	 molecular,	 and	physiological	characteristics23.		
1.2.2	Brown	and	beige	adipose	tissue		
1.2.2.1	Development	of	brown	and	beige	adipocytes		The	first	adipose	depot	that	forms	in	mice	during	embryogenesis	is	BAT37.	BAT	provides	newborns	with	the	crucial	capacity	for	NST,	thereby	enabling	them	to	acclimatize	to	cold	temperatures.	Clusters	of	brown	adipocytes	can	be	located	in	the	interscapular	region	of	developing	mice	 as	 early	 as	 embryonic	 day	14.5	 (E14.5)38.	 By	 executing	 fate-mapping	studies	 in	mice,	 it	 has	 been	 demonstrated	 that	most	 brown	 adipocytes	 in	 dorsal	 BAT	depots	 emanate	 from	 a	 mesodermal	 progenitor	 population	 in	 the	 somites38–40.	 In	humans,	 BAT	 is	 primarily	 localized	 in	 the	 neck,	 the	 supraclavicular,	 and	 mediastinal	regions41.		Brown	 fat	 has	 a	 different	 developmental	 pattern	 and	 transcriptional	 program	compared	 to	 white	 fat.	 Brown	 adipocytes	 are	 marked	 by	myogenic	 factor	 5	 (Myf5)39	which	 encodes	 a	 transcription	 factor	 that	 marks	 myogenic	 precursor	 cells	 and	 is	involved	 in	 important	processes	 in	skeletal	myogenesis.	The	close	relation	of	BAT	and	skeletal	muscle	is	confirmed	by	other	shared	characteristics.	For	example,	as	shown	by	various	 gene	 expression	 studies,	 brown	 adipocyte	 precursor	 cells	 express	 several	skeletal-muscle-specific	 genes42.	 Moreover,	 it	 has	 been	 demonstrated	 that	 the	mitochondrial	proteome	of	brown	adipocytes	is	more	akin	to	that	of	muscle	cells	than	to	white	 adipocytes43.	 A	 cell-fate	 decision	 between	 muscle	 cells	 and	 brown	 fat	 cells	 is	
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regulated	by	factors	such	as	PR	domain	zinc	finger	protein	16	(PRDM16),	euchromatic	histone-lysine	N-methyltransferase	1	(EHMT1),	and	miR-13339,44–46.		As	 soon	 as	 precursor	 cells	 are	 committed	 to	 developing	 into	 BAT	 cells,	adipogenic-specific	 transcription	 factors	 and	 signaling	pathways	 are	necessary	 for	 the	cells´	 development	 into	 mature	 brown	 adipocytes.	 Early	 B-cell	 factor	 2	 (EBF2)	 is	 a	marker	 for	 committed	 brown	 preadipocytes38.	 EBF2	 potentially	 regulates	 the	 lineage	specification	and	is	involved	in	the	development	of	BAT.	A	different	factor	that	assists	in	the	differentiation	of	brown	adipocytes	is	PR	domain	zinc	finger	protein	16	(PRDM16)	which	 interacts	 with	 the	 adipogenic	 transcription	 factors	 CCAAT/enhancer-binding	protein-b	 (C/EBPb),	 peroxisome	 proliferator	 activated	 receptor-g	 (PPARg),	 zinc	 finger	protein	 516	 (ZFP516),	 and	 euchromatic	 histone-lysine	 N-methyltransferase	 1	(EHMT1)24.		The	recently	identified	beige	fat47,48	is	defined	as	clusters	of	uncoupling	protein	1	(Ucp1)-expressing	 adipocytes	 that	 are	 located	 outside	 of	 common	 brown	 fat	 depots.	These	 beige	 adipocytes	 have	 an	 abundance	 of	mitochondria	 and	 develop	 in	 depots	 of	WAT	upon	cold	exposure	or	when	exposed	to	other	particular	stimuli.	 Just	 like	brown	adipocytes,	 beige	 adipocytes	 are	 able	 to	 convert	 energy	 into	 heat49.	 The	 embryonic	origin	of	beige	adipocytes	is	less	clear.	It	has	been	demonstrated	that	beige	cells	in	the	subcutaneous	 depot	 do	 not	 stem	 from	 Myf5	 positive	 cells39,50.	 Therefore,	 it	 can	 be	concluded	 that	 beige	 and	 brown	 adipocytes	 stem	 from	 different	 cell	 lineages.	 The	question	 emerged	whether	 beige	 adipocytes	 originate	 from	white	 adipocytes	 through	trans-differentiation	 or	 through	de	 novo	 differentiation	 and	maturation	 of	 precursors.	Some	publications	 report	 indications	 that	 large	unilocular	white	 adipocytes	 transform	into	beige	adipocytes	upon	stimulation51.	Conversely,	a	study	by	Wang	et	al.	(2013),	 in	which	authors	pulse	labeled	mature	adipocytes	in	WAT	using	LacZ,	showed	convincingly	that	most	 beige	 adipocytes	 derive	 from	 a	 precursor	 population	 rather	 than	 from	pre-existing	adipocytes52.	
1.2.2.2	Characteristics	of	brown	and	beige	adipocytes		In	terms	of	morphological	and	biochemical	characteristics,	brown	and	beige	adipocytes	show	 compelling	 similarities53.	 As	 both	 contain	 many	 small	 lipid	 droplets,	 they	 are	termed	 multilocular	 in	 contrast	 to	 unilocular	 white	 adipocytes.	 Moreover,	 both	adipocytes	 are	 densely	 packed	 with	 mitochondria	 and	 express	 marker	 thermogenic	
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genes	 such	 as	 Ucp1,	 cell	 death-inducing	 DFFA-like	 effector	 A	 (Cidea),	 peroxisome	
proliferator-activated	 receptor	 gamma	 coactivator	 1a	 (Pgc1a),	 and	 peroxisome	
proliferator-activated	 receptor	a	 (Ppara).	 Furthermore,	 in	 response	 to	 specific	 stimuli,	both	adipocytes	display	thermogenesis49.		Despite	 these	 striking	 similarities,	 brown	 and	 beige	 adipocytes	 also	 exhibit	unique	 phenotypic	 and	 functional	 features:	 Whereas	 brown	 adipocytes	 contain	 an	abundance	 of	 mitochondria	 and	 express	 high	 levels	 of	 Ucp1	 and	 other	 thermogenic	components	 under	 basal	 conditions,	 beige	 adipocytes	 express	 those	 only	 upon	 b-adrenergic	 stimulation48.	 This	 difference	 between	 brown	 and	 beige	 fat	 cells	 can	 be	observed	 in	vivo	and	ex	vivo48,54.	More	specifically,	 the	stable	 thermogenic	character	of	brown	fat	cells	is	at	least	partly	cell	autonomous	as	adipogenic	precursors,	isolated	from	BAT,	induce	the	expression	of	Ucp1	during	the	process	of	differentiation	in	cell	culture54.	In	 contrast,	 specific	 beige	 precursors	 or	 adipogenic	 precursors	 from	 WAT	 lack	 the	capacity	to	activate	the	thermogenic	program	in	culture	unless	they	are	stimulated	with	inducers	 like	 thiazolidinediones47,55	 or	 b-adrenergic	 agonists48.	 Beige	 adipocytes	 are,	therefore,	 more	 flexible	 and	 can	 both	 function	 as	 either	 energy	 storing	 or	 energy	dissipating	cell	types	depending	on	environmental	or	physiological	circumstances.		Moreover,	mouse	and	human	beige	adipocytes	have	the	capacity	to	activate	the	thermogenic	 mechanism	 which,	 consequently,	 affects	 systemic	 energy	 homeostasis	independently	of	UCP1	function,	by	running	a	futile	creatine	cycle	that	produces	heat	as	a	 reaction	 to	 stimuli	 such	 as	 cold	 or	b-adrenergic	 activation.	 By	 blocking	 this	 cycle,	 a	reduction	of	the	thermogenic	capacity	of	inguinal	WAT	(and	other	WAT	depots)	can	be	observed	 which	 leads	 to	 a	 decline	 in	 the	 animal´s	 oxygen	 consumption56.	 The	phenomenon	of	this	UCP1-independent	pathway	for	thermogenesis	in	beige	adipocytes	may	 be	 utilized	 to	 explain,	 at	 least	 partially,	 why	 UCP1-deficient	 animals	 are	 able	 to	survive	in	the	cold	through	gradual	acclimatization24.			
1.2.2.3	Induction	of	thermogenesis	in	brown	and	beige	fat			Upon	 cold	 exposure,	 NST	 in	mammal	 BAT	 is	 activated	 aimed	 at	maintaining	 constant	body	 temperatures	 through	 the	production	of	heat	 independently	 from	shivering57.	 In	order	 to	 fuel	 NST	 heat	 production,	 BAT	 combusts	 nutrients	 and	 oxygen	 delivered	through	blood	circulation.	UCP1,	and	its	activity	in	the	mitochondrial	membrane	of	BAT	cells,	 plays	 and	 important	 role	 in	 this	 process.	 As	 an	 electron	 transporter,	 UCP1	
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uncouples	the	electron	transport	from	ATP	synthesis	thereby	inducing	heat	production	and	subsequently	EE22.		Cold,	as	an	important	regulator	of	different	aspects	of	BAT,	is	sensed	by	diverse	mechanisms	 such	 as	 thermoreceptors	 in	 the	 skin.	 These	 thermoreceptors	 elicit	sympathetic	outflow	 to	BAT	 through	a	 complex	neural	 circuitry	 (Figure	1)49.	 In	detail,	the	 cascade	 is	 activated	 by	 sympathetic	 neurons	 releasing	 catecholamines	 such	 as	norepinephrine	(NE)	that	bind	to	b-adrenoreceptors	which	are	located	on	the	surface	of	brown	adipocytes	 and	 activating	 adenylyl	 cyclase	 (AC),	 consequently	 increasing	 cyclic	AMP	 (cAMP;	 light	 green	 circles)	 concentrations	 and	 PKA	 activity.	 Among	 different	 b-adrenoreceptors,	the	b3-adrenoreceptors	can	be	identified	as	the	most	efficient	subtype	of	 BAT	 thermogenesis22.	 Next	 to	 catecholamines,	 natriuretic	 peptides	 (NPs)	 bind	 to	natriuretic	peptide	receptor	A	(Npra)	and	activate	guanylyl	cyclase	(GC)	to	increase	the	concentrations	of	cyclic	GMP	(cGMP)	and	activate	PKG.	Upon	activation	of	PKA	and	PKG,	similar	mechanisms	lead	to	transcriptional	responses	in	brown	adipocytes	through	the	activity	 of	 phosphorylated	 cAMP	 response	 element-binding	 protein	 (Creb)	 and	 p38	mitogen-activated	 protein	 kinases	 (Mapk).	 The	 transcription	 of	 downstream	thermogenic	 genes	 such	 as	 Ucp1	 results	 from	 phosphorylated	 Mapk	 causing	 the	phosphorylation	and	activation	of	activating	transcription	factor	2	(ATF2)	and	PGC1a.	As	 a	 transcriptional	 cofactor,	 PGC1a	 regulates	 specialized	 functions	 of	 brown	adipocytes	 and	 is	 considered	 as	 a	 dominant	 regulator	 of	 mitochondrial	 biogenesis,	oxidative	metabolism,	 and	 thermogenesis	 in	brown	 fat58.	 It	 also	 interacts	with	PPARg,	PPARa,	retinoid	X	receptors	(RXRs),	and	thyroid	receptors	(TRx)	and	has	been	shown	to	be	crucial	for	thermogenesis	rather	than	adipogenesis59.	It	has	as	well	been	shown	that	catecholamines	 lead	 to	 an	 increase	 of	 miR-196a	 causing	 an	 increase	 in	 C/ebpb	expression49.	This	process	supports	the	drive	of	the	thermogenic	gene	program.		The	activation	of	PKA	and	PKG	not	only	triggers	the	thermogenic	gene	program,	it	induces	lipolysis	as	well.	Upon	lipolysis	induction,	lipid	droplets	release	FFAs	that	are	subsequently	 oxidized	 for	 heat	 production	 by	 the	 mitochondria.	 The	 release	 of	 long-chain	fatty	acids	from	the	mitochondrial	membrane	by	phospholipase	A2	(PLA2)	results	in	the	proton	leak	through	UCP1.	Other	stimuli	that	are	able	to	induce	thermogenesis	in	BAT	comprise	b-adrenergic	pharmaceuticals	such	as	isoproterenol,	hormones,	as	well	as	calorie	consumption60.		
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Figure	1:	Activation	of	the	adipocyte	thermogenic	program	by	the	b-adrenergic	receptor	and	
natriuretic	signalling	pathway			Upon	cold	exposure,	sensory	nerves	of	peripheral	tissues	signal	to	the	hypothalamus,	which	is	responsible	for	the	control	of	the	sympathetic	nervous	system	(SNS).	This	signalling	process	triggers	the	release	of	the	catecholamine	norepinephrine	(NE)	from	nerve	terminals	in	the	adipose	tissue	that	binds	to	b-adrenergic	receptors	 (ARs).	 Natriuretic	 peptides	 (NPs)	 are	 produced	 in	 the	 heart	 and	 increase	 with	 cardiac	 wall	stress,	cold	exposure,	and	exercise61.	The	binding	of	NE	to	ARs	and	NPs	to	the	natriuretic	peptide	receptor	A	(Npra),	both	located	on	adipocytes,	leads	to	the	activation	of	signalling	transduction	cascades	that	result	in	 the	 expression	 of	 thermogenic	 genes	 such	 as	uncoupling	 protein	 1	 (Ucp1).	 AC,	 adenyl	 cyclase;	 cAMP,	cyclic	 adenosine	 monophosphate;	 cGMP,	 cyclic	 guanosine	 monophosphate;	 FFA,	 free	 fatty	 acids;	 GC,	guanylyl	 cyclase;	 Gs,	 a	 G	 protein	 subunit;	 LCFA,	 long-chain	 fatty	 acids;	 P,	 phosphate;	 Gs,	 a	 G	 protein	subunit;	PKA,	protein	kinase	A;	PKG,	protein	kinase	G.	From	Harms	et	al.	(2013)49.	Artwork	by	D.	Maizels.			As	 the	 cell´s	 need	 for	 energy	 supply	 increases,	 the	 respiratory	 activity,	 often	accompanied	by	an	increase	in	mitochondrial	mass,	is	enhanced	to	meet	this	demand62.	During	 the	 process	 of	 adaptive	 thermogenesis,	 mitochondrial	 respiration	 increases,	among	 other	 things,	 due	 to	 a	 partial	 uncoupling	 of	 the	 electron	 transport	 from	 ATP	synthesis.	 In	this	way,	energy	is	dissipated	in	the	form	of	heat,	consequently	making	it	possible	 for	 the	 animal	 to	 adapt	 to	 the	 cold.	 In	 addition,	 this	 process	 can	 counteract	obesity	by	decreasing	the	possibility	of	fat	storage.			 An	 increase	 in	 mitochondrial	 proliferation	 presents	 a	 challenge	 to	 the	 cells	 as	mitochondrial	 biogenesis	 depends	 on	 the	 generation	 of	 products	 that	 are	 encoded	 by	both	 the	nuclear	 and	mitochondrial	 genome62.	 These	products	 are	 assembled	 into	 the	complexes	 of	 the	 electron	 transport	 chain,	 the	 ATP	 synthase	 machine,	 and	 the	
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mitochondrial	 protein	 synthesis	 apparatus62.	 The	 coordinated	 expression	 of	 a	 diverse	set	 of	 genes	 controls	 the	 challenge	 of	 orderly	 assembly	 of	 these	 mitochondrial	complexes	and	the	maintenance	of	mitochondrial	DNA	copy	number62.	An	 important	 factor	 in	 the	 assembly	 process	 is	 PGC1a.	 PGC1a	 leads	 to	 the	expression	 of	molecules	 responsible	 for	 the	 synthesis	 of	 components	 of	 the	 oxidative	phosphorylation	 apparatus	 such	 as	 mtTFA	 —	 a	 mitochondrial	 transcription	 factor	controlling	the	replication	and	transcription	of	the	mitochondrial	genome63	—	as	well	as	UCP1-UCP3.	 UCP1-UCP3	 regulate	 the	 uncoupling	 from	 the	 mitochondrial	 electron	transport	 from	 ATP	 synthesis64.	 Moreover,	 PGC1a	 also	 activates	 the	 expression	 of	nuclear	respiratory	factors,	NRF-1	and	NRF-2.	Various	genes	are	targeted	by	these	two	transcription	 factors	many	 of	which	 encode	 subunits	 of	 cytochrome	 oxidase,	 the	 ATP	synthase	complex,	and	enzymes	of	heme	biosynthesis65.	
1.2.2.4	Brown	adipose	tissue	as	therapeutic	target	for	human	obesity		In	 adult	 mice,	 major	 BAT	 depots	 can	 be	 identified	 in	 the	 dorsal	 anterior	 region	comprising	 the	 interscapular,	 cervical,	 and	 axillary	 BAT66.	 Interscapular	 BAT	 depots,	with	 a	molecular	 profile	 comparable	 to	 that	 of	 classical	 rodent	 BAT,	 can	 be	 found	 in	infant	humans	as	well67.	For	a	 long	time,	 it	was	assumed	that	BAT	would	only	exist	 in	meaningful	 amounts	 in	 infants	 and	 regress	 and	 become	 metabolically	 negligible	 in	adults.	However,	lately,	positron-emission	tomography	(PET)	imaging	studies	of	glucose	uptake	have	shown	that	substantial	deposits	of	thermogenic	fat	reside	in	adult	humans	(in	addition	to	interscapular	BAT,	also	perirenal	BAT	and	an	adipose	depot	in	the	deep	neck	region	can	be	detected)41,68–71.	Therefore,	estimations	have	been	made	that	50%	of	the	 population	 possibly	 possesses	 BAT	 in	 a	 thermogenically	 active	 form	 although	 it	declines	both	with	age	and	obesity27,72.		Just	 like	WAT,	BAT	as	an	endocrine	organ	produces	different	hormones	such	as	batokines	and	lipokines.	These	hormones	are	involved	in	the	regulation	of	the	cross-talk	existing	 between	 the	 brain	 and	 peripheral	 organs73.	 The	 analysis	 of	 marker	 gene	expression	in	thermogenic	tissues	confirmed	the	expression	of	UCP1.	However,	several	studies	 have	 suggested	 that	 some	 human	 depots	 have	 a	 molecular	 profile	 which	 is	comparable	to	rodent	BAT	whereas	other	depots	display	a	profile	of	adipocytes	which	are	 more	 similar	 to	 beige	 fat41,48,74.	 Enerback	 et	 al.	 (1997)	 demonstrated	 that	 the	condition	of	certain	strains	of	mice	lacking	UCP1	deteriorate	under	cold	conditions75.	In	
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contrast,	 another	 study	 has	 demonstrated	 that	 long-term	 adaptation	 to	 cold	 does	 not	require	UCP176.		Another	 trigger	 for	BAT	 thermogenesis	 is	high-calorie	or	high-fat	diets77	which	depends	 on	 UCP1	 function	 and	 can	 obstruct	 obesity78.	 Mice	 without	 BAT	 are	 highly	susceptible	 to	 the	 development	 of	 obesity79	 while	 those	 with	 elevated	 brown	 and/or	beige	fat	function	are	protected	against	several	damaging	metabolic	effects	of	a	high-fat	diet,	such	as	obesity	and	insulin	resistance80,81.	This	beneficial	effect	was	also	observed	in	humans,	 in	which	 increased	 levels	of	brown	and	beige	 fat	activity	correlated	with	a	lean	 body	 type.	 These	 observations	 suggest	 that	 brown	 and	 beige	 fat	 could	 have	 an	important	 protective	 role	 in	 the	 metabolism	 of	 humans68–70,82.	 Another	 factor	 that	correlated	with	an	improved	metabolism	in	lean83	and	diabetic84	subjects	was	reduction	in	 ambient	 temperature.	Moreover,	 treatment	with	b3-adrenergic	 agonists	 resulted	 in	enhanced	 human	 BAT	 and	 beige	 fat	 activity	 and	 EE83,85.	 These	 studies	 have	 spurred	enthusiasm	for	understanding	how	the	catabolic	properties	of	BAT	can	be	harnessed	for	therapeutic	purposes.			
1.3	The	non-coding	genome		The	 term	noncoding	RNA	 (ncRNA)	 refers	 to	RNA	 that	 does	 not	 code	 for	 protein.	 This	does	 not	 mean,	 however,	 that	 these	 ncRNAs	 do	 not	 contain	 information	 or	 have	 a	specific	 function.	 For	 a	 long	 time,	 it	 was	 assumed	 that	 the	 part	 of	 the	 genome,	 not	translated	 in	 protein,	 was	 ‘junk’.	 Only	 recently,	 with	 the	 help	 of	 transcriptome	sequencing,	 it	 was	 discovered	 that	 only	 1-2%	 of	 the	 mammalian	 genome	 codes	 for	protein.	 More	 than	 80%	 of	 the	 genome	 is	 transcribed	 into	 RNA,	 which	 results	 in	 the	production	 of	 many	 ncRNAs86,87.	 These	 ncRNAs	 include	 microRNAs	 (miRNAs;	 small	ncRNA	molecules	that	are	involved	in	silencing	and	post-transcriptional	gene	regulation	processes88),	piwi-interacting	RNAs	(piRNAs;	small	ncRNAs	which	are	part	of	silencing	processes	 in	 the	 germline	 or	 of	 the	 RNA-induced	 silencing	 complex	 (RISC)89),	 small	nucleolar	 RNAs	 (snoRNAs;	 small	 RNA	 molecules	 that	 are	 known	 to	 regulate	 the	modification	and	processing	of	other	RNAs90)		and	other	classes	of	yet-to-be	discovered	small	 regulatory	RNAs	as	well	 as	 longer	 transcripts.	Although	 the	 function	of	many	of	those	ncRNAs	is	not	yet	discovered,	they	seem	to	act	as	a	 layer	of	 internal	signals	that	regulate	different	levels	of	gene	expression	in	physiology	and	during	development91.		
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1.3.1	Long	noncoding	RNAs	and	genomic	localization			Long	 noncoding	 RNAs	 (lncRNAs)	 are	 categorized	 as	 RNA	 transcripts	 that	 lack	 open	reading	 frames	 and	 protein-coding	 potential92,93.	 In	 former	 days,	 lncRNAs	 were	arbitrarily	defined	as	transcripts	longer	than	200	nucleotides	compared	to	other	ncRNA	species	 such	 as	 miRNA,	 piRNA,	 and	 small	 interfering	 RNA	 (siRNA).	 Similar	 to	 mRNA	transcripts,	most	 lncRNAs	 are	 transcribed	by	RNA	polymerase	 II	 and	undergo	 further	steps	of	processing	 like	 splicing	and	polyadenylation.	 Initially,	 large-scale	discovery	of	lncRNAs	 was	 performed	 with	 tiling	 microarray94,95	 and	 full-length	 RNA-sequencing96.	Nowadays,	 epigenome	 analysis97	 and	 techniques	 like	 whole	 transcriptome	 RNA-sequencing	 (RNA-Seq)	 have	 led	 to	 the	 identification	 of	 even	 greater	 numbers	 of	lncRNAs98,99.	 Although	 lncRNA	 numbers	 remain	 debated,	 RNA-Seq	 meta-analyses	 in	human	 tissues	 identified	>60,000	 lncRNAs	which	 surpassed	 the	approximately	22,000	coding	genes	found	in	the	same	study100.		Despite	 this	 progress,	 challenges	 still	 remain	 to	 accurately	 annotate	 and	characterize	lncRNA	transcripts.	In	a	recent	study	it	has	been	shown,	for	example,	that	a	transcript	originally	defined	as	a	muscle	 lncRNA	encodes	a	small	protein	 in	 the	cell101.	With	bioinformatics	tools	such	as	PhyloCSF,	the	coding	potential	of	RNA	transcripts	can	be	 predicted,	 which	 uses	 comparative	 genomic	 analysis	 of	 the	 coding	 probability	 of	nucleotides	 across	multiple	 species102.	 Next	 to	 PhyloCSF,	 other	 tools	 to	 assess	 coding	potential	can	be	applied	such	as	Coding	Potential	Calculator	(CPC)103,	PORTRAIT104	and	Coding	Potential	Assessment	Tool	(CPAT)	which	is	advertised	as	being	faster	and	more	accurate	than	the	aforementioned	techniques105.		In	 the	 genome	 lncRNAs	 can	 be	 categorized	 into	 sense,	 antisense,	 intronic,	divergent,	 and	 intergenic	 groups	 based	 on	 their	 location	 relative	 to	 nearby	 protein-coding	genes.	The	expression	of	lncRNAs	is	tissue-specific	and	strongly	regulated	during	tissue	development	and	in	response	to	physiological	signals106–109.		
1.3.2	Multifaceted	control	of	gene	expression	by	lncRNAs		In	recent	years,	gain-and-loss-of	function	research	has	discovered	several	lncRNAs	that	are	involved	in	diverse	biological	processes	in	almost	all	eukaryotes	including	animals,	plants,	and	yeast110–114.	LncRNAs	can	be	localized	in	different	areas	of	the	cells	such	as	the	 nucleus,	 the	 cytosol,	 or	 both86	 depending	 on	 their	 function	 in	 the	 regulation	 of	
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various	biological	processes	such	as	transcription115,116,	cell	differentiation117,118,	tissue	development119,120,	and	tumorigenesis/metastasis106,121,122.		Furthermore,	studies	have	shown	different	mechanisms	through	which	lncRNAs	are	 able	 to	 regulate	 gene	 expression	 (Figure	 2).	 In	 the	 nucleus,	 lncRNAs	 can	 either	function	 as	 transcriptional	 coactivators	 by	 direct	 interaction	 with	 transcription	factors123,124	or	prevent	the	assembly	of	 transcriptional	complexes	and	thereby	 lead	to	the	 inhibition	 of	 gene	 expression125,126.	 Moreover,	 lncRNAs	 can	 exert	 their	posttranscriptional	 effects	 on	 gene	 expression	 by	 assisting	 as	 molecular	 sponges	 for	microRNAs	as	it	has	been	shown	for	the	lncRNAs	H19	as	well	as	lincRNA-RoR127,128.		One	 mechanism	 by	 which	 lncRNAs	 exert	 silencing	 of	 other	 genes	 is	 the	recruitment	 of	 repressive	 chromatin-remodeling	 complexes,	 such	 as	 the	 Polycomb	Repressive	 Complex	 2	 (PRC2)	 and	 the	 SWItch/Sucrose	 Non-Fermentable	 (SWI/SNF)	complexes115,129.	 In	 this	way,	 lncRNAs	 facilitate	 the	 recruitment	of	PRC2	 to	 chromatin,	possibly	by	building	complexes	with	several	components	of	 the	PRC2	complex	such	as	Enhancer	of	 zeste	homolog	2	 (EZH2),	 Jumonji,	AT	 rich	 interactive	domain	2	 (JARID2),	and	 Suppressor	 of	 zeste	 12	 homolog	 (SUZ12)130,131.	 Additionally,	 lncRNAs	 can	 also	regulate	 post-transcriptional	 events	 during	 gene	 expression	 such	 as	 mRNA	translation132,	splicing133,	and	mRNA	degradation134.			
	
	
Figure	2:	Multifaceted	control	of	gene	expression	by	lncRNAs		LncRNAs,	 a	 subclass	of	ncRNAs,	 stand	out	at	being	 tissue-	and	species-specific	and	at	exhibiting	unique	conservation	patterns.	They	have	been	found	to	interact	with	DNA,	other	RNA	molecules,	and	proteins	to	fulfil	 regulatory	 functions.	 These	 interactions	 can	 result	 in	 transcriptional	 regulation	 in	which	 lncRNAs	function	as	decoys	for	transcription	factors	(1)	or	miRNA	sponges	(2)	and	with	that	preventing	them	to	bind	to	 their	mRNA	target	or	by	 lncRNAs	building	ribonucleoprotein	complexes	(3).	Moreover,	 lncRNAs	can	 be	 involved	 in	 chromatin	 remodelling	 by	 recruiting	 chromatin	modifiers	 (4)	 or	 by	 regulating	 post-transcriptional	events	(5),	(6),	and	(7).		From	Hu	et	al.	(2012)135.	
1	Introduction	
	 15	
1.3.3	Metabolic	regulation	by	lncRNAs		The	 regulation	 of	 nutrient	 and	 energy	 metabolism	 in	 mammals	 is	 controlled	 by	reciprocal	signaling	between	different	tissues	that	primarily	serve	regulatory	functions	such	as	 the	CNS,	 the	pancreatic	 islets,	and	metabolic	 tissues	 like	adipose	 tissues,	 liver,	and	skeletal	muscle136.	Currently,	we	are	faced	with	an	 increased	rise	of	obesity	 in	the	world	 which	 is	 accompanied	 by	 a	 rise	 in	 obesity-associated	 diseases	 such	 as	 insulin	resistance	 and	 T2DM5.	 A	 better	 understanding	 of	 the	 master	 regulator	 insulin	 which	controls	peripheral	as	well	as	central-nervous	system-related	aspects	of	metabolism	is	inevitable	to	understand	whole-body	metabolism137.		A	 key	 step	 in	 the	 development	 of	 metabolic	 disease	 is	 resistance	 toward	 the	metabolic	effects	of	insulin.	Interestingly,	it	has	been	shown	that	insulin	and	insulin-like	growth	 factor	 1	 (IGF1)	 signaling	 also	 lead	 to	 changes	 in	 lncRNA	 expression138.	 This	finding	 supports	 the	 hypothesis	 that	 lncRNAs	may	 be	 involved	 in	metabolic	 effects	 of	insulin	 and	 progression	 of	 insulin	 resistance.	 Thus,	 a	 strong	 interest	 lies	 within	 the	identification	and	understanding	of	new	lncRNAs	governing	mechanisms	in	energy	and	glucose	homeostasis	at	cell-intrinsic,	organ,	and	whole-body	levels.		
1.3.4	Regulation	of	brown	and	beige	adipocyte	differentiation	by	lncRNAs			In	the	last	years	studies	have	focused	on	understanding	and	functionally	dissecting	the	transcriptional	 and	epigenetic	 regulation	of	BAT	by	protein-coding	genes139.	However,	sequencing	 initiatives	 like	 ENCODE140	 project	 have	 recently	 demonstrated	 that	 RNA	transcription	is	a	phenomenon	observed	throughout	the	majority	of	genomes	in	higher	organisms	 and	 that	 small	 noncoding	 RNAs	 (sncRNAs)	 such	 as	 microRNAs	 but	 also	lncRNAs	 have	 important	 functions.	 The	 extent	 to	 which	 lncRNAs	 are	 involved	 in	 the	regulation	of	brown/beige	fat	development,	homeostasis	and	function	is,	however,	still	poorly	 understood.	 Yet,	 recent	 work	 on	 lncRNAs	 has	 led	 to	 the	 discovery	 of	 several	candidates	that	may	be	involved	in	adipocyte	biology.		Using	 whole	 transcriptome	 RNA-Seq,	 Sun	 et	 al.	 (2013)	 discovered	 a	 cluster	 of	lncRNAs	 that	 exhibited	 differential	 expression	 during	 adipogenesis.	 This	 cluster	contained	several	lncRNAs	that	appeared	to	be	required	for	adipocyte	differentiation108.	One	 candidate,	 linc-RAP-1	 (Firre),	 has	 been	 shown	 to	 interact	 with	 heterogeneous	nuclear	ribonucleoprotein	(hnRNP)	U141.	Another	brown	fat	lncRNA,	Blnc1,	identified	by	Zhao	 et	 al.	 (2014),	 has	 been	 shown	 to	 promote	 brown	 and	 beige	 adipocyte	
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differentiation	 and	 function124.	 Blnc1	 is	 mainly	 localized	 in	 the	 nuclear	 compartment	suggesting	 a	 role	 in	 transcriptional	 regulation.	 Mechanistically,	 Blnc1	 interacts	 with	EBF2.		EBF2	is	a	transcription	factor	that	regulates	adipocyte	differentiation	and	brown	fat	 development142,143	 and	 it	 forms	 a	 ribonucleoprotein	 transcriptional	 complex	 to	induce	the	expression	of	genes	involved	in	fuel	oxidation	and	uncoupled	respiration.	The	expression	of	Blnc1	itself	is	regulated	by	EBF2	by	forming	a	feedforward	regulatory	loop	that	probably	serves	as	a	regulator	for	the	thermogenic	differentiation	of	adipocytes142.		In	 a	paper	by	Alvarez-Dominguez	et	 al.	 (2015),	 a	 cluster	of	brown	 fat-enriched	lncRNAs	 was	 identified	 by	 RNA-Seq	 analysis	 of	 transcriptomes	 from	 various	 adipose	tissues120.	 One	 candidate,	 Lnc-BATE1,	 has	 been	 shown	 to	 be	 induced	 during	 brown	adipocyte	differentiation	and	more	highly	expressed	in	BAT	as	compared	to	WAT.	Lnc-BATE1	 appeared	 to	 be	 equally	 distributed	 between	 the	 cytosol	 and	 nucleus	 and	physically	interacts	with	the	nuclear	matrix	factor	hnRNP	U;	a	factor	required	for	brown	adipocyte	differentiation,	as	already	shown	for	Firre.		Although	several	profiling	studies	have	been	performed	to	explore	the	regulation	of	 lncRNA	 expression	 during	 thermogenic	 adipocyte	 development,	 the	 involvement	 of	lncRNAs	 in	 adipocyte	 biology	 remains	 poorly	 understood.	 Therefore,	 future	 work	 is	needed	for	understanding	the	role	of	these	lncRNAs	in	adipocyte	metabolism.			
1.4	Genomic	imprinting		Genomic	 imprinting	 is	 an	 epigenetic	 mechanism	 resulting	 in	 parent-of-origin	 specific	monoallelic	expression	which	affects	 less	 than	1%	of	all	 genes	 in	eutherians144.	 It	was	first	 discovered	 in	 mammals	 in	 1984	 when	 pronuclear	 transplantation	 experiments	revealed	 that	 both	 the	 maternal	 and	 paternal	 genomes	 are	 needed	 for	 the	 proper	development	of	mouse	embryos145,146.	 In	addition,	mouse	genetic	experiments	showed	that	 in	 specific	 regions	 of	 the	 genome,	 genes	 fulfil	 different	 functions	when	 inherited	maternally	than	when	inherited	paternally147.	The	phenomenon	of	genomic	 imprinting	must	have	arisen	with	the	development	of	the	placenta	around	125	million	years	ago148.	However,	 a	 plausible	 explanation	 of	 this	 epigenetic	 process	 has	 not	 yet	 been	 brought	forward.	Because	imprinted	genes	are	monoallelically	expressed,	one	might	hypothesize	that	there	are	selective	advantages	for	the	evolution	and	maintenance	of	the	organism.	Two	widely	cited	theories	exist	that	give	reason	for	the	existence	of	the	phenomenon	of	
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genomic	 imprinting:	the	 ‘kinship	theory’	and	the	 ‘coadaptation	theory’	(for	review,	see	Peters	et	al.	(2014)148).		The	kinship	theory,	also	called	the	parental	conflict	hypothesis,	states	that	there	is	 a	 conflict	 of	 ‘interest’	 between	maternal	 and	 paternal	 genes	 in	 a	 fetus	 or	 infant	 at	those	 developmental	 stages	 where	 it	 is	 reliant	 on	 the	 nutritional	 resources	 of	 the	mother148,149.	 The	 idea	 of	 the	 kinship	 theory	 can	 be	 explained	 through	 the	 fact	 that	mothers	are	able	to	bear	and	nurture	progeny	from	several	fathers.	The	consequence	is	that	offspring	from	one	female	are	equally	related	to	their	mother	whereas	the	father	is	only	related	to	a	subgroup	of	the	offspring.	Due	to	the	difference	in	relatedness,	different	interests	 of	maternal	 and	paternal	 genomes	 in	 the	 offspring	 emerge.	 To	provide	 ideal	fitness	 for	 the	 father	 it	 is	 beneficial	 for	 paternal	 genes	 in	 the	 fetus	 or	 infant	 to	make	maximal	 use	 of	maternal	 resources	without	 regard	 to	 the	detrimental	 effects	 to	 other	siblings	or	the	mother.	With	this,	siblings	larger	in	size	will	be	raised	that	have	a	better	chance	 of	 survival	 and	 thereby	 secure	 the	 reproduction	 of	 the	 father´s	 genes.	 On	 the	other	 hand,	 to	 provide	 optimal	 fitness	 for	 the	mother,	maternal	 genes	 in	 the	 fetus	 or	infant	 should	 be	 reduced	 in	 demands	 for	 maternal	 resources,	 and	 thus	 provide	 the	mother	 with	 better	 chances	 to	 raise	 more	 progeny.	 This	 hypothesis	 is	 in	 accordance	with	the	observation	that	numerous	paternally	expressed	genes	(PEGs)	enhance	growth,	whereas	maternally	 expressed	genes	 (MEGs)	 supress	 growth,	which	might	 also	 give	 a	reason	for	adult	phenotypes	such	as	maternal	care	and	social	behaviour148,150.	The	 coadaptation	 theory,	 in	 contrast,	 proposes	 that	 for	 optimization	 of	 fetal	development	 and	 maternal	 provisioning	 and	 nurturing	 imprinted	 genes	 act	 co-adaptively151.	 The	 theory	 only	 refers	 to	 a	 subset	 of	 predominantely	 PEGs	 that	 are	expressed	 in	 the	 placenta	 and	 the	 hypothalamus.	 During	 development	 of	mammalian	species,	complex	interactions	happen	between	the	fetus,	the	placenta,	and	the	mother´s	hypothalamus148.	 These	 interactions	 not	 only	 influence	 fetal	 growth	 and	 brain	development	 but	 also	 the	 provision	 of	 maternal	 resources	 at	 prenatal	 and	 postnatal	stages	 of	 development	 and	 postnatal	 maternal	 care.	 This	 is	 likely	 regulated	 by	 the	parent-infant	 coadaptation	 through	 a	 selection	 of	 co-expression	 of	 genes	 both	 in	 the	placenta	 and	 the	 hypothalamus	 of	 the	 mother148.	 One	 example	 for	 which	 this	 theory	applies	is	the	gene,	paternally	expressed	3	(Peg3)151.	Deregulation	of	imprinting,	via	(epi)mutations	in	individual	imprinting	genes	or	imprinted	 gene	 clusters,	 results	 in	 diverse	 imprinting	 disorders	 (IDs).	 IDs	 can	 affect	growth,	development	and	metabolism	of	an	individual	and	often	have	a	severe	lifelong	
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impact	 on	 the	 person´s	 quality	 of	 life.	 Some	 examples	 of	 IDs	 are	 Prader-Willi´s,	Beckwith-Wiedemann´s	 (BWS)	 and	 Angelman´s	 syndromes152,153.	 Interestingly,	 in	Silver-Russell´s	 syndrome	(SRS)	 it	has	been	shown	 that	 the	 ID	 is	due	 to	defects	 in	 the	
H19-Igf2	locus154,	a	locus	which	is	of	great	relevance	to	this	thesis.		In	 spite	 of	 progress	 in	 understanding	 the	 molecular	 basis	 of	 imprinting,	 the	etiology	 of	 IDs155–157	 and	 approaches	 to	 cure	 IDs158,	 the	 question	 remains	 as	 to	 why	some	 genes	 but	 not	 others	 are	monoallelically	 expressed149,159.	 To	date,	 it	 is	 not	 clear	whether	specific	similarities	between	PEGs	or	MEGs	as	two	differing	gene	sets	exist	at	all,	 mainly	 because	 PEGs/MEGs	 represent	 a	 collection	 of	 genes	 with	 heterogeneous	functions.		Interestingly,	 one	 consequence	 of	 ID	 in	 patients	 and	 also	 mouse	 models	 are	metabolic	 sequelae,	 for	 instance	 altered	 adiposity,	 lipodystrophy	 and	 alterations	 in	insulin	 sensitivity	 and	 EE148.	 All	 these	 processes	 are	 closely	 linked	 to	 BAT	 and	WAT	(dys)function.		
1.4.1	Genomic	imprinting	and	thermogenesis			To	assure	survival	of	newborn	mammals,	especially	those	progeny	that	are	born	nude,	the	maintenance	of	body	temperature	in	the	cold	is	vital.	Newborn	mice	cannot	regulate	their	own	body	temperature	until	one	week	after	birth160.	This	makes	them	dependent	not	only	on	the	mother	to	provide	body	heat	but	also	on	the	litter	staying	together	in	the	nest	to	conserve	heat.	In	neonates	the	regulation	of	temperature	is	provided	through	the	process	 of	 NST	 in	 BAT,	 which	 has	 evolved	 in	 mammals	 to	 overcome	 hypothermia22.	During	 this	 process	 chemical	 energy	 is	 dissipated	 in	 the	 form	 of	 heat	 through	mitochondrial	brown	fat	UCP122.	Several	genes	have	already	been	identified	that	affect	BAT	and	possibly	NST.		The	Gnas	 cluster	 harbours	 two	 genes	 –	Gnas	 (encodes	 the	 G	 protein	a-subunit	Gsa)	and	Gnasxl	(gives	rise	to	a	variant	Gsa	subunit	known	as	XLas).	Normally,	Gnas	 is	known	to	be	a	biallelically	expressed	gene.	However,	it	shows	maternal	expression	in	a	few	tissues148.	Gnasxl	on	the	other	hand	is	a	PEG	depending	on	the	tissue	in	which	it	is	expressed161,162.	Thus,	both	genes	act	antagonistically	and	have	opposite	effects	on	BAT	metabolism	with	Gsa	promoting	and	XLas		repressing	the	production	of	heat161,163,164.		Two	 other	 PEGs	 have	 been	 shown	 to	 inhibit	 the	 differentiation	 of	 brown	adipocytes:	Necdin	(Ndn)	and	delta-like	1	homologue	(Dlk1)165,	although	the	role	of	Dlk1	
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in	 BAT	 differentiation	 before	 weaning	 is	 not	 clear166.	 However,	 Charalambous	 et	 al.	(2012)	could	show	that	Dlk1	as	well	as	the	PEG	Dio3	(encodes	deiodinase,	iodothyronine	
type	III)	are	important	for	a	second	phase	of	BAT	recruitment	two	weeks	after	birth.	This	stage	 was	 not	 recognized	 until	 recently	 and	 is	 necessary	 for	 thermoregulation	 when	mice	start	to	become	independent	of	the	mother	by	leaving	the	nest166.	When	Dlk1	was	overexpressed,	 BAT	 differentiation	 and	 b-adrenergic	 signalling	 was	 impaired,	 and	overexpression	of	both	Dlk1	and	Dio3	even	resulted	in	reduced	Ucp1	expression.	Thus,	through	impaired	thermogenesis	and	instable	body	temperature,	BAT	is	defective	in	its	response	to	cold.	These	data	support	the	prediction	of	the	kinship	theory	of	imprinting	that	PEGs	act	to	reduce	thermogenic	output	and	that	MEGs	on	the	other	hand	invest	in	increasing	thermogenic	output148,167.		
1.4.2	The	lncRNA	H19		In	1984,	the	 imprinted	RNA	transcript	H19	was	 identified	in	a	murine	fetal	 liver	cDNA	library	for	clones	containing	mRNA	sequences	that	decrease	in	expression	after	birth168.	The	 clone	which	 hybridized	 only	 to	 a	 fetal	 but	 not	 to	 an	 adult	 liver	 cDNA	 probe	was	designated	H19	based	on	its	position	as	the	19th	clone	in	row	H.	H19	is	expressed	from	the	maternal	 allele	 in	mouse	 and	human169,170	 and	 transcribed	by	RNA	polymerase	 II,	capped,	polyadenylated	and	 spliced.	However,	 it	 lacks	 conserved	open	 reading	 frames	(ORFs)	between	human	and	mouse171	and	is	noncoding.	The	H19	gene	encodes	a	2.3	kb	noncoding	mRNA	which	is	strongly	expressed	during	embryogenesis	and	consists	of	five	exons	and	 four	 introns	which	are	shorter	 than	most	 lncRNA	genes,	each	 less	 than	100	bp172.	The	H19	locus	harbours	several	transcripts,	among	them	H19	which	functions	as	a	full	 lncRNA.	Moreover,	H19	 encodes	 two	variants	 of	microRNAs,	miR-675173	within	 its	first	exon,	but	also	two	antisense	transcripts,	91H	and	HOTS174.		
H19	 is	 part	 of	 an	 imprinted	 gene	 cluster,	 which	 is	 conserved	 on	 mouse	chromosome	7	and	human	chromosome	11p15	(Figure	3).	H19	is	located	adjacent	to	the	protein-coding	 gene,	 insulin-like	 growth	 factor	 2	 (IGF2)	 which	 is	 an	 important	 fetal	growth	 factor.	H19	 and	 Igf2	 are	 oppositely	 imprinted	 and	 co-expressed	 in	 endoderm-	and	 mesoderm-derived	 tissues	 during	 embryonic	 development,	 which	 suggests	 that	they	 are	 regulated	 by	 a	 common	mechanism.	 Both	 genes	 share	 regulatory	 sequences	which	 control	 their	 expression,	 including	 two	 enhancers	 which	 are	 located	 3’	downstream	 of	 H19175.	 Furthermore,	 an	 imprinting	 control	 region	 (ICR)	 is	 located	
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between	 the	 two	 gene	 loci	 which	 exhibits	 differential	 methylation	 and	 controls	 the	expression176.		Although	 H19	 is	 noncoding,	 it	 is	 abundantly	 expressed	 during	 mammalian	development	 in	 both	 embryonic	 and	 extraembryonic	 tissues.	H19	 is	 expressed	 in	 the	embryo	 and	 downregulated	 shortly	 after	 birth	 in	 all	 tissues	 except	 from	 skeletal	muscle177.	H19	has	various	biological	functions	and	a	vast	amount	of	reviews	have	been	published	which	discuss	research	on	H19.	Prior	reviews	 focus	on	 topics	such	as	H19´s	regulation178,179	or	its	broad	role	in	cancer180	specifically	the	role	of	H19	to	act	either	as	an	 oncogene181	 or	 tumour	 suppressor182–184.	 In	 addition,	 its	 participation	 in	 the	regulation	of	cell	proliferation185	and	differentiation173	has	been	investigated.		In	 the	developing	 fetus,	H19	 regulates	 several	 important	 genes	 that	 are	part	 of	the	imprinting	gene	network	(IGN).	One	of	these	genes	is	Igf2	which	is	responsible	for	proper	 embryonic	 development186.	 Moreover,	 it	 has	 been	 shown	 to	 influence	 mouse	growth	independently	of	the	mechanism	co-regulating	imprinted	expression	of	Igf2	and	
H19187.	 H19	 may	 influence	 the	 regulation	 of	 growth	 through	 at	 least	 two	 distinct	mechanisms	 involving	 miRNAs.	 Sequences	 within	 exon	 1	 of	 H19	 are	 the	 source	 of	microRNA	miR-675,	which	is	solely	expressed	in	placenta	and	serves	to	suppress	genes	that	promote	placental	growth,	including	Igf	type-1	receptor	gene	(Igf1r)188.		In	addition,	H19	RNA	acts	as	a	sponge	for	 let-7	 family	microRNAs188.	By	binding	to	let-7	microRNAs,	H19	has	been	shown	to	influence	the	expression	of	let-7	target	genes	which	end	up	promoting	the	differentiation	of	myoblasts127.	Although	H19	is	one	of	the	most-well	studied	lncRNAs,	based	on	its	status	as	being	the	first	lncRNA	discovered	and	characterized	and	its	participation	in	many	known	biological	functions,	to	date,	nothing	is	known	about	its	involvement	in	BAT	homeostasis.							
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Figure	3:	H19-Igf2	imprinting	gene	cluster	The	ICR	of	the	paternal	allele	is	DNA	methylated.	The	ICR	on	the	maternal	allele	is	unmethylated	and	the	insulator	protein	CTCF	can	bind	and	prevent	enhancers	from	interacting	with	the	Igf2	promoter.	Instead,	the	enhancers	activate	the	expression	of	H19.	On	the	paternal	allele,	DNA	methylation	prevents	CTCF	from	binding	to	the	ICR,	and	the	enhancers	activate	Igf2	expression.		
1.4.2.1	Regulation	of	H19	expression		The	expression	of	H19	is	regulated	via	genomic	imprinting,	an	epigenetic	phenomenon.	
H19	 is	 only	 expressed	 on	 the	 maternal	 allele	 and	 silenced	 on	 the	 reciprocal	chromosome.	The	paternal	allele	is	imprinted	which	means	that	the	ICR	region,	which	is	located	 between	H19	 and	 Igf2,	 is	 highly	methylated,	 and	 thus	 silenced.	 The	 ICR,	 also	called	 differentially	 methylated	 region	 (DMR),	 exhibits	 different	 methylation	 statuses	depending	on	the	origin	of	the	parental	chromosome.	On	the	maternal	allele,	the	ICR	is	hypomethylated	and	H19	 is	expressed.	Igf2,	which	is	adjacent	to	H19,	 is	 imprinted	and	regulated	in	opposite	direction:	its	expression	is	driven	from	the	paternal	allele	and	it	is	silenced	on	the	maternal	allele189.	In	normal	circumstances,	the	ICR	is	hypermethylated	at	the	paternal	allele	and	hypomethylated	on	the	maternal	allele.		The	 mechanism	 that	 controls	 imprinting	 at	 this	 locus	 involves	 the	 binding	 of	either	Methyl-CpG-binding	 protein	 2	 (MeCP2)	 or	 CTCF	 depending	 on	 the	methylation	status	 of	 the	 ICR.	 The	 expression	 of	H19	 is	 silenced	 through	 histone	 deacetylation	 by	MeCP2	 binding	 to	 methylated	 CpG	 dinucleotides.	 Afterwards,	 histone	 deacetylases	(HDACs)	 interact	 with	 MeCP2	 to	 silence	 H19176.	 On	 the	 maternal	 chromosome	 H19	expression	is	not	repressed	by	MeCP2	binding	and	can	interact	with	its	enhancer	region.	CTCF	 can	 bind	 to	 the	 ICR	 thereby	 preventing	 the	 expression	 of	 Igf2.	 The	 ICR	 and	 its	methylation	status	are	important	for	normal	expression	of	H19	and	Igf2.	Dysregulation	
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of	 this	 ICR,	and	 thus	abnormal	expression	of	either	H19	or	 IGF2	 can	have	 tremendous	negative	effects	and	result	in	various	diseases	as	mentioned	in	1.4.	
1.4.2.2	Regulation	of	gene	expression	by	H19		To	 treat	 epigenetic	 abnormalities	 in	 different	 diseases,	 the	 activation	 or	 repression	 of	
H19	could	be	an	important	epigenetic	therapy174.	One	way	in	which	H19	acts	as	a	guide	to	repress	gene	expression	is	through	the	interaction	with	epigenetic	modifiers174.	In	a	publication	 by	 Monnier	 et	 al.	 (2013)	 it	 has	 been	 shown	 that	 H19	 controls	 gene	expression	 of	 maternal	 expressed	 genes	 (Cdkn1c,	 Dcn,	 Meg3)	 and	 paternal	 expressed	genes	(Igf2,	Dlk1,	Slc38a4,	Peg1)	or	biallelically	(Gnas)	expressed	genes	of	the	IGN190.	To	control	 these	genes	H19	 interacts	with	methyl-CpG-binding	domain	protein	1	 (MBD1),	which	 is	 similar	 to	 MeCP2,	 a	 repressor	 of	H19.	 MBD1	 binds	 to	 methylated	 DNA	 and	recruits	 HDACs	 and	 histone	 lysine	 methyltransferase	 (KMT)-containing	 complexes.	These	 two	 complexes	 silence	 genes	 via	 H3K9	 methylation	 resulting	 in	 chromatin	compaction190.		Despite	its	repressing	function,	H19	can	promote	gene	expression	by	interacting	with	epigenetic	modifying	enzymes.	H19	has	been	shown	to	bind	hnRNP	U,	which	is	part	of	 a	 complex	 with	 RNA	 polymerase	 II	 and	 a	 histone	 acetyltransferase	 P300/CBD-associated	factor	(PCAF).	Histone	acetylation	resulted	in	an	upregulation	of	genes	within	the	 miR-200	 family191.	 These	 studies	 show	 that	 H19	 can	 act	 either	 as	 repressor	 or	activator	 of	 gene	 expression	 by	 being	 part	 of	 different	 epigenetic	 mechanisms.	 This	underlines	the	multifaceted	role	of	H19	as	a	lncRNA	on	gene	expression.		
1.4.2.3	H19	in	the	regulation	of	diabetes		Blood	 sugar	 levels	 in	 the	 body	 need	 to	 be	maintained	 at	 precise	 levels	 and	 the	 liver	constitutes	the	major	site	of	glucose	regulation.	If	blood	glucose	is	too	low	the	alpha	cells	of	 the	pancreas	 secrete	glucagon.	Glucagon	 stimulates	 the	 liver	 to	 release	glucose	and	stimulates	 the	 production	 of	 more	 glucose	 through	 glycogenolysis.	 Elevated	 blood	glucose	levels	stimulate	glycogenesis	by,	increasing	insulin	release	and	causing	glycogen	to	be	produced	from	glucose.	Insulin,	generated	in	the	b-cells	of	the	pancreas,	stimulates	the	 liver	and	muscle	 to	 take	up	blood	glucose	resulting	 in	a	decrease	of	blood	glucose	levels.	If	these	processes	are	dysregulated	this	can	result	in	T1DM	and	T2DM192.		
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Research	shows	evidence	for	H19´s	involvement	in	T2DM.	When	cultured	in	the	presence	of	insulin,	smooth	muscle	cells	have	been	shown	to	express	a	five-fold	increase	in	H19	than	when	cultured	in	media	without	insulin.	This	points	to	a	response	of	H19	to	changes	 in	 insulin193.	 Moreover,	 it	 has	 been	 shown	 that	 mice	 with	 a	 whole-body	knockout	of	H19,	and	thus	biallelic	expression	of	Igf2194,	are	heavier	compared	to	control	animals195	 which	 results	 in	 improper	 growth	 after	 birth	 and	 a	 predisposition	 to	T2DM196.		Although	the	liver	is	a	major	site	of	insulin	resistance	in	T2DM,	some	studies	have	also	focused	on	the	involvement	of	muscle	and	the	pancreas.	It	has	been	shown	that	H19	plays	 a	 role	 in	 both	 mice	 and	 humans	 suffering	 from	 T2DM	 in	 the	 muscle.	H19	 was	significantly	decreased	and	shown	to	act	as	a	decoy	for	the	microRNA	let-7197.	Gao	et	al.	(2014)	showed	that	H19	acts	as	a	sponge	that	binds	let-7,	which	interacts	normally	with	
Insr	and	Lpl,	to	inhibit	the	insulin-PI3K-mTOR	pathway.	H19	downregulation	in	diabetic	muscle	 resulted	 in	 limited	binding	of	 let-7	 and	 in	 increased	 inhibition	of	 the	pathway,	consequently,	promoting	insulin	resistance.	Chronic	downregulation	of	H19	resulted	in	a	dysregulation	of	glucose	metabolism197.		When	 researchers	 induced	 diabetes	 in	 pregnant	 females,	 pups	 received	 a	 high	intrauterine	exposure	to	glucose198.	This	resulted	in	a	hypermethylation	of	the	ICR	in	the	pancreatic	islets	of	the	pups	and	consequently	in	the	low	expression	of	H19	and	Igf2.	The	low	expression	of	H19	and	Igf2	was	even	detectable	in	the	sperm	of	these	mice	revealing	a	 mechanism	 for	 the	 inheritance	 of	 childhood	 diabetes	 with	 H19	 as	 an	 important	factor198.		The	studies	discussed	in	this	section	show	that	H19,	due	to	its	diverse	action	in	different	tissues,	impacts	diabetes	in	a	multifaceted	fashion.	However,	more	mechanistic	studies	 examining	 the	 epigenetic	profiles	 and	 changes	of	H19	 and	 IGF2—also	 in	other	tissues	which	have	beneficial	effects	on	whole	body	metabolism	such	as	 the	BAT—are	needed	to	fully	reveal	H19´s	role.		
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1.5	Objectives		The	 aim	 of	 this	 study	 is	 to	 identify	 and	 characterise	 novel	 lncRNAs	 that	 favor	 energy	dissipation	 by	 enhancing	 BAT	 metabolism.	 Obesity	 and	 T2DM	 represent	 two	 of	 the	major	 health	 concerns	 of	 our	 society.	 The	 activation	 of	 BAT	 has	 been	 proposed	 as	therapeutic	target	due	to	its	unique	property	to	convert	dietary	and	stored	nutrients	like	lipids	and	glucose	directly	into	heat.	LncRNAs	have	moved	into	the	focus	of	attention	as	a	novel	 class	of	noncoding	RNAs	due	 to	 their	multifaceted	 control	of	 gene	expression.	However,	 our	 knowledge	 of	 how	 lncRNAs	 control	 BAT	 differentiation	 and	 function	 in	particular	 remains	 limited	 despite	 the	 progress	 in	 identifying	 and	 functionally	characterizing	 lncRNAs	 involved	 in	 processes	 such	 as	 ageing199,	 metabolic	homeostasis136,200,	and	AT	biology120,124,201,202.	Thus,	 this	study	aims	to	reveal	candidate	 lncRNAs	that	can	be	used	 in	the	 long-term	as	link	for	therapeutic	options.	In	order	to	achieve	this	aim,	we	performed	RNA-Seq	to	identify	lncRNAs	correlating	with	BAT	function.	Candidate	lncRNAs	were	tested	for	in	
vitro	functionality	and	gain-and-loss	of	function	analysis	of	lncRNA	H19	was	performed	to	unravel	its	effect	on	BAT	biology	in	vitro	and	in	vivo.	To	elucidate	possible	molecular	effector	circuits	ChART-MS	was	applied	to	find	H19	associated	proteins.		
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2	Materials	and	Methods	
2.1	Materials	
2.1.1	Technical	Equipment		
Machine	 Manufacturer		Analytical	balances,	Quintix®	124-1S	&	Quintix®	612-1S	 Sartorius	AG,	Göttingen,	DE	Blood	glucose	monitoring	system	+	sensors,	Contour®	XT	 Bayer	Healthcare,	Leverkusen,	DE	Cell	culture	cabinet,	Scanlaf	Mars,	safety	class	II	 LaboGene	ApS,	Allorød,	DK	Centrifuge,	5810	R	 Eppendorf	AG,	Hamburg,	DE	CO2-Incubator,	C	170	 BINDER	GmbH,	Tuttlingen,	DE	CO2-Incubator,	Heracell™	150i	 Thermo	Fisher	Scientific,	Waltham,	US	Digital	printer,	P95DE	 Mitsubishi	Electric	Corporation.,	Chiyoda,	JP	Electrophoresis	and	blotting	system,	Mini-PROTEAN	Tetra	Cell	 Bio-Rad	Laboratories,	Inc.,	Hercules,	US	Electrophoretic	transfer	module,	Mini	Trans-Blot	Cell	 Bio-Rad	Laboratories,	Inc.,	Hercules,	US	Fume	cupboard,	CC-30	 Caspar	&	Co.	Labora	GmbH,	Aachen,	DE	Gel	documentation	system,	FastGene®	FAS	V	 Nippon	Genetics	Europe	GmbH,	Düren,	DE	Gel	electrophoresis	chamber,	PerfectBlue™	Mini	 VWR	International	GmbH,	Radnor,	US	Homogenizer,	FastPrep-24™	5G	 MP	Biomedicals	Germany	GmbH,	Eschwege,	DE	Inverted	microscope,	DM	IL	LED		 Leica	Microsystems	CMS	GmbH,	Wetzlar,	DE	Laboratory	freezer,	Forma™	88000	 Thermo	Fisher	Scientific,	Waltham,	US	Laboratory	freezer,	LGex	3410	Mediline	 Liebherr-International	AG,	Bulle,	CH	Microcentrifuge,	refrigerated,	Micro	Star	17R	 VWR	International	GmbH,	Radnor,	US	Microplate	reader,	FilterMax™	F5			 Molecular	Devices,	LLC,	San	José,	US	PCR-Thermocycler,	FlexCycler2	 Analytik	Jena	AG,	Jena,	DE	PhenoMaster,	Automated	Home	Cage	Phenotyping	 TSE	Systems	GmbH,	Bad	Homburg	vor	der	Höhe,	DE	Platform	shaker,	Polymax	1040	 Heidolph	Instruments	GmbH	&	Co.	KG,	Schwabach,	DE	Power	Supply,	PowerPac™	HC	 Bio-Rad	Laboratories,	Inc.,	
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Hercules,	US	Real-Time	PCR	System,	QuantStudio™	7	Flex	 Applied	Biosystems,	Foster	City,	US	Refrigerator,	KT	1730-26		 Liebherr-International	AG,	Bulle,	CH	Shaker,	IKA®	MS	3		 IKA	Werke	GmbH	&	Co.	KG,	Staufen	im	Breisgau,	DE	Spectrophotometer,	NanoDrop™	ND-1000			 NanoDrop	Technologies,	LLC,	Wilmington,	US	Thermoshaker,	MKR	23			 Hettich	Benelux	B.V.,	Geldermalsen,	NL	Ultracentrifuge,	Heraeus™	Megafuge™	16R		 Thermo	Fisher	Scientific,	Waltham,	US	Vortex	mixer,	Vortey-Genie	2		 Scientific	Industries,	Inc.,	Bohemia,	US	Water	bath,	model	1003	 GFL	Gesellschaft	für	Labortechnik	mbH,	Burgwedel,	DE	Water	purification	system,	Milli-Q®	Advantage	A10	 Merck	Millipore,	Darmstadt,	DE	
	
2.1.2	General	Materials			
Material	 Manufacturer	 Reference	Cell	Scraper	[25	cm,	39	cm]	 Sarstedt	AG	&	Co.,	Nümbrecht,	DE	 83.1830,	83.1831	Cell	strainer	EASYstrainer™,	40	µm			 Greiner	Bio-One	GmbH,	Kremsmünster,	AT	 542000	Centrifugation	tubes,	Falcon®,	polypropylene	[15	ml,	50	ml]	 Corning	Corp.,	Corning,	US	 352096,	352070	Ceramic	beads,	Precellys®	zirconium	oxide	beads,	1.4	mm	 Cayman	Chemical,	Ann	Arbor,	US	 03961-1-103	Chromatography	paper,	Whatman™	 GE	Healthcare,	Chicago,	US	 3030-861	Cryo	tubes,	CryoPure®,	1.8	ml		 Sarstedt	AG	&	Co.,	Nümbrecht,	DE	 72.379.005	Disinfectant,	Bacillol®	AF	 BODE	Chemie	GmbH,	Hamburg,	DE	 9733803	Dispenser,	Multipette®	E3	 Eppendorf	AG,	Hamburg,	DE	 4987000010	Dispenser-tips,	Combitips	advanced®	[0.2	ml,	2.5	ml]	 Eppendorf	AG,	Hamburg,	DE	 613-2059,	613-2062	Improved	Neubauer	hemacytometer	chamber,	0.01	mm	 W.	Schreck,	Hofheim	am	Taunus,	DE	 N/A	Multichannel	pipette,	Transferpette®	S-8	 Brand	GmbH	+	CO	KG,	Wertheim,	DE	 703708	Needles,	Sterican®,	0.45	x	12mm	 B.	Braun	Melsungen	AG,	Melsungen,	DE	 4665457	
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Nitrocellulose	western	blotting	membrane,	Amersham™	Protran®	Premium,	0,45	µm	 GE	Healthcare,	Chicago,	US	 10600047	Optical	384-well	reaction	plate	with	barcode,	MicroAmp™	 Thermo	Fisher	Scientific,	Waltham,	US	 4309849	Optical	adhesive	film,	MicroAmp™	 Thermo	Fisher	Scientific,	Waltham,	US	 4311971	PCR	lid	strips,	Multiply®	8-lid	chain,	flat	 Sarstedt	AG	&	Co.,	Nümbrecht,	DE	 65.989.002	PCR	tubes,	Multiply®-µStrip,	0.2	ml	 Sarstedt	AG	&	Co.,	Nümbrecht,	DE	 72.985.002	Petri	dishes,	94	x	16	mm	 A.	Hartenstein	GmbH,	Würzburg,	DE	 PP90	Pipetboy,	accu-jet®	pro	 Brand	GmbH	+	CO	KG,	Wertheim,	DE	 26300	Pipettes,	Transferpette®	S	Starter	Kit	 Brand	GmbH	+	CO	KG,	Wertheim,	DE	 613-3478	Pipette-tips	[10	µl,	200	µl,	1000	µl]	 Greiner	Bio-One	GmbH,	Kremsmünster,	AT	 771255,	739265,	686271	Pipette-tips,	filtered	[0.5-10	µl,	5-100	µl,	50-1000	µl]	 Brand	GmbH	+	CO	KG,	Wertheim,	DE	 732724,	732730,	732734	Pipette	with	tip,	sterile	[5	ml,	10	ml,	25	ml,	50	ml]	 Greiner	Bio-One	GmbH,	Kremsmünster,	AT	 606180,	607180,	760180,	768180	Precast	gels,	Mini-PROTEAN®	TGX™,,	10-well	[4-15	%,	7.5	%]	 Bio-Rad	Laboratories,	Inc.,	Hercules,	US	 4561084,	4561023	Reaction	tubes,	SafeSeal®	[0.5	ml,	1.5	ml,	2.0	ml]	 Sarstedt	AG	&	Co.,	Nümbrecht,	DE	 72.704,	72.706,	72.695.600	Syringes,	Injekt®-F,	1	ml	 B.	Braun	Melsungen	AG,	Melsungen,	DE	 9166017V	Tissue	culture	dish,	TPP®,	15	cm	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 Z707694	Tissue	culture	plate,	Falcon®,	polystyrene	[6-well,	24-well	 Corning	Corp.,	Corning,	US	 353046,	353047	Amicon	Ultra-0,5	Centrifugal	Filter	Unit	 Merck	Millipore,	Darmstadt,	DE	 UFC500324		
2.1.3	Chemicals	and	Reagents		
Chemical	 Manufacturer	 Reference	2-Propanol	(isopropanol),	for	molecular	biology,	min.	99.5%	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 I9516	ß-Glycerophosphate	disodium	salt	hydrate,	min.	99%	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 G9422	
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ß-Mercaptoethanol,	min.	99%		 AppliChem	GmbH,	Darmstadt,	DE	 A1108	Acetic	acid,	glacial,	min.	90%		 VWR	International	GmbH,	Radnor,	US	 BAKR9522	Agarose,	for	molecular	biology		 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 A9539	D-(+)-Glucose,	min.	99.5%	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 G7021	DynabeadsÒ	MyOneÔ	Streptavidin	C1	 Thermo	Fisher	Scientific,	Waltham,	US	 65001	Ethanol	absolut,	AnalaR	NORMAPUR®,	min.	99.8%	 VWR	International	GmbH,	Radnor,	US	 20821.296	Ethylene	glycol-bis(2-aminoethylether)-tetraacetic	acid	(EGTA),	min.	99%	
AppliChem	GmbH,	Darmstadt,	DE	 A0878	
Ethylenediaminetetraacetic	acid	(EDTA),	min.	98%	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 E6758	Formaldehyde	solution	37%	 AppliChem	GmbH,	Darmstadt,	DE	 A0823,0500	Glucose-solution	20	%,	ad	us.	vet.		 bela-pharm	GmbH	&	Co.	KG,	Vechta,	DE	 2069.97.99	GlycoBlueÔ	Coprecipitant		 Thermo	Fisher	Scientific,	Waltham,	US	 AM9515	Hydrochloric	acid	(HCl),	37%	 AppliChem	GmbH,	Darmstadt,	DE	 211020	Insulin	solution,	human	recombinant,	9.5	-	10.5	mg/ml	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 I9278	Methanol,	ROTIPURAN®,	min.	99.9%	 Carl	Roth	GmbH	+	Co.	KG	 4627.1	N-2-hydroxyethylpiperazine-N-2-ethane	sulfuric	acid	(HEPES)	buffer	solution,	1M	
Thermo	Fisher	Scientific,	Waltham,	US	 15630049	
Protease	inhibitor	tablets,	Complete™	Mini	 Roche	Diagnostics,	Rotkreuz,	CH	 4693159001	RNase	inhibitor,	RNasin®	Plus	 Promega	GmbH,	Mannheim,	DE	 N2511	Sodium	acetate	(NaAc),	min.	99%	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 S5636	Sodium	chloride	(NaCl),	pure	 VWR	International	GmbH,	Radnor,	US	 443827W	Sodium	dodecyl	sulfate	(SDS),	min.	99%		 AppliChem	GmbH,	Darmstadt,	DE	 A1112	Sodium	hydroxide	(NaOH),	AnalaR	NORMAPUR®,	solid	 VWR	International	GmbH,	Radnor,	US	 28244.295	Transfection	reagent,	Lipofectamine™	2000	 Thermo	Fisher	Scientific,	Waltham,	US	 11668019	
2	Materials	and	Methods	
	 29	
Trichlormethane	(chloroform),	min.	99.8	%		 Carl	Roth	GmbH	+	Co.	KG	 4432.1	Tween®	20	(polysorbate),	for	molecular	biology			 VWR	International	GmbH,	Radnor,	US	 437082Q	
2.1.4	Commercialized	test	systems	(Kits)		
Kits	 Manufacturer	 Reference	DreamTaq	Green	DNA	Polymerase	(5	U/µl)	 Thermo	Fisher	Scientific,	Waltham,	US	 EP0714	High-Capacity	cDNA	Reverse	Transcription	Kit	 Thermo	Fisher	Scientific,	Waltham,	US	 4368814	MinElute	PCR	Purification	Kit	 QIAGEN	N.V.,	Venlo,	NL	 28006	mirVanaÔ	miRNA	Isolation	Kit	 Fisher	Scientific,	Hampton,	US	 AM1560,	AM1561	PCR	Mycoplasma	Test	Kit	 AppliChem	GmbH,	Darmstadt,	DE	 A3744	Pierce	BCA	Protein	Assay	Kit	 Thermo	Fisher	Scientific,	Waltham,	US	 23225	Seahorse	XF	Cell	Mito	Stress	Test	Kit	 Agilent,	Santa	Clara,	US	 103015-100		SYBR™	Select	Master	Mix	 Thermo	Fisher	Scientific,	Waltham,	US	 4472903	TaqMan	Gene	Expression	Master	Mix			 Thermo	Fisher	Scientific,	Waltham,	US	 4369016	TURBO	DNA-free™	Kit			 Thermo	Fisher	Scientific,	Waltham,	US	 AM1907	
2.1.5	Buffer	and	Solutions		
Buffer/Solution		 Composition/Manufacturer	 Reference	Bacillol	 BODE	(Hamburg,	DE)	 973380	Diethylpyrocarbonate	(DEPC)	H2O	 0,1%	(v/v)	DEPC	in	H2O	 	DNA	gel	loading	dye,	6X	 Thermo	Fisher	Scientific,	Waltham,	US)	 R0611	DNA	ladder	mix,	GeneRuler™	 Thermo	Fisher	Scientific,	Waltham,	US	 SM0331	dNTP	Set,	100	mM	Solutions	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 R0182	Dream	Taq	Green	Buffer	(10x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 B71	Erythrocyte	lysis	buffer	 Qiagen	(Hilden,	DE)	 79217	GeneRuler	DNA	Ladder	Mix	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 SM0332	GeneRuler	DNA	Ladder	Mix	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 SM0331	Laemmli	sample	buffer,	4X			 Bio-Rad	Laboratories,	Inc.,	Hercules,	US	 1610747	
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Midori	Green	Advance	DNA	stain	 Biozym	Scientific	GmbH,	Hessisch	Oldendorf,	DE	 617004	Ni-NTA	Agarose	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 R90115	Oil	Red	O	Staining	Solution	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 O1391-9	PageRuler™	Prestained	Protein	Ladder	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 26616	Membrane	staining	solution,	Ponceau	S,	0.1	%	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 P7170	peqGOLD	TriFastÔ	 VWR	(Darmstadt,	DE)	 30-2010	RNase	Zap	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 R2020	TAE	buffer	(Tris-Acetate-EDTA	buffer)	 0.04	M	Tris-Acetate,	0.001	M	EDTA	in	H2O	 	Tail	Lysis	Buffer	 	 	TaqMan	Gene	Expression	Master	Mix	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 4369016	Tissue	freezing	medium	 Leica	Biosystems	Nussloch	GmbH,	Nussloch,	DE	 14020108926	Trypan	blue	solution,	0.4%			 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE	 T8154	Western	blocking	reagent,	solution	 Roche	Diagnostics	GmbH,	Mannheim,	DE	 11921673001		
2.1.6	Reagents	for	cell	culture	experiments		
Reagent	 Manufacturer	 Reference		3-Isobutyl-1-methylxanthin	(IBMX)	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 I5879-5G	3,3’,5-Triiodo-L-thyronine	(T3)	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 T2877	Biotin	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 B4639	Bovine	Serum	Albumine	(BSA)	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 A8806-5G	CL-316,243	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 C5976	D(+)-Glucose-Monohydrat			 AppliChem	(Darmstadt,	DE)	 A3730	D-Pantothenic	acid	hemicalcium	salt	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 P5155	Dexamethasone	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 D1756	DMEM/Ham’s	F-12	(1:1)	 Merck	(Darmstadt,	DE)	 FG4815	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	(1x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 11960-044	Dulbecco’s	Phosphate	Buffered	Saline	(DPBS)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 14190-094	
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Fetal	Bovine	Serum	(FCS)	 Biochrom	AG	(Berlin,	DE)	 S0115	Indomethacin	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 I7378	Insulin	solution	human	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 I9278-5ML	L-Ascorbic	acid	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 A4544-25G	L-Glutamine	200	mM	(100x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 25030-024	Lipofectamine®	2000	Reagent	(1	mg/mL)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 	52758	Minimum	Essential	Medium	Non-Essential	Amino	Acids	(MEM	NEAA)	(100x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 11140-035	OPTI-MEMÔ	(1x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 31985-062	Penicillin/Streptomycin	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 	15140-122	Rosiglitazone	 Sigma-Aldrich	(St.	Louis,	MO,	USA)	 	R2408-10MG	Sodium	Pyruvate	100	mM	(100x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 11360-039	Trypsin-EDTA	(10x)	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 15400-054		
2.1.7	Antibodies		
Protein	target	 Product	no.		 Company	 Dilution	Calnexin	 208-880	 Calbiochem	 1:5000	PGC1a	 sc-13067	 Santa	Cruz	 1:500	UCP1	 sc-6528	 Santa	Cruz	 1:500		
2.1.8	List	of	utilized	TaqMan	assays	
	
TaqMan	 Full	Gene	Name	 TaqMan	ID	AdipoQ	 adiponectin,	C1Q	and	collagen	domain	containing	 Mm00456425_m1	CD34	 Cluster	of	Differentiation	34	 Mm00519283_m1	Cebpa	 CCAAT/enhancer	binding	protein	(C/EBP),	alpha	 Mm00514283_s1	Cebpb	 CCAAT/enhancer	binding	protein	(C/EBP),	beta	 Mm00843434_s1	Cidea	 cell	death-inducing	DNA	fragmentation	factor,	alpha	 Mm00432554_m1	Ctcf	 CCCTC-binding	factor	 Mm00484027_m1	Dcn	 Decorin	 Mm00514535_m1	Dio2	 deiodinase,	iodothyronine,	type	II	 Mm00515664_m1	Dlk-1/Pref-1	 Delta	Like	Non-Canonical	Notch	Ligand	1	 Mm00494477_m1	
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Elovl3	 elovl	family	member	3	 Mm01194164_m1	Fabp4	 fatty	acid	binding	protein	4,	adipocyte	(AP2)	 Mm00445878_m1	Gapdh	 glyceraldehyde-3-phosphate	dehydrogenase	 Mm99999915_g1	Hprt	 hypoxanthine	guanine	phosphoribosyl	transferase	1	 Mm00446968_m1	H19		 H19,	imprinted	maternally	expressed	transcript	 Mm01156721_g1	Igf2	 Insulin-like	growth	factor	2	 Mm00439564_m1	Lep	 leptin	 Mm00434759_m1	Mest	 Mesoderm	specific	transcript	 Mm00485003_m1	Nnat	 Neuronatin	 Mm00731416_s1	Pdgfra	 Platelet	Derived	Growth	Factor	Receptor	Alpha	 Mm01211685_m1	Pdgfrb	 Platelet	Derived	Growth	Factor	Receptor	Beta	 Mm01262489_m1	Peg3	 Paternally	expressed	3	 Mm01337379_m1	Peg	10	 Paternally	expressed	10	 Mm01167724_m1	Plagl1	 Pleiomorphic	adenoma	gene-like	1	 Mm00494251_m1	Pparg	 peroxisome	proliferator	activated	receptor	gamma	 Mm01184322_m1	Pparg	 Peroxisome	proliferator	activated	receptor	gamma	 Mm01184322_m1	Ppargc1a	 peroxisome	proliferative	activated	receptor,	gamma,	coactivator	1	alpha	 Mm01208835_m1	Runx2	 Runt	Related	Transcription	Factor	2	 Mm00501580_m1	Ucp1	 uncoupling	protein	1	 Mm01244861_m1		All	TaqMan	assays	have	been	purchased	from	ThermoFisher	Scientific,	Waltham,	US.	
2.1.9	Indication	of	utilized	miRNA	TaqMan	assays		
miRNA	TaqMan	
Assay	
TaqMan	ID	 Mature	miRNA	Sequence/Control	
Sequence	(5’	®	3’)	snoRNA429	 001240	 AAACAGTCTCCCTCTTCTGAATCTCGCTGAGGAAACTGCACGTCACCCTCCTGAAA	mmu-miR-675-5p	 mmu482834_mir	 UGGUGCGGAAAGGGCCCACAGU	mmu-miR-675-3p	 mmu-miR-675-3p	 CUGUAUGCCCUAACCGCUCAGU		
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2.1.10	 Sequences	 of	 oligonucleotides	 used	 for	 qRT-PCR	 quantification	 of	 gene	
expression	using	SYBR	method		
Nucleotide	
oligo	
Sequence	(5´->	3´)	 Type	Adipoq_F	 CGTGATGGCAGAGATGGCACTC	 Adipogenesis	(Late	marker)	Adipoq_R	 CCTTAGGACCAAGAAGACCTGCATC	Afg3l2_F	 GTTGATGGGCAATACGTCTGG	 Mitochondrial	Biogenesis	Afg3l2_R	 GACCCGGTTCTCCCCTTCT	CD24_F	 TGCTCCTACCCACGCAGATT	 Adipocyte	Progenitor	Marker	CD24_R	 GCGTTACTTGGATTTGGGGAAGCA	CD29_F	 GGACCTTTTGGGTTGAGCTTATT	 Adipocyte	Progenitor	Marker	CD29_R	 AAAAAGTCTAACCCCCATATTGGA	Cdkn1c_F	 CCGGTCGAGGAGCAGAAT	 Imprinted	Gene	(MEG)	Cdkn1c_R	 TTCGACGCCTTGTTCTCCT	Cox4i1_F	 ACCAAGCGAATGCTGGACAT	 Mitochondrial	Biogenesis	Cox4i1_R	 GGCGGAGAAGCCCTGAA	Cox7a1_F	 CAGCGTCATGGTCAGTCTGT	 Mitochondrial	Biogenesis	Cox7a1_R	 AGAAAACCGTGTGGCAGAGA	Cox8b_F	 GAACCATGAAGCCAACGACT	 Mitochondrial	Biogenesis	Cox8b_R	 GCGAAGTTCACAGTGGTTCC	Cebpa_F	 GAACAGCTGAGCCGTGAACT	 Adipogenesis	(Transcription	Factor)	Cebpa_R	 AAACCATCCTCTGGGTCTCC	Drp1_F	 CAGGAATTGTTACGGTTCCCTAA	 Mitochondrial	Fission	/	Fusion	Drp1_R	 CCTGAATTAACTTGTCCCGTGA	Fabp4_F	 TTCGATGAAATCACCGCAGA	 Adipogenesis	(Late	marker)	Fabp4_R	 AGGGCCCCGCCATCT	Fis1_F	 AGAGCACGCAATTTGAATATGCC	 Mitochondrial	Fission	/	Fusion	Fis1_R	 ATAGTCCCGCTGTTCCTCTTT	Gata2_F	 AACGCCTGTGGCCTCTACTA	 Adipocyte	Progenitor	Marker	Gata2_R	 TGCTGGACATCTTCCGATTC	H19_F	 AGTGATCGGTGTCTCGAAGAG	 Imprinted	Gene	(MEG)	H19_R	 CCTTCTGTCCTCTCCATCAC	hnNctc1_F	 CCCTATCTGCAATGTTTTCCT	 Nuclear	localisation	marker	hnNctc1_R	 GATGGTGCGTATTGTTGCTA	Igf2r_F	 ACACCTACTACTTGCGGGTC	 Imprinted	Gene	(MEG)	Igf2r_R	 ATAGATGGTTGTGGAGCGCT	Ly6a_F	 GTTTGCTGATTCTTCTTGTGGCCC	 Adipocyte	Progenitor	Marker	Ly6a_r	 ACTGCTGCCTCCTGAGTAACAC	Mff_F	 ATGCCAGTGTGATAATGCAAGT	 Mitochondrial	Fission	/	Fusion	Mff_R	 CTCGGCTCTCTTCGCTTTG	Mfn1_F	 ATGGCAGAAACGGTATCTCCA	 Mitochondrial	Fission	/	Fusion	Mfn1_R	 GCCCTCAGTAACAAACTCCAGT	Mfn2_F	 AGAACTGGACCCGGTTACCA	 Mitochondrial	Fission	/	Fusion	Mfn2_R	 CACTTCGCTGATACCCCTGA	Mrpl12_F	 GCCACCGAAGGAGTGAAGC	 Mitochondrial	Biogenesis	Mrpl12_R	 GGAGCGTAAGGCTGGCAAT	Nctc1_F	 CCACCAAAGCAGAAGACCAC	 Imprinted	Gene	(PEG)	
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Nctc1_R	 TGATAGTCCTGGTGTGGTGG	Ndufaf2_F	 CACGGACCATCTGGGGAAC	 Mitochondrial	Biogenesis	Ndufaf2_R	 CTTTTCTCTCGAATAGTCTGCCC	Ndufaf7_F	 ATCTTCGGGGAGCTACTAGGG	 Mitochondrial	Biogenesis	Ndufaf7_R	 ATGGCACAGGTCTTTAGCACA	Ndufs2_F	 TCGTGCTGGAACTGAGTGGA	 Mitochondrial	Biogenesis	NdufS2_R	 GGCCTGTTCATTACACATCATGG	Ndufv2_F	 GGCTACCTATCTCCGCTATGA	 Mitochondrial	Biogenesis	Ndufv2_R	 TCCCAACTGGCTTTCGATTATAC	Nrf1_F	 TATGGCGGAAGTAATGAAAGACG	 Mitochondrial	Biogenesis	Nrf1_R	 CAACGTAAGCTCTGCCTTGTT	Nrf2_F	 CTTTAGTCAGCGACAGAAGGAC	 Mitochondrial	Biogenesis	Nrf2_R	 AGGCATCTTGTTTGGGAATGTG	Opa1_F	 TGGAAAATGGTTCGAGAGTCAG	 Mitochondrial	Fission	/	Fusion	Opa1_R	 CATTCCGTCTCTAGGTTAAAGCG	Peg10_F	 AGAGCAGCCAACCGAGAAG	 Imprinted	Gene	(PEG)	Peg10_R	 TCGTGGTTGGCGTCTTTTG	Plagl1_F	 TCGTCACCCTGGAGAAGTTC	 Imprinted	Gene	(PEG)	Plagl1_R	 ATCTTGTTGGGATCGTGGGT	Polg_F	 ATCTTGTTGGGATCGTGGGT	 Mitochondrial	Biogenesis	Polg_R	 CAG	GTA	GGA	CAC	ACC	CAT	CT	Ppara_F	 AGAGCCCCATCTGTCCTCTC	 Adipogenesis	(Transcription	Factor)	Ppara_R	 ACTGGTAGTCTGCAAAACCAAA	Pparg_F	 GCATGGTGCCTTCGCTGA	 Adipogenesis	(Transcription	Factor)	Pparg_R	 TGGCATCTCTGTGTCAACCATG	Ppargc1a_F	 CCGATCACCATATTCCAGGT	 Adipogenesis	(Cofactor)	Ppargc1a_R	 GTGTGCGGTGTCTGTAGTGG	Ppargc1a_F	 TATGGAGTGACATAGAGTGTGCT	 Mitochondrial	Biogenesis	Ppargc1a_R	 CCACTTCAATCCACCCAGAAAG	Prdm16_F	 CACAGCACGGTGAAGCCATTC	 Adipogenesis	(Cofactor)	Prdm16_R	 GGCGTGCATCCGCTTGTG	Rnu6b_F	 GCTCGCTTCGGCAGCACA	 Nuclear	localisation	marker	Rnu6b_R	 AACGCTTCACGAATTTGCGTG	Sdha_F	 GAACACTCCAAAAACAGACCTGC	 Mitochondrial	Biogenesis	Sdha_R	 TCCACCACTGGGTATTGAGTAG	Slc22a3_F	 CCTGGATGACTTGCTTCGTG	 Imprinted	Gene	(MEG)	Slc22a3_R	 AGAGAAAGCTGGGCAGAGAG	Ucp1_F	 AGCTGTGCGATGTCCATGTAC	 Uncoupling	Protein	Ucp1_R	 TGATGACGTTCCAGGACC	Tgfb2_F	 TGGAGTTCAGACACTCAACACA	 Adipocyte	Progenitor	Marker	Tgfb2_R	 GTTCCAGATCCTGGGACACA	Uqcr10_F	 CGAGCGAGCCTTCGATCAG	 Mitochondrial	Biogenesis	Uqcr10_R	 ACAGTTTCCCCTCGTTGATGT		If	not	stated	otherwise	all	primers	were	designed	using	the	Primer3web	online	tool.	All	primer	 oligonucleotides	 were	 purchased	 in	 100	 pmole	 stocks	 from	 Sigma-Aldrich	Chemie	GmbH,	Schnelldorf,	DE.		
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2.1.11	List	of	utilized	Locked	Nucleic	Acid	(LNA)	GapmeR	inhibitors		
LNA	Power	Inhibitor	 Sequence	(5’	®	3’)	 Manufacturer	Negative	Control	A,	scr	LNA	 AACACGTCTATACGC	 Exiqon	(Vedbaek,	DK)	H19_3	LNA,	Imprinted	Maternally	Expressed	Transcript	(Non-Protein	Coding)	
GGCAAAGGATGAAGTA		 Exiqon	(Vedbaek,	DK)	
H19_2	LNA,	Imprinted	Maternally	Expressed	Transcript	(Non-Protein	Coding)	
CCTTGCTGTAAAATC		 Exiqon	(Vedbaek,	DK)	
	All	LNA	GapmeRs	have	been	purchased	from	Exiqon	A/S,	Vedbaek,	DK.	
2.1.12	List	of	utilized	small	interfering	RNAs	(siRNAs)		
LNA	Power	Inhibitor	 Sequence	(5’	®	3’)	 Manufacturer	Negative	Control	A,	scr	LNA	 GUCUCGUUCUGAAUCAAGAtt,	UCUUGAUUCAGAACGAGACgg	 Invitrogen		
2.1.13	Enzymes		
Enzymes		 Manufacturer	 Reference	Dispase	II		 Roche	Diagnostics	GmbH,	Mannheim,	DE	 4942078001	DNAse	I	 Roche	Diagnostics	GmbH,	Mannheim,	DE	 10104159001	Dream	Taq	DNA	Polymerase	 Thermo	Fisher	Scientific	(Waltham,	MA,	USA)	 EP0705	Proteinase	K,	recombinant,	PCR	grade		 Roche	Diagnostics	GmbH,	Mannheim,	DE	 3115844001	RNase	A,	DNase	and	protease-free	(10	mg/ml)	 Thermo	Fisher	Scientific,	Waltham,	US	 EN0531		
2.1.14	Software		
Software	 Manufacturer	 Version	ImageJ	 Wayne	Rasband/NIH	 version	1.48v	Keynote	 Apple	Inc.	 version	8.0.1	Mendeley	 Elsevier	 Version	1.18	NanoDrop™	1000	software	 Thermo	Fisher	Scientific	Inc.	 version	3.8.1	Primer3web	 web-based	application,	http://primer3.ut.ee/	[March,	2018]	 version	4.1.0	
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Prism	 GraphPad	Software	Inc.	 version	7.0c	PyRAT	 Scionics	Computer	Innovation	GmbH	 version	3.6-365	QuantStudio™	6	 Applied	Biosystems	 version	1.3	
	
2.2	Cell	biology	methods			All	 methods	 described	 in	 this	 section	 were	 performed	 under	 a	 Mars	 Safety	 Class	 2	Laminar	 Airflow	 Cabinet	 (LaboGene).	 Incubation	 steps	 were	 performed	 in	 a	 CO2	Incubator	CB	160	(Binder)	at	37	°C	and	5	%	CO2.	
2.2.1	Mycoplasma	test		Prior	 to	 usage,	 cells	 were	 tested	 for	 mycoplasma	 contamination	 using	 the	 PCR	Mycoplasma	 Test	 Kit	 according	 to	 the	 manufacturer´s	 protocol.	 PCRs	 products	 of	mycoplasma-positive	 samples	 are	 270	 bp	 in	 size.	 Cells	 were	 discarded	 if	 the	 test	outcome	was	positive.		
2.2.2	Cryoconservation		For	cryoconservation,	cells	were	expanded	prior	to	freezing.	Freezing	medium	(DMSO	in	growth	medium	1:10)	was	prepared	and	stored	on	ice.	The	medium	was	aspirated	and	followed	by	a	wash	with	1x	PBS.	Subsequently,	PBS	was	removed	and	5	ml	1x	Trypsin	was	 added	 to	 each	 15	 cm	 plate.	 After	 a	 10	 min	 incubation	 at	 37°C,	 5	 ml	 of	 growth	medium	 was	 added	 and	 the	 cell	 suspension	 was	 transferred	 to	 a	 15	 ml	 tube	 and	centrifuged	at	1200	rpm	for	5	min.	The	cell	pellet	was	resuspended	in	freezing	medium	after	aspiration	of	the	medium.	1	ml	of	cell	suspension	was	added	to	1	cryotube	(1x	15	cm	plate	was	used	for	3x	cryotubes).	The	tubes	were	stored	in	a	freezing	container	at	–	80	°C	and	transferred	to	liquid	nitrogen	after	two	weeks.		
2.2.3	Reconstitution	of	cryopreserved	stocks		For	the	reconstitution	of	cells	from	the	cryopreserved	stocks,	growth	medium	was	pre-warmed	 to	37	 °C.	9	ml	of	growth	medium	was	 transferred	 to	a	15	ml	 falcon	 tube	and	stored	 at	 37	 °C.	 The	 sample	 was	 kept	 on	 dry	 ice	 and	 500	 µl	 of	 pre-warmed	 growth	medium	was	used	for	resuspension	in	warm	growth	medium.	After	thawing,	cells	were	transferred	 to	 a	 15	 ml	 falcon	 tube	 and	 centrifuged	 at	 1200	 rpm	 for	 5	 min	 at	 room	temperature	 (RTemp).	 The	 supernatant	with	DMSO	was	 aspirated	 and	 discarded	 into	DMSO-waste.	After	resuspension	in	10	ml	medium,	the	cells	were	plated	in	two	different	
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concentrations	(1:10	and	1:1,11).	Afterwards,	the	cells	were	incubated	at	37	°C	with	5%	CO2.	Cells	were	passaged	every	2-3	days	and	split	in	a	ratio	of	1:10	or	1:20.		
2.2.4	Primary	immortalized	brown	pre-adipocyte	(PIBA)	cell	line	
2.2.4.1	Cultivation	and	passage	of	the	PIBA	cell	line		Primary	immortalized	brown	pre-adipocyte	(PIBA)	cells	were	generated	in-house	using	standard	protocols203	and	maintained	in	Dulbecco´s	modified	Eagle´s	medium	(DMEM)	growth	medium	containing	4.5	g	l-1	glucose	supplemented	with	10%	fetal	bovine	serum	(FCS),	 1%	 L-glutamine,	 1%	 penicillin/streptomycin	 (P/S),	 1%	 minimum	 essential	medium	 non-essential	 amino	 acids	 (MEM	 NEAA),	 and	 1%	 sodium	 pyruvate.	 For	passaging,	 cells	were	 grown	 in	 growth	medium	 until	 states	 of	 80-90%	 confluency.	 At	this	stage,	 the	medium	was	aspirated	and	cells	cultured	 in	15	cm	dishes	were	washed	with	10	ml	of	1x	PBS.	Next,	cells	were	detached	using	5	ml	of	1x	Trypsin,	for	which	the	plate	was	 stored	 at	 37	 °C	 for	 10	min.	 5	ml	 of	 growth	medium	was	 added	 to	 stop	 the	Trypsin	activity,	followed	by	transfer	to	a	15	ml	falcon	tube.	The	tube	was	centrifuged	at	1200	rpm	for	5	min	and	the	supernatant	was	aspirated.	10	ml	growth	medium	was	used	for	 pellet	 resuspension	 and	 cells	 were	 seeded	 in	 a	 ratio	 of	 1:10	 or	 1:20.	 Cells	 were	incubated	 at	 37	 °C	 and	 5%	 CO2	 and	 passaged	 every	 2-3	 days	 at	 approximately	 80%	confluency.	Modified	after	Schmidt	et	al.	(2018)204.	
2.2.4.2	Induction	of	adipogenesis		Prior	to	the	induction	of	adipogenesis,	cells	were	grown	until	confluent	in	differentiation	medium	 (DMEM,	 20	 nM	 insulin,	 1	 nM	 T3).	 The	 differentiation	 process	 to	 brown	adipocytes	was	induced	via	one-day	incubation	in	differentiation	medium	supplemented	with	 0.125	 mM	 indomethacin,	 2	 mg/1	 dexamethasone	 and	 0.5	 mM	isobutylmethylxanthine	 and	 subsequent	 incubation	 in	 differentiation	 medium	 for	 5	days.	Modified	after	Schmidt	et	al.	(2018)204.	
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2.2.4.3	LNA	mediated	gene	knockdown	of	PIBA	cells			For	 transfection	 with	 LNA	 GapmeRs,	 cells	 were	 cultivated	 until	 confluent	 in	differentiation	medium	(growth	medium,	20	nM	insulin,	1	nM	T3).	To	carry	out	lncRNA-mediated	 inhibition,	 custom-made	 LNA	 GapmeRs	 (sequences	 are	 provided	 in	2.1.11)	were	 transfected	 once	 the	 cells	 reached	 confluency.	 Lipofectamine	 2000	 was	 diluted	1:62,5	 in	Opti-MEM.	 To	 achieve	 a	 final	 concentration	 of	 25	 nM,	 the	 appropriate	 LNAs	(stock	 concentration	10	µM)	were	diluted	1:50	 in	Opti-MEM.	After	 incubation	 of	 both	solutions	 at	 RTemp	 for	 5	min,	 LNA	 and	 Lipofectamine	 solutions	were	mixed	 at	 equal	volumes	 and	 incubated	 for	 20	min	 at	RTemp.	 Pre-warmed	PBS	was	used	 to	wash	 the	cells	and	750	µl	of	growth	medium	without	P/S	was	added	to	each	well.	250	µl	of	 the	LNA/Lipofectamine	mix	was	added	and	the	cells	were	 incubated	for	24	h	at	37	°C	and	5%	CO2,	before	exchanging	the	medium	to	induction	medium.	Differentiation	of	brown	adipocytes	 was	 induced	 using	 differentiation	 medium	 supplemented	 with	 0.125	 mM	indomethacin,	 2	 mg/l	 dexamethasone	 and	 0.5	 mM	 isobutylmethylxanthine	 for	 1	 day,	followed	 by	 incubation	 in	 differentiation	 medium	 for	 5	 more	 days.	 Modified	 after	Schmidt	et	al.	(2018)204.	
2.2.5	Primary	cell	culture	
2.2.5.1	Isolation	of	adipose-depots	specific	stromal	vascular	fraction	(SVF)	cells			In	 order	 to	 isolate	 depot-specific	 SVF	 cells,	 the	 mice	 were	 sacrificed	 by	 cervical	dislocation.	Next,	the	interscapular	BAT,	posterior	inguinal	subcutaneous	(scWAT),	and	perigonadal	visceral	(vWAT)	tissue	of	5-6	weeks	old	male	C57BL/6	N	or	H19	TG	mice	was	 isolated	 and	 transferred	 into	 pre-warmed	 DMEM/Ham’s	 F-12	 medium	 without	supplements.	Tissue	samples	were	pooled	according	to	genotype	and	AT	depot	to	obtain	sufficient	 cell	 numbers	 for	 cultivation.	 In	 a	 sterile	 environment,	 the	 medium	 was	aspirated	 before	 cutting	 the	 AT	 into	 1	 mm	 x	 1	 mm	 pieces	 to	 reach	 homogenized	consistency.	 Homogenized	 tissue	 was	 collected	 in	 a	 50	 ml	 tube	 filled	 with	 10	 ml	DMEM/Ham’s	F-12	medium	without	supplements.	For	debris	removal,	5	ml	of	the	lower	aqueous	phase	was	aspirated,	5	ml	serum-free	DMEM/Ham’s	F-12	medium	was	added,	and	in	a	final	wash	5	ml	of	the	infranatant	was	removed.	1	mg/ml	Collagenase	II,	1.5%	BSA,	 6.6	ml	 serum-free	medium,	 and	100	µl	DNase	 (15kU/ml)	was	prepared	 for	 each	scWAT	and	vWAT	sample.	Each	BAT	sample	received	the	aforementioned	reagents	as	in	
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addition	 to	 240	 µl	 Dispase	 I	 (50	 U/ml).	 To	 each	 AT	 preparation,	 10	ml	 of	 the	mixed	enzyme	 solution	 was	 added.	 Next,	 the	 tubes	 were	 placed	 in	 a	 37°C	 water	 bath	 and	shaken	 at	 120	 rpm	 for	 15	min.	After	 vigorous	 inversion	of	 the	 samples	 by	hand,	 they	were	 placed	 on	 a	 shaking	 incubator	 at	 37°C	 for	 another	 15	 min	 at	 120	 rpm.	 For	purification,	 the	 cell	 suspension	 was	 filtered	 through	 100	 µm	 EASYstrainer™	 Cell	Strainer	 into	 a	 50	 ml	 tube	 filled	 with	 20	 ml	 DMEM/Ham’s	 F-12	 growth	 medium	(DMEM/Ham´s	F12	medium	plus	10%	Fetal	Calf	Serum,	1%	P/S,	0.1%	Biotin,	and	0.1%	pantothenic	 acid).	 The	 suspension	 was	 centrifuged	 at	 200	 g	 at	 21°C	 for	 5	 min.	 The	supernatant	was	discarded	and	 the	pellets	were	 resuspended	 in	1	ml	growth	medium	and	filled	up	to	10	ml.	The	cells	were	then	centrifuged	at	200	g	for	5	min	at	21°C	and	the	medium	was	aspirated	down	to	1	ml,	the	pellet	was	resuspended	and	transferred	into	a	15	ml	tube.	Growth	medium	was	added	to	reach	13	ml	and	centrifuged	for	5	min	on	21°C	and	with	200	g.	Next,	supernatants	were	aspirated	and	pellets	were	resuspended	in	1	ml	Erythrocyte	 Lysis	 Buffer	 for	 5	min.	 Once	 again	 the	 tubes	were	 filled	 up	 to	 13	ml	 and	centrifuged	for	5	min	at	21°C	and	with	200	g.	The	supernatant	was	aspirated	down	to	1	ml,	 which	 was	 used	 for	 resuspension	 of	 the	 pellet	 containing	 the	 SVF.	 The	 cell	suspension	 was	 filtered	 through	 a	 30	 µm	 Partec	 CellTrics®	 filters	 (Sysmex	 Partec,	Görlitz,	Germany)	dampened	with	500	µl	growth	medium.	After	filtration,	the	filter	was	rinsed	 with	 500	 µl	 growth	 medium	 and	 isolated	 cells	 quantified	 using	 a	 Neubauer	Counting	 Chamber	 to	 seed	 50,000	 cells/well	 in	 a	 flat	 bottom	 24-well	 Falcon™	 tissue	culture	plate.	The	 cells	were	 incubated	at	37	 °C	with	5%	CO2	until	 confluenct	 and	 the	medium	was	changed	daily.	Modified	after	Schmidt	et	al.	(2018)204.	
2.2.5.2	Induction	of	SVF	adipogenesis		To	induce	the	SVFs	isolated	from	scWAT	and	vWAT	into	mature	adipocytes,	a	cocktail	of	freshly	 prepared	 0.05%	 Insulin,	 0.005%	 Dexamethasone,	 0.001%	 Rosiglitazone,	 and	0.05%	3-Isobutyl-1-methylxanthin	(IBMX)	 in	growth	medium	(induction	medium)	was	added	 to	 fully	 confluent	 cells.	 In	 order	 to	 induce	 BAT-isolated	 SVFs	 into	 mature	adipocytes,	 a	mix	 of	 freshly	 prepared	0.05%	 Insulin,	 0.005%	Dexamethasone,	 0.001%	Rosiglitazone,	 0.05%	 3-Isobutyl-1-methylxanthin	 (IBMX),	 0.1%	 Indomethazine,	 and	0.001%	 Triiodothyronine	 in	 growth	 medium	 (induction	 medium)	 was	 added	 to	 fully	confluent	 cells.	 After	 48h	 of	 induction,	 cell	 differentiation	 was	 initiated	 using	 freshly	prepared	 0.0015%	 Rosiglitazone	 (scWAT	 and	 vWAT)	 or	 0.001%	 Triiodothyronine	
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(BAT)	 in	 growth	 medium	 (differentiation	 medium)	 which	 was	 exchanged	 every	 24h.	After	 48	 -72h	 incubation	with	 primary	 adipogenic	 differentiation	medium,	 the	 vWAT	and	 BAT	 were	 considered	 fully	 differentiated	 whereas	 scWAT	 usually	 differentiated	after	a	72-96	h	incubation	period.	Modified	after	Schmidt	et	al.	(2018)204.	Details	of	the	media	composition	are	shown	in	Table	1.		
Table	1:	Composition	of	media	used	for	primary	cell	culture	Media		 Supplementation	Primary	growth	medium		 10	%	(v/v)	FCS	1	%	(v/v)	Penicillin/Streptomycin	0.1	%	(v/v)	Biotin	(stock	33	mM	in	0.1	M	NaOH)	0.1	%	(v/v)	D-Pantothenic	acid	(stock	17	mM	in	H2O)		in	DMEM/Ham’s	F-12	(1:1)	(1x)		Primary	brown	adipogenic	induction	 1	μM	Rosiglitazone	850	nM	Insulin	1	μM	Dexamethasone	250	μM	IBMX	125	nM	Indomethacin	1	nM	T3	in	primary	growth	medium		Primary	white	adipogenic	induction	 1	μM	Rosiglitazone	850	nM	Insulin	1	μM	Dexamethasone	250	μM	IBMX	in	primary	growth	medium		Primary	brown	adipogenic	differentiation	 1	μM	Rosiglitazone	1	nM	T3	in	primary	growth	medium		Primary	white	adipogenic	differentiation	 1	μM	Rosiglitazone	in	primary	growth	medium		
2.2.5.3	LNA	mediated	gene	knockdown	of	primary	adipocytes		Primary	brown	adipocytes	were	isolated	from	depots-specific	SVFs	as	described	above.	For	lncRNA	inhibiton,	confluent	cells	were	transfected	with	custom-made	LNA	GapmeRs	(sequences	 are	 provided	 in	 2.1.11).	 Lipofectamine	 2000	 was	 diluted	 1:62,5	 in	 Opti-MEM.	For	a	 final	concentration	of	25	nM,	 the	respective	LNAs	(stock	concentration	10	µM)	were	diluted	1:50	 in	Opti-MEM.	Both	solutions	were	 incubated	 for	5	min	at	room	
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temperature.	 LNA	 and	 Lipofectamine	 solutions	 were	 mixed	 at	 equal	 volumes	 and	incubated	for	20	min	at	RTemp.	Cells	were	washed	with	pre-warmed	PBS	and	750	µl	of	growth	medium	without	P/S	was	added	to	each	well.	250	µl	of	LNA/Lipofectamine	mix	was	added	and	cells	incubated	for	24	h	at	37	°C	and	5%	CO2	before	exchanging	for	the	induction	medium.	Modified	after	Schmidt	et	al.	(2018)204.	
2.2.5.4	siRNA	mediated	gene	knockdown	of	primary	adipocytes		SiRNAs	 targeting	H19	 (siH19,	oligo	n253571)	or	non-targeting	Control	 (siCtrl,	Cat.	No.	4390843;	both	100nmol/l,	Invitrogen)	were	delivered	into	1°	BAT	adipocytes	by	Amaxa	nucleofection	 (Lonza	Bioscience)	 according	 to	 the	manufacturer´s	protocol.	 Cells	were	utilized	 48-72	 h	 after	 transfection.	 SiRNA	 sequences	 are	 provided	 in	2.1.12.	Modified	after	Schmidt	et	al.	(2018)204.	
2.2.5.5	Subcellular	fractionation	protocol		For	subcellular	localization	analyses,	RNAs	were	purified	from	nuclear	and	cytoplasmic	fractions	 obtained	 using	 the	 PARIS	 kit	 (Ambion)	 according	 to	 the	 manufacturer´s	protocol.	Modified	after	Schmidt	et	al.	(2018)204.		
2.2.6	Determination	of	oxygen	consumption	rates	(OCR)		SVF	from	indicated	AT	depots	were	isolated	and	cells	were	seeded	into	Agilent	Seahorse	XFe96	 Bioanalyzer	 microplates.	 50,000	 cells	 were	 seeded	 per	 well	 and	 incubated	 in	DMEM/Ham´s	F12	medium	plus	10%	Fetal	Calf	Serum,	1%	P/S,	0.1%	Biotin,	and	0.1%	Pantothenic	acid	 (Growth	medium)	at	37	 °C	and	5%	CO2	 in	a	standard	 incubator	until	confluent.	 For	 lncRNA	 inhibition	 cells	were	 transfected	 as	 described	 in	2.2.5.3	 in	 the	Seahorse	setup.	For	this,	cells	were	washed	with	pre-warmed	PBS	and	75	µl	of	growth	medium	w/o	P/S	added	 to	each	well.	25	µl	of	LNA/Lipofectamine	mix	was	added	and	cells	 were	 incubated	 for	 24	 h	 at	 37°C	 and	 5%	 CO2	 before	 changing	 the	 medium	 to	induction	 medium.	 A	 cocktail	 of	 freshly	 prepared	 0.05%	 insulin,	 0.005%	Dexamethasone,	 0.001%	Rosiglitazone,	 and	 0.05%	 IBMX	 (scWAT	 and	 vWAT)	 or	 0.1%	Indomethazine,	0.001%	Triiodothyronine	(BAT)	in	growth	medium	(induction	medium)	was	used	to	induce	commitment	of	SVFs	into	mature	adipocytes	directly	in	the	Seahorse	microplates.	After	48	h	of	induction,	differentiation	was	initiated	using	freshly	prepared	0.001%	 Rosiglitazone	 (scWAT	 and	 vWAT)	 and	 0.001%	 Triiodothyronine	 (BAT)	 in	
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growth	 medium	 (differentiation	 medium).	 3-4	 days	 of	 incubation	 in	 differentiation	medium	 was	 sufficient	 for	 cell	 differentiation.	 For	 each	 Seahorse	 plate	 the	corresponding	 calibration	 plate	 was	 prepared	 24	 h	 prior	 to	 experiments,	 which	contained	200	µl	XF	Seahorse	Calibrant	Agilent	per	well.	The	plate	was	incubated	for	24	h	in	a	non-CO2	incubator	at	37	°C	and	the	instrument	was	set	to	37	°C,	24	h	before	the	start	 of	 the	 experiment.	 The	 cells	 were	 washed	 with	 PBS	 and	 the	 medium	 was	exchanged	an	hour	before	 the	experiment,	according	 to	 the	corresponding	experiment	analysis	kit	(MitoStressKit,	provided	by	the	manufacturer).	The	calibration	was	carried	out	using	calibration	plates,	measuring	O2,	and	pH	LED	Value/emission/Initial	reference	Delta	for	each	well,	before	sample	measurement.	After	calibration,	cartridges	were	kept	within	 the	 machine	 and	 the	 measurement	 of	 adipocyte-containing	 microplates	commenced.	 The	 measurement	 parameters	 wereas	 follows:	 Mix:	 3	 min,	 wait	 0	 min,	measure	3	min	with	each	reagent´s	effect	assessed	within	3	min	(MitoStressKit)	with	a	total	duration	of	18	min	or	24	min	per	reagent	injection.	All	measurements	started	with	measuring	basal	values,	followed	by	the	injection	of	Oligomycin,	FCCP,	and	Rotenone	+	Antimycin	A	(MitoStressKit).			For	MitoStress	Kits,	corresponding	media	were	freshly	prepared	before	the	experiment	and	 consisted	 of	 Basal	 Seahorse	 Medium	 supplemented	 with	 25	 mM	 Glucose,	 1	 mM	Glutamine,	2	mM	Sodium	Pyruvate,	 (pH	=	7,4)	 that	were	 filtered	sterile.	Subsequently,	medium	of	 the	 Seahorse	 cell	 plates	was	 aspirated	and	180	µl	MitoStress	medium	was	added	1	h	prior	to	calibration.	The	plate	was	stored	in	a	non-CO2	incubator	at	37	°C	for	1	h.	 Part	 of	 the	 calibration	 plate	 was	 a	 cartridge	 with	 4	 pockets	 per	 well.	 Prior	 to	measurement,	pocket	A	was	filled	with	20	µl	10	µM	Oligomycin,	pocket	B	with	22	µl	10	µM	 FCCP,	 and	 pocket	 C	 with	 25	 µl	 5	 µM	 Antimycin	 A	 and	 Rotenone.	 Modified	 after	Schmidt	et	al.	(2018)204.		
2.3	Total	RNA	isolation	
2.3.1	Trizol	based	method		Total	RNA	was	 isolated	 from	primary	adipocytes	and	 tissues	using	peqGOLD	TriFast™	(PEQLAB	Biotechnologies).	500µl	of	peqGOLD	TriFast™	was	used	for	cells	whereas	1	ml	was	 used	 for	 isolated	 tissue	 sections.	 The	 samples	 were	 stored	 for	 10	 min	 at	 room	temperature.	 Afterwards,	 the	 RNA	 was	 isolated	 according	 to	 the	 manufacturer´s	
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protocol.	RNA	was	finally	resuspended	in	50	µl	of	DEPC-H20	(0,1%	DEPC).	Subsequently,	the	concentration	of	RNA	was	quantified	using	a	Nanodrop	Spectrophotometer	ND-1000	(Thermo	Fisher	Scientific).		
2.3.2	miRVana	kit		For	RNA	sequencing,	RNA	of	tissues	was	isolated	using	the	manufacturer´s	instructions	of	the	total	RNA	isolation	procedure	of	the	mirVana	miRNA	isolation	kit.			
2.4	Real-time	quantitative	RT-PCR	(qRT-PCR)	
2.4.1	Reverse	Transcription	from	total	RNA	to	cDNA			In	order	to	convert	single-stranded	RNA	molecules	into	double-stranded	complimentary	DNA	 (cDNA)	 molecules,	 total	 RNA	 solutions	 were	 subjected	 to	 reverse	 transcription	using	 the	 High-Capacity	 cDNA	 Reverse	 Transcription	 Kit	 according	 to	 the	manufacturer´s	protocol.	The	synthesis	of	cDNA	molecules	 in	 this	protocol	 is	based	on	random	hexamer	 primers,	which	 allow	 conversion	 of	 all	 possible	RNA	 sequences.	 For	the	preparation	of	the	reaction,	1	µg	of	total	RNA	in	10	µl	was	added	to	the	master	mix	indicated	in	the	table	below.	
	
Table	2:	Composition	of	RT	master	mix	for	total	cDNA.	Reagent	 Volume[µl]	10x	RT	buffer	 2,0	dNTPs	 0,8	Random	hexamer	primers	 2,0	H20	 4,2	Reverse	Transcriptase	 1,0		Reverse	 transcription	of	 total	RNA	was	performed	 in	FlexCycler2	 PCR	 cycler	using	 the	following	program:			Primer	annealing	 	 25°C		 10´	Reverse	transcription		 37°C		 120´	Enzyme	inactivation		 85°C		 5´	Final	hold		 	 	 4°C	 ¥		After	 the	RT-PCR	reaction,	180µl	MPW	was	added	 to	 the	cDNA	and	stored	at	 -20°C	or	directly	used	for	RNA	expression	analysis	in	quantitative	PCR	(qRT-PCR)	experiments.		
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2.4.2	Quantitative	RT-PCR	(qRT-PCR)	analysis		For	quantification	of	 the	expression	of	specific	RNA	molecules,	cDNA	was	subjected	 to	quantitative	 PCR	 (qRT-PCR)	 analysis	 using	 a	 QuantStudioÔ	 7	 Flex	 Real-Time	 PCR	System.	 For	 RNA	 molecules	 with	 commercially	 available	 gene	 expression	 assays,	 the	TaqMan	 Gene	 Expression	 Master	 Mix	 was	 used	 in	 combination	 with	 the	 respective	transcript-specific	TaqMan	Gene	Expression	Assays.	For	other	genes,	the	SYBRÔ	Select	Master	 Mix	 was	 used	 in	 combination	 with	 self-designed	 and	 DNA	 primers	 tested	 for	good	quality.			TaqMan-	based	qRT-PCRs		6	µl		 	 TaqMan	Master	Mix	0,3	µl		 	 TaqMan	probes	4	µl		 	 cDNA	solution			SYBR	Green-based	qRT-PCRs	5	µl		 	 SYBR	Select	Master	Mix	(10x)	4	µl		 	 cDNA	solution	1	µl		 	 SYBR	primer	mix	(5	µM)		
qRT-PCR	program	Initial	Denaturation		95°C		 2	min	Denaturation		 95°C		 30	sec	Annealing		 	 60°C		 30	sec			 40x	Elongation		 	 72°C	 1	min	Final	Elongation		 72°C		 5	min	Hold	 	 	 4°C			The	 relative	 abundance	 of	mRNAs	was	 calculated	 using	 comparative	methods	 (2-ddCT)	according	 to	 ABI	 Relative	 Quantification	 Methods.	 Transcript	 levels	 of	 mRNAs	 were	normalized	 to	 hypoxanthine	 phosphoribosyltransferase	 1	 (Hprt1)	 expression.	 Hprt	abundances	were	unaffected	across	all	experimental	conditions.	SYBR	primer	sequences	are	provided	in	2.1.10	and	utilized	TaqMan	assays	in	2.1.8.	
2.4.3	Reverse	Transcription	of	microRNAs	and	qRT-PCR		For	reverse	transcription	of	particular	miRNAs,	the	samples	were	diluted	1:50	to	have	a	concentration	 of	 4	 ng/µl	 and	 added	 to	 the	 master	 mix,	 shown	 in	 the	 table	 below.	
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Reagents	 of	 the	High	 Capacity	 cDNA	Reverse	 Transcription	 Kit	were	 used.	 The	 list	 of	miRNA	RT	primers	can	be	seen	in	the	Materials	section.		Reagents		0,15	µl		 100mM	dNTPs	1	µl		 	 MultiScribe	RT	1,5	µl		 	 10x	RT	buffer	1	µl		 	 of	each	TaqMan	MicroRNA	RT	primer		5	µl	 	 total	RNA	sample	up	to	15	µl		 DEPC-H20		Reverse	 transcription	of	 total	RNA	was	performed	 in	FlexCycler2	 PCR	 cycler	using	 the	following	program:			Primer	annealing	 	 16°C		 30´	Reverse	transcription		 42°C		 30´	Enzyme	inactivation		 85°C		 5´	Final	hold		 	 	 4°C	 ¥		After	the	RT-PCR	reaction,	75	µl	MPW	was	added	to	15	µl	of	the	RT	product	and	stored	at	 -20°C	 or	 directly	 used	 for	 RNA	 expression	 analysis	 in	 quantitative	 PCR	 (qRT-PCR)	experiments.	For	quantification	of	the	expression	of	specific	RNA	molecules,	cDNA	was	subjected	 to	 quantitative	 PCR	 (qRT-PCR)	 analysis	 using	 a	 QuantStudioÔ	 7	 Flex	 Real-Time	PCR	System.	9,5	µl	 of	 the	RT	product	was	 transferred	 to	 the	384-well	 plate	 and	10,5	µl	of	the	Master	mix	was	added.			TaqMan	MircoRNA	assay-	based	qRT-PCRs		10	µl			 	 TaqMan	Master	Mix	0,5	µl		 	 TaqMan	probes	9,5	µl		 	 cDNA	solution			
qRT-PCR	program	Initial	Denaturation		95°C		 2	min	Denaturation		 95°C		 30	sec	Annealing		 	 60°C		 30	sec			 40x	Elongation		 	 72°C	 1	min	Final	Elongation		 72°C		 5	min	Hold	 	 	 4°C			
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2.5	RNA	sequencing	
2.5.1	Mouse	RNA	isolation		RNA	of	tissue	samples	for	RNA	sequencing	was	isolated	using	the	miRVana	Isolation	Kit	following	 the	 protocol	 for	 total	 RNA	 isolation.	 RNA	 concentration	 and	 integrity	 was	assessed	 using	 the	 Experion	 Bioanalyzer	 system	 (Bio-Rad)	 according	 to	 the	manufacturer´s	 instructions.	 Furthermore,	 contaminating	DNA	was	 removed	using	 the	TURBO	DNA-freeä	kit	following	the	manufacturer´s	protocol.		
2.5.2	Deep	RNA-Sequencing	procedure		Library	preparation	and	sequencing	was	performed	at	 the	Max	Planck-Genome-Centre	Cologne,	 Germany.	 Quality	 checks	 were	 carried	 out	 for	 4°C-exposed	 versus	 22°C-exposed	samples	as	well	as	the	CD	versus	HFD	BAT	samples.	To	do	so,	1	µg	of	total	RNA	of	 each	 sample	 was	 depleted	 for	 rRNA	 using	 the	 NEBNextâ	 rRNA	 depletion	 Kit	(human/mouse/rat).	For	 library	preparation	NEBNext	Ultraä	Directional	RNA	Library	Prep	Kit	 for	Illumina	(New	England	Biolabs)	was	used.	All	 libraries	were	sequenced	in	parallel	on	a	HiSeq2500	instrument	(Illumina)	in	2	x	100bp	sequencing	mode.	Modified	after	Schmidt	et	al.	(2018)204.			RNA	 sequencing	 experiments	 were	 performed	 at	 the	 Cologne	 Center	 for	 Genomics,	Cologne,	DE	with	the	following	conditions:			Sample	input	 2	µg	of	total	RNA		rRNA	depletion		 Ribo-Zero	rRNA	Removal	Kit	(Illumina)	cDNA	library	preparation	 TruSeq	RNA	Library	Prep	Kit	v2	(Illumina)	Normalization	 ERCC	RNA	Spike-In	(ThermoFisher)	Sequencing	Platform		 HiSeq2500,	paired-end	flow	cells		Sequencing	condition	 2	x	100bp	read	length,	strand	specific		Sequencing	depth	 50-100	million	reads	per	sample		
2.5.3	Data	processing	of	deep	RNA-Sequencing		RNA-Seq	 data	 were	 processed	 using	 the	 QuickNGS	 analysis	 pipeline205,	 version	 1.2.7,	based	 on	 Ensembl	 release	 87.	 Reads	 were	 mapped	 to	 the	 GRCh38	 assembly	 of	 the	human	genome	using	Tophat2,	version	2.0.10,	and	reassembled	with	Cufflinks,	version	2.1.1.	 Differential	 gene	 expression	 was	 analysed	 using	 the	 DESeq2	 package,	 version	
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1.10.1.	Finally,	the	results	were	uploaded	to	the	QuickNGS	database	and	combined	with	multiple	annotations	using	the	biomaRt	package.	Modified	after	Schmidt	et	al.	(2018)204.		
2.6	Protein	biochemistry	
2.6.1	Protein	isolation		For	protein	isolation,	the	medium	of	cells	was	aspirated	and	the	plates	were	stored	on	ice.	The	cell	monolayer	was	washed	gently	1x	with	 ice-cold	1xPBS	and	the	excess	was	aspirated.	50	µl	of	RIPA	lysis	buffer	with	inhibitors	was	added	to	each	well	of	the	24-well	plate.	RIPA	buffer	was	composed	of	50	mM	Tris-HCl	pH	8,0,	150	mM	NaCl,	1%	NP-40	(IPEGAL	CA-630),	5	mM	EDTA,	0,5	%	sodium	deoxycholate,	0,1	%	of	10%	SDS,	0,2	M	b-glycerol	phosphate,	and	1	protease	inhibitor	tablet	(cOmplete,	Roche	Diagnostics)	for	10	ml	 of	 buffer.	 An	 ice-cold	 cell	 scraper	 was	 used	 to	 scrape	 the	 cells.	 The	 lysate	 was	transferred	to	1,5	ml	Eppendorf	tubes.	The	samples	were	snap-frozen	in	liquid	nitrogen	and	thawed	on	ice	for	three	repeated	cycles.	After	10	min	of	centrifugation	at	12,000	g	and	4°C	the	supernatant	was	transferred	to	fresh	tubes	and	stored	at	-80	°C.		
2.6.2	Protein	concentration	measurements		Protein	concentration	was	determined	following	the	manufacturer´s	instructions	of	the	Pierce	BCA	Protein	Assay	Kit.		
2.6.3	Sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)		Samples	were	 separated	by	SDS-PAGE	after	being	mixed	1:4	with	4x	Laemmli	 Sample	Buffer	(Bio-Rad)	containing	10%	b-mercaptoethanol	and	heated	to	95	°C	for	5	min.	20-40µl	of	protein	was	loaded	in	4-15%	gradient	gels	depending	on	the	concentration	of	the	protein.	PageRuler™	Prestained	Protein	Ladder	(ThermoScientific)	was	used	as	 ladder.	The	SDS-gel	was	run	for	about	1h	in	1x	SDS	running	buffer	at	100V.	Afterwards,	proteins	were	transferred	to	a	nitrocellulose	membrane	for	incubation	with	primary	antibodies.	For	the	transfer,	1x	transfer	buffer	+	20%	methanol	was	prepared.	The	membrane,	gel,	whatman	papers,	and	sponges	were	pre-wet	in	transfer	buffer.	The	cassette	was	set	up	in	 the	 following	order:	 black	part	 of	 the	 cassette,	 sponge,	 3	wet	whatman	papers,	 gel,	membrane,	3	whatman	papers,	sponge,	and	 finally	 the	holder,	which	was	closed.	After	every	step,	bubbles	were	removed.	Blotting	was	performed	in	cold	conditions	for	2-3h	at	
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0,2	 Am/gel.	 After	 protein	 transfer,	 the	 membrane	 was	 incubated	 with	 Ponceau	 S	 for	approximately	2	min	to	check	for	protein	abundance.	Ponceau	S	was	discarded	and	the	membrane	was	rinsed	with	MPW.	A	picture	was	taken.	Afterwards,	the	membrane	was	incubated	 with	 20	 ml	 of	 blocking	 solution	 for	 one	 hour	 under	 permanent	 shaking.	Following	overnight	incubation	with	10	ml	of	the	respective	primary	antibody	solution	(9,5	ml	TBST,	500µl	of	Blocking	reagent,	and	appropriate	amount	of	primary	antibody)	at	4°C	and	permanent	shaking,	the	membrane	was	washed	with	1x	TBS-T	for	3x	10	min	at	RTemp	and	shaking.	Afterwards,	the	membrane	was	incubated	in	solution	containing	secondary	 antibody	 (19	 ml	 TBST,	 1ml	 Blocking	 reagent	 and	 appropriate	 amount	 of	secondary	 antibody)	 for	 1h	 at	RTemp	and	 shaking.	Another	washing	 step	 followed	 as	before	 and	 1	 ml	 of	 ECL	 Western	 Blotting	 Substrate	 (ThermoFisher)	 (mix	 1:1)	 was	applied	on	the	membrane.	The	cheminoluminescence	was	detected	using	the	Agfa	Curix	60	x-ray	developing	machine.			10x	SDS-Running	Buffer	(1L)		 	 	144,2	g		 Glycine	[1,92	M]	 	 	 	 	30,3	g			 Tris	base	[250mM]	50	ml		 	 20%	SDS	[1%]	 	 	 	 	 	up	to	1L		 Millipore	H20		 	 		10x	Wet	transfer	buffer	(1L)		 for	1x+20%MeOH	29,15	g		 Glycine	[390mM]	 	 	 	 	58,1	g			 Tris	base	[480mM]	18,5	ml			 20%	SDS	[0,37%]	 	 	 	 	 	up	to	1L		 Millipore	H20			10x	TBST	(1L)	pH=8,00	60,5	g			 Tris	base	[500mM]	87	g		 	 1,5M	NaCl	5ml		 	 0,5%	Tween	up	to	1L		 Millipore	H20		 		Blocking	solution	18	ml		 	 1x	TBST	2	ml		 	 Blocking	Reagent		
	
2.6.4	Stripping	and	reprobing	western	blot	membranes	
	Stripping	buffer	(see	below)	was	pre-warmed	to	50°C	and	transferred	to	a	small	plastic	box	with	a	lid.	The	membrane	was	added	and	incubated	at	50°C	for	up	to	45	min	with	
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some	agitation.	The	solution	was	disposed	of	as	required	for	b-mercaptoethanol	based	buffers	and	the	membrane	rinsed	under	running	water	tap.	The	membrane	was	washed	extensively	for	5	min	in	TBST	and	therewith	it	was	ready	for	blocking	stage.			Harsh	stripping	buffer	(0,1L)	20	ml		 	 SDS	10%	12,5	ml		 0,5	M	Tris	HCl	pH	6,8		67,5	ml		 MPW	add	0,8	ml		 b-mercaptoethanol	under	the	fumehood		
2.7	Immunohistochemistry	
2.7.1	Oil	Red	O	staining		The	Oil	Red	O	(ORO)	solution	was	prepared	by	dissolving	0.3	g	ORO	dye	was	dissolved	in	60	ml	isopropanol	in	the	dark	at	RTemp	overnight.	Afterwards,	40	ml	dH20	was	added	and	the	solution	was	filtered.	Cell	media	was	aspirated	under	a	fume	hood	and	the	cells	were	rinsed	with	2	ml	of	sterile	PBS	per	well.	Subsequently,	PBS	was	aspirated	and	the	cells	were	incubated	for	1.5	h	at	RTemp	in	1	ml	10%	formalin.	Next	the	excess	formalin	was	removed;	wells	washed	with	2	ml	PBS	and	stained	with	1	ml	ORO	staining	solution	for	 2	 h.	 The	 stained	 cells	 were	 washed	 twice	 with	 dH20	 for	 5	 min	 before	 acquiring	images.	Modified	after	Schmidt	et	al.	(2018)204.	
2.7.2	Hematoxylin	and	eosin	staining		Haematoxylin	and	eosin	(H&E)	stainings	were	performed	by	the	histology	facility	of	the	Max-Planck	Institute	for	Metabolism	Research.	BAT,	scWAT,	vWAT	and	liver	specimens	were	incubated	at	4°C	in	4%	paraformaldehyde	overnight,	embedded	in	paraffin	(FFPE),	and	 sliced	 according	 to	 standard	 protocols.	 H&E	 staining	 and	 insulin	immunohistochemistry	 were	 performed	 after	 de-paraffination	 as	 previously	described206.	 A	 Zeiss	 Axioskop	 40microscope	 (Carl	 Zeiss	 MicroImaging)	 and	 Zeiss	AxioVision	4.2	software	(Carl	Zeiss	MicroImaging)	were	used	for	the	imaging.	Modified	after	Schmidt	et	al.	(2018)204.	
2.7.3	Automated	adipocyte	quantification		H&E	 stainings	were	 carried	 out	 as	 described	 above.	 The	 adipocyte	 quantification	was	performed	 by	 the	 CECAD	 Imaging	 facility.	 An	 automated	 workflow	 was	 utilized	 to	
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segment	 and	measure	 adipocytes	 from	 the	 images.	 First,	 the	 interactive	 learning	 and	segmentation	toolkit	ilastik207	(www.ilastik.com)	was	used	to	train	tissue	specific	pixel-level	 classifiers	 on	 the	RGB	photomicrographs.	 For	 classification	 of	BAT,	 three	 classes	were	 defined	 (membrane,	 vacuole,	 nucleus)	 and	 a	 classifier	 using	 a	 set	 of	 eleven	optimized	 features	 selected	 by	 the	 filter	 method	 was	 trained	 based	 on	 a	 manually	labelled	 training	 dataset.	 For	 images	 from	 scWAT	 and	 vWAT	 a	 unified	 classifier	 was	trained	with	 just	two	classes	(membrane	and	vacuole)	and	using	all	available	features.	Application	of	the	classifiers	to	the	respective	image	sets	resulted	in	two	or	three	class	probability	maps	which	were	fed	in	Cellprofiler208	to	segment	and	individually	measure	single	 adipocytes.	 The	 vacuole	 probability	 map	 was	 smoothed	 and	 automatically	thresholded.	The	obtained	binary	vacuole	mask	was	subjected	to	morphological	closing	to	 fill	 small	holes.	The	 result	was	used	 to	mask	 the	original	vacuole	probability	 image	which	then	was	used	to	perform	intensity/probability	based	cell	segmentation	by	means	of	the	Cellprofiler	Identify	Primary	Objects	module.	The	cell	masks	were	expanded	until	touching	 their	 neighbouring	 cells	 and	 cells	 intersecting	with	 the	 image	 border	 before	expansion	 were	 excluded.	 Size	 and	 shape	 parameters	 of	 the	 remaining	 cells	 were	measured.	Modified	after	Schmidt	et	al.	(2018)204.	
2.7.4	Electron	microscopy	and	mitochondrial	morphometry		To	 fix	 tissues,	 the	specimens	were	cut	 into	small	 (~1	mm3)	pieces	and	stored	 in	 fresh	fixative	(10	ml	Caco-buffer,	1.6	ml	of	25	%	Glutardialdehyde,	5	ml	of	8	%	PFA	in	H2O,	filled	up	to	20	ml	with	DEPC-treated	H2O	with	pH-value	adjusted	to	7.3)	for	16-24	h	at	4°	C.	Electron	microscopy	(EM)	and	mitochondrial	morphometry	was	performed	by	the	CECAD	imaging	facility.	In	order	to	embed	the	fat	tissue,	samples	were	washed	4x	for	20	min	in	0.1	M	Caco-buffer	(pH=7.2-7.3)	at	4°	C	and	incubated	in	2	%	OsO4	in	0.1	M	Caco-buffer	(pH=7.2-7.3)	at	4°	C	in	the	dark	for	2h.	Afterwards,	samples	were	washed	in	0.1	M	Caco-buffer	 (pH=7.2-7.3)	 4x	 for	 20	min	 at	 4°C.	 They	were	 then	 incubated	 in	 ice-cold	50%	EtOH	for	20	min	at	4°	C	to	dehydrate	them.	Subsequently,	samples	were	stored	in	ice-cold	70%	EtOH	at	4°C	overnight	which	was	followed	by	a	20	min	incubation	in	ice-cold	90%	EtOH	at	4°C	the	next	day.	After	that,	samples	were	stored	3x	for	20	min	in	ice-cold	100%	EtOH	at	4°C,	20	min	in	equal	volumes	of	Propylenoxide:EtOH	at	4°C,	and	2x	20min	 in	 pure	 Propylenoxide	 at	 4°C.	 For	 sample	 transfer	 to	 epon	 (20	 g	 Epoxy,	 11	 g	DDSA,	9	g	NMA,	0.8	g	DMP30,	 freshly	prepared)	samples	were	stored	 for	5	h	 in	equal	volumes	 of	 Epon:Propylenoxide	 at	 4°C.	 Afterwards,	 samples	 were	 incubated	 in	 3:1	
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volumes	 of	 Epon:Propylenoxide	 overnight	 at	 4°C.	 On	 the	 next	 day,	 samples	 were	immersed	in	fresh	epon	for	2	h	with	an	open	lid.	The	final	embedding	was	performed	in	flat	form	in	fresh	epon	for	72	h	at	62	°C,	subsequent	too	which,	semi-thin	sections	(500	nm)	were	 cut	using	a	Leica	UC6	ultramicrotome	as	 a	quality	 control	 check	 for	 for	 the	samples.	 If	 the	 sections	 were	 of	 good	 quality,	 ultrathin	 sections	 were	 produced.	 The	sections	were	fit	to	the	grid	and	contrasted.	The	grid	was	incubated	for	15	min	in	1.5%	aqueous	 Uranylacetate,	washed	 5x	 in	 distilled	H2O,	 incubated	 again	 for	 4	min	 in	 lead	citrate,	 and	 washed	 5x	 in	 distilled	 H2O.	 Finally,	 samples	 were	 checked	 with	 electron	microscope	Jeol	2100	Plus	equipped	with	a	Gatan	camera.	Modified	after	Schmidt	et	al.	(2018)204.		
2.8	 Capture	 hybridization	 analysis	 of	 RNA	 targets	 (ChART)	 –	 Mass	
spectrometry	(MS)	
2.8.1	ChART		PIBA	cells	were	seeded	and	either	grown	to	confluency	or	induced	to	differentiate.	The	cells	 were	 fixed	 with	 1%	 Formaldehyde	 for	 10	 min	 after	 a	 wash	 with	 1x	 PBS.	 The	fixation	was	quenched	with	0.125	M	Glycine,	followed	by	another	wash	with	ice-cold	1x	PBS,	scraped	off,	and	centrifuged	for	5	min	at	100	g.	The	supernatant	was	aspirated	and	cells	stored	at	-80	°C.	The	cells	were	lysed	in	400	µl	lysis	buffer,	resuspended,	and	stored	on	ice	for	5	min.	This	step	was	repeated	with	an	addition	of	0.1%	of	NP-40	to	the	lysis	buffer.	1ml	of	sucrose	buffer	was	pipetted	into	a	new	tube	and	the	lysed	cells	(max.	400	µl)	were	carefully	pipetted	into	the	center	of	 the	buffer	which	were	centrifuged	for	10	min	at	7,000g	at	4°C.	The	 lysis	 step	was	 repeated	with	only	400	µl	of	 lysis	buffer	and	afterwards	 the	sucrose	step	was	repeated.	After	centrifugation,	 the	supernatants	were	discarded	and	the	nuclei	were	washed	with	1ml	PBS.	The	tube	was	centrifuged	for	1	min	at	 7,000	 g,	 the	 supernatants	 were	 discarded,	 and	 1ml	 of	 PBS	 was	 added.	 The	suspensions	were	resuspended	and	vortexed	to	achieve	a	single	nucleus	suspension.	2%	formaldehyde	was	added	to	crosslink	the	nuclei	for	30	min	and	the	tubes	were	vortexed	and	 stored	 for	30	min	on	a	 rotating	wheel	 at	RTemp.	For	quenching,	0.125	M	Glycine	was	 added	 and	 the	 samples	 were	 centrifuged	 for	 1	 min	 at	 7,000	 g	 at	 4°C.	 Prior	 to	another	centrifugation	step	at	7,000	g	for	1	min,	the	supernatant	was	discarded	and	the	nuclei	were	washed	with	1ml	PBS.	Washing	was	repeated	with	2	min	of	centrifugation	in	between.	The	supernatants	were	discarded	and	300	µl	nuclear	 lysis	buffer	and	RNAse	
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inhibitor	were	added.	The	samples	were	vortexed	and	incubated	for	5	min	on	ice.	PBS	and	 protease	 inhibitor	 were	 added	 in	 equal	 amounts	 to	 the	 nuclear	 suspension	 and	vortexed.	A	tip	sonicator	was	used	to	lyse	the	residual	nuclei,	with	the	following	settings:	3x	cycles	10%,	3x	10	sec,	POWER	10%.	The	suspension	was	transferred	into	Diagenode	TPX	microtubes	and	sonicated	with	following	conditions:	Amplitude:	35%,	15	sec	ON,	15	sec	 OFF,	 36	 cycles,	 time:	 9	 min	 for	 appropriate	 shearing	 of	 mature	 brown	 adipocyte	chromatin.	 This	 was	 followed	 by	 a	 centrifugation	 at	 17,000	 g	 for	 5	 min	 and	 the	supernatants	 were	 transferred	 to	 new	 tubes.	 Gross	 nucleic	 acid	 abundances	 were	quantified	 using	 a	 Nanodrop	 instrument	 and	 75	 µg	 chromatin	 mixed	 with	 RNAse	inhibitor	 and	 650	 pmol	 of	 oligonucleotides	 (OGNs)	 was	 conjugated	 to	 Biotin-TEG.	(Biotin-TEG	 increases	 OGN–biotin	 distances	 to	 approximately	 15	 atoms	 using	 a	triethyleneglycol	 (TEG)	 spacer.	 Biotin-TEG	 is	 used	 to	 avoid	 steric	 hindrances	 and	improve	 attachment	 of	OGNs	 to	 the	 beads).	 The	 samples	were	 vortexed	 carefully	 and	spun	down,	 incubated	at	55	°C	while	shaking	at	600	rpm	for	10	min.	The	temperature	was	decreased	 to	RTemp	and	 the	samples	stored	o/n	at	55	 °C.	The	beads	were	mixed	with	1	ml	of	Solution	1	(1	M	NaCl	and	0.1%	Tween),	vortexed,	centrifuged	shortly,	and	transferred	 to	 a	 magnetic	 rack.	 After	 a	 three-fold	 wash	 with	 Solution	 1,	 the	 samples	were	adjusted	to	1	M	NaCl,	vortexed,	and	50	µl	of	beads	and	RNase	inhibitor	was	added	to	 the	 solution.	The	 tubes	were	stored	on	a	 rotator	 for	30	min	at	RTemp,	 centrifuged,	incubated	on	 the	magnetic	 rack,	 and	 the	 supernatants	were	discarded.	The	next	wash	step	consisted	of	a	2x	wash	with	1ml	of	Solution	1	and	3x	with	1ml	of	Solution	2	(1M	NaCl,	0.1%	Tween,	0.1%	SDS).	For	this,	solutions	were	added,	the	tubes	were	vortexed	and	stored	on	a	shaker	1050	rpm	set	to	16	°C	for	5	min.	After	an	incubation	step	on	the	magnetic	 rack,	 the	 supernatant	 was	 discarded.	 For	 the	 final	 elution,	 the	 beads	 were	resuspended	in	300µl	elution	buffer	(0.2	M	NaCl,	0.1%	SDS,	10	mM	Tris	pH=8.0)	and	1x	proteinase	 inhibitor.	 The	 samples	 were	 incubated	 on	 a	 ThermoShaker	 for	 4-5	 h	 and	shaken	at	1450	rpm	at	65	°C.	Finally,	the	eluate	was	concentrated	with	Amicon	Ultra-0,5	Centrifugal	filter.	To	degrade	RNA	contaminations,	samples	were	treated	with	RNAse	A.	Modified	 after	 Schmidt	 et	 al.	 (2018)204.	 Sequences	 for	 H19	 sense	 and	 antisense	oligonucleotides	for	RNA-immunoprecipitation	are	provided	in	Table	3.		
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Whole	Cell	Lysis	buffer	10	mM	Tris	pH	7,5	150	mM	NaCl	0,15%	NP-40				1mM	DTT,	protease	inhibitors	and	RNAse	inhibitor	was	added	freshly.			Sucrose	buffer	10	mM	Tris	pH	7,5	150	mM	NaCl	24%	sucrose		1mM	DTT,	protease	inhibitors	and	RNAse	inhibitor	was	added	freshly.			Nuclear	Lysis	Buffer	10	mM	Hepes	pH	7,6	7,5	mM	MgCl2	0,2	mM	EDTA	0,3	M	NaCl	1	M	Urea	1%	NP-40		1	mM	DTT	was	added	freshly.		
Table	3:	List	of	biotinylated-oligonucleotide	sequences.		
Description	 Sequence	(5’-3’)	 Type	#probe	1	sense	90	 GAAGCAGTTCCATCATAAAGTG[BtnTg]	 Biotinylated	H19	sense	OGN	(sense	H19	pulldown	Control)	#probe	2	sense	225	 CGTATGAATGTATACAGCGAGT[BtnTg]	 Biotinylated	H19	sense	OGN	(sense	H19	pulldown	Control)	#probe	3	sense	551	 ACAGATGGTGTCAACATTTTGA[BtnTg]	 Biotinylated	H19	sense	OGN	(sense	H19	pulldown	Control)	#probe	4	sense	714	 CTTGAACCCTCAAGATGAAAGA[BtnTg]	 Biotinylated	H19	sense	OGN	(sense	H19	pulldown	Control)	#probe	5	sense	894	 GTGTGGTCAATGTGACAGAAAG[BtnTg]	 Biotinylated	H19	sense	OGN	(sense	H19	pulldown	Control)	#probe	6	sense	1186	 ATGACAGACAGAACATTTCCAG[BtnTg]	 Biotinylated	H19	sense	OGN	(sense	H19	pulldown	Control)	#probe	4	antisense	1497	 AGTGTTAGCTCTTTGGGAAAAG[BtnTg]	 Biotinylated	H19	antisense	OGN	(antisense	H19	pulldown)	#probe	5	antisense	1623	 GATTCAGAACGAGACGGACTTA[BtnTg]	 Biotinylated	H19	antisense	OGN	(antisense	H19	pulldown)	#probe	6	antisense	1726	 AGTCTGCTCTTTCAAAATGTTG[BtnTg]	 Biotinylated	H19	antisense	OGN	(antisense	H19	pulldown)	#probe	8	antisense	2201	 AAAGGATGAAGTAGGGCATGTT[BtnTg]	 Biotinylated	H19	antisense	OGN	(antisense	H19	pulldown)	
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#probe	11	antisense	1953	 GGTAAATGGGGAAACAGAGTCA[BtnTg]	 Biotinylated	H19	antisense	OGN	(antisense	H19	pulldown)	#probe	12	antisense	2061	 ATTGCCAAAGAGGTTTACACAC[BtnTg]	 Biotinylated	H19	antisense	OGN	(antisense	H19	pulldown)	
2.8.2	Sample	preparation	for	mass	spectrometry	(MS)		DTT	was	added	to	yield	a	final	concentration	of	5	mM	and	the	samples	were	incubated	at	55	°C	for	30	min.	Next,	the	samples	were	cooled	down	to	RTemp	and	Chloroacetamide	(CAA)	was	added	at	a	final	concentrations	of	40	mM	for	an	incubation	period	of	30	min	in	the	dark.	The	CECAD	proteomics	facility	carried	out	the	protein	digestion	by	using	the	Single-Pot	Solid-Phase-enhanced	Sample	Preparation	 technology.	 In	brief,	2	µL	of	a	10	mg/mL	mixture	of	hydrophilic	and	hydrophobic	carboxylate	coated	paramagnetic	beads	(SeraMag	Speed	Beads,	Cat	No.	44152105050250	and	24152105050250,	GE	Healthcare)	were	 added	 to	 each	 sample.	 Acidified	 acetonitrile	 was	 added	 to	 achieve	 a	 final	concentration	of	50%	organic	solvent.	Bound	proteins	were	washed	with	70%	ethanol	and	 100%	 acetonitrile.	 The	 beads	 were	 resuspended	 in	 5	 µL	 50	 mM	Triethylammoniumbicarbonate	 buffer	 containing	 0.1	 µg	 Trypsin	 (Sigma)	 and	 0.1	 µg	LysC	(Wako).	Digestion	was	carried	out	for	16	h	at	37	°C	in	a	thermocycler	to	maintain	constant	temperatures.	Recovered	peptides	were	resuspended	in	1%	formic	acid	/	5%	DMSO	and	stored	at	-20°	C	prior	to	MS	analysis.	Modified	after	Schmidt	et	al.	(2018)204.	
2.8.3	MS		Mass	 spectrometry	 was	 performed	 at	 the	 proteomics	 facility	 of	 the	 CECAD	 research	center.	 The	 samples	 were	 analysed	 on	 a	 Q-Exactive	 Plus	 (Thermo	 Scientific)	 mass	spectrometer,	 coupled	 to	 an	EASY	nLC	1000	UPLC	 (Thermo	 Scientific).	 Peptides	were	loaded	with	solvent	A	(0.1%	formic	acid	in	water)	onto	an	analytical	column,	packed	in-house	 (50	cm	×	75	µm	I.D.,	 filled	with	2.7	µm	Poroshell	EC120	C18,	Agilent).	Peptides	were	 chromatographically	 separated	 at	 a	 constant	 flow	 rate	 of	 250	 nL/min	 using	 the	following	gradient:	5-30%	solvent	B	(0.	1%	formic	acid	in	80%	acetonitrile)	within	119	min,	30-50%	solvent	B	within	19	min,	 followed	by	washing	and	column	equilibration.	The	 mass	 spectrometer	 was	 operated	 in	 data-dependent	 acquisition	 mode.	 The	 MS1	survey	 scan	was	 acquired	 from	 300-1750	m/z	 at	 a	 resolution	 of	 70,000.	 The	 top	 ten	most	 abundant	 peptides	 were	 isolated	 within	 a	 2	 Da	 window	 and	 subjected	 to	 HCD	
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fragmentation	at	a	normalized	collision	energy	of	27%.	The	AGC	target	was	set	to	5x105	charges,	allowing	a	maximum	injection	time	of	55	ms.	Product	ions	were	detected	in	the	Orbitrap	 at	 a	 resolution	 of	 17,500.	 Precursors	 were	 dynamically	 excluded	 for	 20	 s.	Modified	after	Schmidt	et	al.	(2018)204.	
2.8.4	Bioinformatic	analysis	of	MS	data		Bioinformatic	 analysis	 of	 MS	 data	 was	 performed	 by	 the	 proteomics	 facility	 at	 the	CECAD	 research	 center.	 The	 mass	 spectrometric	 raw	 data	 were	 processed	 with	Maxquant	 (version	 1.5.3.8)	 using	 default	 parameters.	 The	 acquired	MS2	 spectra	were	searched	 against	 the	 Uniprot	MOUSE.fasta	 database	which	 included	 a	 list	 of	 common	contaminants.	 False	 discovery	 rates	 on	 protein	 and	 PSM	 level	 were	 estimated	 by	 the	target-decoy	approach	to	0.01%	(Protein	FDR)	and	0.01%	(PSM	FDR).	Minimal	peptide	length	was	 set	 to	 7	 amino	 acids	 and	 carbamidomethyolation	 at	 cysteine	 residues	was	considered	 as	 a	 fixed	 modification.	 Oxidation	 (M)	 and	 Acetyl	 (Protein	 N-term)	 were	included	 as	 variable	modifications.	 The	match-between-runs	 option	was	 enabled.	 LFQ	quantification	was	enabled	using	default	settings.	The	Maxquant	output	was	processed	as	 follows:	 protein	 groups	 flagged	 as	 ‘reverse’,	 ‘potential	 contaminant’,	 or	 ‘only	identified	 by	 site’	 were	 removed	 from	 the	 proteinGroups.txt.	 The	 resulting	 table	 was	analysed	using	R	through	which	the	protein	groups	with	at	least	two	valid	values	out	of	three	 replicates	 (or	 2	 out	 of	 2)	 in	 at	 least	 one	 of	 the	 bait	 subgroups	were	directed	 to	statistical	 analysis.	 The	 R	 ‘STATS’	 Package	 was	 used	 to	 perform	 Student’s	 t-tests	 to	distinguish	significantly	changed	proteins.	Those	peptides	with	p-values	<	0.05	and	log2	fold-changes	>	1	were	considered	as	significantly	different.	Proteins	that	provide	2	or	3	valid	values	in	one	bait	group	and	zero	in	the	other,	were	also	considered	as	significantly	different.	Modified	after	Schmidt	et	al.	(2018)204.	
2.8.5	Ingenuity	pathway	analysis	and	AMIGO2	GO	Term	Analysis		By	using	ChART-MS,	3,590	proteins	were	detected	 in	 total.	All	168	uniquely	 identified	and	 significantly	 enriched	 peptides	 with	 fold-changes	 ≥1.5	 between	 H19	 antisense	compared	 to	 sense	 oligonucleotide	 immunoprecipitation	 in	 confluent	 (n=114)	 or	differentiated	(n=102)	conditions	were	analysed	using	the	Ingenuity	Pathway	Analysis	(IPA).	 To	 construct	 a	 functionally	 interconnected	H19	 protein	 interactome,	 all	 n=168	genes	were	loaded	into	IPA	and	gene	nodes	with	≥1	edges	to	other	genes	retained.	For	
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GO	Term	classification	of	 the	remaining	n=61	H19	 interaction	partners,	corresponding	Gene	 Symbols	 were	 loaded	 into	 AMIGO2	 (http://amigo.geneontology.org)	 and	 those	proteins	 counted	 classified	 by	 GO	 Terms	 ‘RNA	 binding’	 or	 ‘Chromatin	 binding’	 or	‘Chromatin	modification’.	Modified	after	Schmidt	et	al.	(2018)204.		
2.9	Mouse	procedures	
2.9.1	Animal	care	and	research	diets		All	 animals	 were	 maintained	 on	 a	 C57BL/6	 N	 background,	 housed	 in	 individually	ventilated	cages	(IVC	Type	II	long)	in	groups	of	3-5	animals	per	cage	on	a	constant	12	h	light/dark	 cycle	at	 a	 temperature	of	22-24°C	with	 relative	air	moisture	 (50-70%)	 in	a	SPF	 controlled	 facility	with	 regular	 testing	 for	 pathogens.	 All	 experimental	mice	were	17-18	weeks	of	age	at	sacrifice.	Experimental	mice	were	exposed	to	HFD	feeding	for	15	weeks	(H19	TG	and	H19∆AT	mice	versus	littermate	Controls)	and	17-18	weeks	of	age	at	sacrifice.	 The	 care	 of	 animals	 was	 within	 institutional	 and	 animal-care	 committee	guidelines	 approved	 by	 local	 government	 (Bezirksregierung	 Köln)	 and	 regional	authorities	(Tierschutzkommission	acc.	§15	TSchG	of	the	Landesamt	for	Natur,	Umwelt	and	Verbraucherschutz	(LANUV)	North-Rhine	Westphalia,	Germany,	 internal	reference	no.	84-02.04.2014.A068).	Unless	otherwise	 indicated,	animals	were	allowed	ad	 libitum	access	to	food	and	drinking	water.			 For	 maintenance	 animals	 received	 a	 normal	 chow	 diet	 (NCD)	 containing	 57%	carbohydrate,	 34%	 protein	 and	 9%	 fat.	 For	 diet-induced	 obesity	 (DIO)	 experiments,	mice	 were	 fed	 a	 high-fat	 diet	 (HFD)	 containing	 54%	 fat,	 24%	 protein	 and	 22%	carbohydrate,	starting	at	3	weeks	of	age.	Control	animals	were	 fed	a	Control	diet	(CD)	containing	 62	%	 carbohydrate,	 20%	 protein	 and	 13%	 fat	 starting	 at	 3	 weeks	 of	 age.	Modified	after	Schmidt	et	al.	(2018)204.		NCD:		 ssniffÒ	R/M-H	Low-Phytoestrogen		 (Product-ID:	V1554)	HFD:		 ssniffÒ	EF	acc.	D12492	(I)	mod.		 	 (Product-ID:	E15742)	CD:		 ssniffÒ	EF	D12450B*	mod.	LS	 	 (Product-ID:	E15748)		All	diets	were	purchased	from	ssniff	Spezialdiäten	GmbH,	Soest,	DE.	
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2.9.2	Experimental	mouse	models		Specific	 AT	 reduction	 of	H19	 expression	was	 achieved	 via	 Cre	 recombinase-mediated	excision	 of	 LoxP-flanked	 (‘floxed’)	 gene	 sequences.	Mice	 harbouring	 loxP-flanked	H19	differentially	 methylated	 regions	 (DMR;	 H19-DMRflDMR/flDMR)	 were	 obtained	 from	 the	group	of	Linheng	Li	(Stowers	Institute)	and	generated	as	described209	and.	Female	H19-DMRflDMR/flDMR	 mice	 were	 bred	 with	 male	 C57BL76	 mice	 expressing	 adipose-selective	Adiponectin	 (Adipoq)-promoter	 driven	 Cre	 (H19-DMRwt/wt;Adipoq-Cretg/wt)	 to	 obtain	H19-DMRflDMR/wt;Adipoq-Cretg/wt	 (H19∆AT)	 and	 H19-DMRflDMR/wt;Adipoq-Crewt/wt	 as	control	 littermates	 (control	 for	 H19∆AT).	 Adipoq-Cre	 mice	 were	 originally	 purchased	from	 Jackson	 Laboratory	 (Bar	 Harbor,	 ME,	 USA;	 stock	 number	 010803-JAK)	 and	maintained	in-house.	The	Cre	recombinase	is	expressed	heterozygously	under	control	of	the	 fat-specific	Adipoq	 promotor	 in	 these	 transgenic	mice.	 For	H19	 overexpression,	 a	strain	 harbouring	 yeast	 artificial	 chromosomes	 (YACs,	 present	 in	 ten	 genomic	 copies)	was	used.	Each	YAC	cassette	contained	a	130	kb	transgene	spanning	the	entire	H19-Igf2	cluster	 in	which	 the	 Igf2	coding	sequence	was	 inactivated	with	 the	 lacZ	reporter	gene	(MGI	accession	number	5648556,	Symbol:	Tg(Igf2/LacZ,H19)YZ15Aco;	H19	TG)210.	Only	male,	 non-randomized	 mice	 were	 used	 for	 the	 experiments	 and	 the	 non-transgenic	littermates	were	used	as	experimental	controls.			 Tissues	from	C57BL/6	N	mice	exposed	to	4°C	either	for	1	or	7	days	were	kindly	provided	 by	 the	 laboratory	 of	 Prof.	 Dr.	 Jörg	 Heeren,	 Institute	 for	 Biochemistry	 and	Molecular	 Cell	 Biology,	 Medical	 Center	 Hamburg-Eppendorf,	 Hamburg,	 Germany.	 All	other	experiments	were	performed	using	C57BL/6	N	mice.	Modified	after	Schmidt	et	al.	(2018)204.	
2.9.3	Genotyping	
2.9.3.1	Genomic	DNA	extraction	from	mouse	tails			Mouse	 tail	 biopsies	 were	 obtained	 at	 weaning	 age	 and	 incubated	 in	 500	 µL	 tail	 lysis	buffer	by	shaking	overnight	at	56	°C	and	400	rpm.		
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2.9.3.2	Polymerase	chain	reaction	(PCR)		For	 genotyping	 genomic	 DNA	 was	 tested	 for	 H19lxDMD,	 LacZ,	 and	 Adipoq-cre	 gene	presence.	 In	 brief,	 2	 µl	 of	 extracted	 genomic	 DNA	 (gDNA)	 were	 mixed	 with	 23	 µl	 of	corresponding	 PCR	 master	 mix	 (Table	 4)	 and	 polymerase	 chain	 reaction	 (PCR)	 was	performed	using	primers	listed	in	Table	5.	PCR	master	mix	consisted	of	approximately	25pMol	of	each	primer,	25	µM	dNTP	mix,	1%	Dream	Taq	Green	Buffer,	and	1	unit	Dream	Taq	DNA	polymerase	per	25	µl	reaction.	PCR	cycling	parameters	have	been	determined	for	each	 individual	PCR	according	 to	 the	annealing	 temperature	of	 the	 specific	primer	pair	and	the	length	of	the	DNA	product.			
Table	4:	Composition	of	PCR	master	mix.	Reagent	 H19lxDMD	 LacZ		 AdipoQ-Cre		Dream	Taq	Green	Buffer	(10x)	 2.5	µl	 2.5	µl	 2.5	µl	dNTPs	(10mM)	 0,4	µl		 0,4	µl	 0,5	µl	Primer	(10	µM)	 22745	0,4	µl	 ARTE_bGAL3	0,4	µl		 mom0137	0,2µl		 22746	0,4	µl	 ARTE_bGAL4	0,4	µl	 mom0138	0,2µl		 	 	 oIMR6694	0,4µl		 	 	 oIMR6695	0,4µl	Millipore	H20	 19,1	µl	 19,5	µl	 20,4	µl	Dream	Taq	Green	DNA	Polymerase	 0,2	µl	 0,2	µl	 0,4	µl		All	 PCRs	 were	 performed	 using	 FlexCycler²	 PCR-Thermocycler	 using	 the	 following	programs:		
AdipoQ-cre	Temperature	[°C]	 Time	[m:s]	 	94	 3:00	 	94	 0:30	 33x	60	 1:00	72	 1:00	72	 2:00	 	12	 ∞	 	
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H19-flox	 	Temperature	[°C]	 Time	[m:s]	 	95	 5:00	 	95	 0:30	 34x	56,3	 0:30	72	 1:00	72	 10:00	 	12	 ∞	 		LacZ	Temperature	[°C]	 Time	[m:s]	 	94	 5:00	 	94	 0:30	 26x	60	 0:30	72	 0:30	72	 5:00	 	14	 ∞	 		
2.9.3.3	Agarose	gel	electrophoresis		Amplified	 DNA	 fragments	 were	 separated	 by	 native	 gel	 electrophoresis.	 For	 the	preparation	of	the	gel,	3g	of	agarose	was	dissolved	in	100ml	1x	TAE	buffer,	boiled	and	poured,	 resulting	 in	 gels	 of	 3%	 containing	 5%	 Midori	 Green	 Advance	 DNA	 stainÒ	(Nippon	Genetics	Europe)	for	DNA	visualization.	DNA	fragments	were	separated	at	140V	by	a	Gene	power	supply	GPS	200/400	(Pharmacia,	Uppsala,	SWE)	and	visualized	under	UV	light	on	a	FastGeneÒ	FAS	V	gel	documentation	system.			50x	TAE	buffer	50	mM		 EDTA	disodium	salt	2	M	 	 Tris	1M		 	 glacial/acetic	acid		Expected	products	sizes	are	indicated	below:		Products	for	AdipoQ-cre:	WT:		 	 542	bp	Tg:		 	 450	bp		Products	for	YZ15:		Tg:		 	 315	bp		
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Products	for	H19-flox:		WT:		 	 300	bp	WT/flox:		 300	bp	and	~350	bp	Flox/flox:		 ~350	bp		
Table	5:	List	of	primers	for	genotyping	PCR.	PCR	 Name	 Sequence	(5’-3’)		
AdipoQ-cre	 mom0137	 CTGCAGTTCGATCACTGGAAC	mom0138	 AAAGGCCTCTACAGTCTATAG	oIMR6694	 TCCAATTTACTGACCGTACA	oIMR6695	 TCCTGGCAGCGATCGCTATT		H19-flox	 22745	 GGCAACCCTGGTCTTTACAC	22746	 GCCCTATTCTTGGACGTCTG	YZ15	 ARTE_bGAL3	 ATCCTCTGCATGGTCAGGTC	
	 ARTE_bGAL3	 CGTGGCCTGATTCATTCC		
2.9.4	Phenotyping	
2.9.4.1	Assessment	of	body	weight			Body	weight	 of	 HFD-	 and	 CD-fed	H19	 TG	 and	H19∆AT	 and	 Control	mice	was	 assessed	weekly	for	each	individual	mouse	for	ages	3-18	weeks.		
2.9.4.2	Glucose	tolerance	test	(GTT)			The	GTT	was	performed	at	13	weeks	of	age,	prior	to	which	the	mice	were	exposed	to	CD	or	HFD	feeding	for	10	weeks.	After	a	6	h	fasting	period,	the	GTT	was	carried	out	at	12	noon.	 The	 basal	 blood	 glucose	 levels	 (0	 min)	 were	 measured	 and	 subsequently,	 the	animals	 received	 an	 intraperitoneal	 bolus	 of	 2	 g	 glucose	 per	 kilogram	of	 body	weight	(20%	glucose,	 Delta	 select).	 An	 automated	 glucose	monitor	was	 used	 to	 record	 blood	glucose	 values	 at	 15,	 30,	 60	 and	120	min	 after	 injection.	Modified	 after	 Schmidt	 et	 al.	(2018)204.	
2.9.4.3	Insulin	tolerance	test	(ITT)		The	ITT	was	performed	when	mice	were	12	weeks	of	age	after	9	weeks	of	exposure	to	either	CD	or	HFD	feeding.	The	ITT	was	carried	out	in	random-fed	state	between	9-10am	in	fresh	cages	with	bedding,	free	access	to	drinking	water	but	no	food.	After	determining	basal	blood	glucose	levels	(0	min)	using	a	glucometer,	each	animal	received	0,75	U/kg	of	body	 weight	 of	 insulin	 (Actrapid;	 Novo	 Nordisk)	 via	 intraperitoneal	 administration.	
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Blood	 glucose	 levels	were	measured	15,	 30	 and	60	min	 after	 injection.	Modified	 after	Schmidt	et	al.	(2018)204.	
2.9.4.4	Indirect	calorimetry	(PhenoMaster)		For	indirect	calorimetry	measurements,	mice	of	all	genotypes	and	diets	were	16	weeks	of	 age	 and	 had	 been	 exposed	 to	 either	HFD	 or	 CD	 for	 13	weeks.	 To	 obtain	metabolic	measurements,	 the	 PhenoMaster	 System	 (TSE)	 was	 used.	 Five	 days	 before	 the	experiment,	mice	were	single-housed	in	trainings	cages,	identical	to	the	7.1-1	chambers	of	the	PhenoMaster	open	circuit	calorimetry	system.	The	mice	received	their	respective	diets	 (HFD,	 CD)	 throughout	 the	 training	 and	 data	 acquisition	 periods	with	ad	 libitum	access	 to	 food	 and	 water.	 Food	 intake	 was	 measured	 using	 the	 built-in	 automated	system.	 Initially,	 parameters	 of	 indirect	 calorimetry	 were	 measured	 for	 96h	 at	 22°C	(warm	measurement).	Subsequently,	temperatures	within	the	PhenoMaster	setup	were	reduced	 to	 4°C	 (cold	 measurement)	 and	 data	 acquired	 for	 96	 h.	 Afterwards,	norepinephrine	 (NE)	was	 administered	 intraperitoneally	 at	 a	 final	 concentration	 of	 1	mg/kg	and	systematic	data	collection	continued	for	another	24	h	(NE	measurement)	at	4°C	 to	 measure	 maximally	 activated	 BAT	 uncoupling	 effects.	 Mean	 values	 for	 every	measurement,	 each	 time	 of	 day,	 were	 calculated	 and	 plotted	 for	 warm,	 cold	 and	 NE	measurement.	Modified	after	Schmidt	et	al.	(2018)204.	
2.9.5	Serum	analyses		Serum	analyses	were	performed	by	the	Institute	for	clinical	chemistry	at	the	University	Clinics	 in	 Cologne.	 Serum	was	 obtained	 by	 allowing	 the	 blood	 to	 clot	 at	 4°C	 for	 4	 h,	followed	 by	 a	 centrifugation	 step	 of	 10	 min	 at	 6,200	 g.	 The	 supernatants	 were	transferred	 to	a	new	 tube	and	centrifuged	 for	another	10	min	at	17,000	g.	The	serum	was	 collected	 and	 stored	 at	 -80	 °C	 diluted	 1:3	 with	 0.9%	 NaCl.	 To	 analyse	 serum	cholesterol	levels,	the	Cholesterin	CHOD-PAP	(Roche	Diagnostics)	was	used.	Similarly,	to	determine	triglycerides	levels,	the	Triglyceride	GPO-PAP	of	Roche	Diagnostics	was	used.	Both	analyses	ran	on	the	Cobas	C	702	(Roche	Diagnostics).	Modified	after	Schmidt	et	al.	(2018)204.		
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2.10	Graphical	representation	of	data	and	statistical	analysis		All	 graphs	 were	 created	 using	 GraphPad	 Prism	 7.0.	 Floating	 bars	 indicate	 minimum,	maximum	 and	 mean	 values.	 GraphPad	 Prism	 7.0	 software	 was	 utilized	 to	 perform	statistical	 calculations.	When	 two	 groups	were	 analysed,	 significance	was	 determined	using	an	unpaired	or	paired	Student´s	t-test.	When	three	groups	were	analysed,	a	one-way	ANOVA	followed	by	Bonferroni	correction	was	used.	Two-way	ANOVA	was	applied	for	 repeated	 measures	 (2WA-RM)	 followed	 by	 Bonferroni	 post-hoc	 test	 to	 judge	 the	effect	of	two	independent	variables.	Statistical	details	are	provided	in	the	figure	legends.	A	p	value	<	0.05	is	considered	statistically	significant.	Significance	was	indicated	as	followed	in	the	figures:		n.s.		 p	>	0.05			*	 p	<	0.05	**	 p	<	0.01	***	 p	<	0.001	****	 p	<	0.0001	
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3	Results	
3.1	 Brown	 adipose	 tissue	 (BAT)-regulatory	 lncRNAs	 correlate	 with	 BAT	
function		 	In	 order	 to	 identify	 mRNAs	 and	 lncRNAs	 correlating	 with	 BAT	 function,	 lean	 male	C57BL/6	 N	 mice	 were	 either	 exposed	 to	 thermal	 stress	 (4°C,	 as	 model	 for	 BAT	activation)	 for	 24	 h	 compared	 to	mice	 housed	 by	 ambient	 temperatures	 (22°C)	 or	 to	chronic	HFD	(as	model	for	BAT	dysfunction)	compared	to	CD	feeding.	Afterwards,	RNA-Seq	was	performed	with	RNA	 from	BAT	samples	of	 these	mice.	Additionally,	RNA-Seq	with	RNA	from	BAT,	scWAT,	and	vWAT	from	C57BL/6	N	male	mice	housed	at	ambient	temperatures	and	fed	a	NCD	was	conducted	to	analyse	the	function	of	candidate	genes	throughout	 all	 ATs.	 Different	 filter	 criteria	 were	 applied	 to	 identify	 candidates	 for	further	characterization.	As	criteria	we	selected	adipose	enrichment,	size	of	noncoding	RNAs	 (>200nt),	 and	 increased	 expression	 (FPKM	 >	 1).	 Across	 cold/DIO	 conditions,	1394/433	 mRNAs	 were	 upregulated	 and	 1147/429	 mRNAs	 were	 downregulated	whereas	 71/6	 lncRNAs	 were	 upregulated	 and	 101/33	 lncRNAs	 were	 downregulated	(fold-change	≥	2	or	≤-2)	(Figure	4).	After	manual	verification	of	the	RNA-Seq	data,	four	candidates	were	selected	for	further	studies:	170007L15Rik,	2500002B13Rik,	Gm12319,	and	H19.	With	this	screen,	we	could	show	that	BAT-regulatory	 lncRNAs	correlate	with	BAT	function	in	vivo.		
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Figure	4:	RNA-Seq	reveals	lncRNAs	correlating	with	BAT	function	in	vivo	(A,	B)	Graph	of	BAT	(A)	mRNA	or	(B)	lncRNA	expression	after	chronic	(24	weeks)	HFD	versus	CD	feeding	in	male	C57BL/6	N	mice	as	obtained	by	RNA-Seq	(n=2	per	biological	condition).	(C,	D)	Graph	of	BAT	(C)	mRNA	 or	 (D)	 lncRNA	 expression	 24	 h	 after	 exposure	 to	 4°C	 or	 22°C	 in	male	 C57BL/6	N	male	mice	 as	obtained	by	RNA-Seq	(n=2	per	biological	condition).	Modified	after	Schmidt	et	al.	(2018)204.	Graphs	were	generated	with	the	help	of	P.	Klemm.		
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For	 the	 verification	 of	 the	RNA-Seq	 results,	 qRT-PCR	 analysis	was	 performed	with	 an	independent	set	of	 samples	 (Figure	5).	The	analysis	of	an	AT	profile	showed	that	BAT	associated	 marker	 genes	 (such	 as	 ELOVL	 Fatty	 Acid	 Elongase	 3	 (Elovl3),	 Uncoupling	
Protein	1	(Ucp1))	as	well	as	candidate	lncRNAs	(1700007Rik15,	250002B13Rik,	Gm12319	and	H19)	were	mainly	expressed	in	BAT	compared	to	scWAT	and	vWAT	(Figure	5A,	B).	Moreover,	 the	RNA-Seq	 results	were	 confirmed	by	 increased	 and	decreased	Ucp1	 and	
Elovl3	mRNA	expression	during	cold	or	DIO,	respectively	(Figure	5C,	E).	Because	of	their	BAT-selective	 expression,	 we	 focussed	 on	 lncRNAs	 1700007Rik15,	 250002B13Rik,	
Gm12319,	 and	H19.	 These	 lncRNAs	 revealed	 the	 same	 pattern	 of	 expression	 as	Elovl3	and	Ucp1	upon	cold	and	DIO	conditions	in	BAT	(Figure	5D,	F).	To	reveal	the	expression	of	the	candidate	lncRNAs	and	the	browning/’beiging’	marker	Ucp1	upon	cold	exposure	and	DIO	 in	 other	ATs,	we	performed	qRT-PCR	 in	 scWAT	and	 vWAT	 (Figure	5G-N).	 In	scWAT	 the	 browning/’beiging’	 marker	 Ucp1	 was	 increased	 upon	 cold	 exposure	 and	decreased	in	DIO.	H19	showed	an	opposite	pattern	in	expression	during	both	conditions.	The	three	lncRNAs	1700007Rik15,	250002B13Rik,	Gm12319	were	not	altered	upon	cold	conditions	whereas	upon	DIO	they	were	decreased	except	from	Gm12319	which	did	not	show	a	difference	 in	 expression.	 In	 vWAT,	1700007Rik15,	250002B13Rik,	and	H19	did	not	show	differences	 in	expression	whereas	Gm12319	was	significantly	decreased	and	
Ucp1	showed	a	tendency	to	be	decreased	upon	cold	exposure.	Upon	HFD	conditions	H19	and	Ucp1	were	both	significantly	increased	whereas	1700007Rik15	was	decreased.	The	expression	of	Gm12319	and	250002B13Rik	was	not	altered	upon	DIO.		These	results	show	that	the	verification	of	RNA-Seq	had	been	successful	and	that	the	 candidate	 lncRNAs	were	mainly	 enriched	 in	 BAT	 and	 reveal	 a	 similar	 expression	pattern	as	BAT-associated	mRNAs.		
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Figure	5:	BAT-specific	candidate	lncRNAs	reveal	similar	expression	pattern	as	BAT-associated	
mRNAs	Relative	 BAT,	 scWAT	 and	 vWAT	 expression	 of	 (A)	Elovl3	 (n=3)	 and	Ucp1	 (n=3)	 and	 (B)	1700007Rik15	(n=3),	2500002B13Rik	(n=3),	Gm12319	(n=3),	and	H19	(n=5	for	BAT,	n=3	for	scWAT	and	vWAT)	 in	 lean	C57BL/6	N	male	mice	as	quantified	per	qRT-PCR	analysis.	Relative	(C-F)	BAT	expression	of	Elovl3,	Ucp1,	
1700007Rik15,	 2500002B13Rik,	 Gm12319,	 and	H19	 in	 lean	C57BL/6	N	male	mice	housed	 at	 22°C	 (n=4)	versus	24h	of	4°C	(n=3)	and	C57BL/6	N	male	mice	exposed	to	chronic	HFD	(n=3	for	Elovl3	and	Ucp1,	n=5	for	 1700007Rik15,	 2500002B13Rik,	 Gm12319,	 and	 H19)	 versus	 CD	 (n=3	 for	 Elovl3	 and	 Ucp1,	 n=7	 for	
1700007Rik15,	2500002B13Rik,	Gm12319,	 and	H19)	 feeding	as	quantified	by	qRT-PCR	analysis.	Relative	(G-J)	 scWAT	 expression	 of	 Elovl3,	 Ucp1,	 1700007Rik15,	 2500002B13Rik,	 Gm12319,	 and	 H19	 in	 lean	C57BL/6	N	male	mice	housed	at	22°C	 (n=2	 for	Ucp1,	 n=4	 for	1700007Rik15,	 2500002B13Rik,	Gm12319,	and	H19)	versus	24h	of	4°C	(n=2	for	Ucp1,	n=4	for	1700007Rik15,	2500002B13Rik,	Gm12319,	and	H19)	and	C57BL/6	N	male	mice	 exposed	 to	 chronic	 HFD	 (n=4)	 versus	 CD	 (n=3	 for	Ucp1,	 n=4	 for	1700007Rik15,	
2500002B13Rik,	 Gm12319,	 and	H19)	 	 feeding	 as	 quantified	 by	 qRT-PCR	 analysis.	 Relative	 (K-N)	 vWAT	expression	 of	Elovl3,	 Ucp1,	 1700007Rik15,	 2500002B13Rik,	 Gm12319,	 and	H19	 in	 lean	 C57BL/6	N	male	mice	housed	 at	 22°C	 (n=2	 for	Ucp1,	 n=4	 for	1700007Rik15,	 2500002B13Rik,	 Gm12319,	 and	H19)	versus	24h	 of	 4°C	 (n=2	 for	Ucp1,	 n=4	 for	1700007Rik15,	 2500002B13Rik,	 Gm12319,	 and	H19)	 and	 C57BL/6	N	male	mice	exposed	to	chronic	HFD	(n=3	for	Ucp1,	n=4	for	1700007Rik15,	2500002B13Rik,	Gm12319,	and	
H19)	 versus	 CD	 (n=4)	 feeding	 as	 quantified	 by	 qRT-PCR	 analysis.	 Transcript	 levels	 of	 mRNAs	 were	normalized	 to	 hypoxanthine	 phosphoribosyltransferase	 1	 (Hprt1)	 expression.	 Graphs	 show	 floating	 bars	with	the	line	at	the	mean	with	all	data	points	plotted;	and	unpaired	two-tailed	Student´s	t-tests	were	used	to	assess	statistical	significance.	*p<0,05,	**p<0,01,	***p<0,001.	If	applicable,	p-values	are	indicated	within	the	panel.	blue	=	4°C,	red	=	high-fat	diet	(HFD).	Modified	after	Schmidt	et	al.	(2018)204.	Figure	continued	on	the	next	page.		
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3.2	 LncRNA	 candidates	 2500002B13Rik	 and	 H19	 control	 brown	
adipogenesis			To	 analyse	 whether	 the	 knockdown	 of	 the	 candidate	 lncRNAs	 leads	 to	 defects	 in	 AT	differentiation,	 we	 performed	 locked	 nucleic	 acid	 (LNA)-mediated	 RNA	 interference	(RNAi)	 in	SVF	adipocyte	precursor	cells.	Generally,	LNA	GapmeRs	are	used	for	 loss-of-function	 studies	 of	 proteins,	 mRNAs,	 and	 lncRNAs.	 These	 single	 stranded	 antisense	oligonucleotides	 function	 through	 catalysis	 of	 RNase	 H-dependent	 degradation	 of	complementary	RNA	targets.		For	 analysis,	 SVF	 cells	 were	 isolated	 from	 three	 major	 adipose	 depots	 BAT,	scWAT,	and	vWAT.	The	experiment	revealed	blunted	 lipid	accumulation	upon	RNAi	of	
2500002B13Rik	 and	 H19	 in	 primary	 brown	 adipocyte	 precursor	 cells	 whereas	 lipid	accumulation	 upon	RNAi	 of	1700007L15Rik	 and	Gm12319	 in	 1°	 BAT	was	 not	 affected	(Figure	6A).	1°	scWAT	and	1°	vWAT	did	not	show	differences	in	lipid	accumulation	upon	RNAi	with	candidate	 lncRNAs	(Figure	6B,	C).	The	transfection	procedure	did	not	affect	lipid	 accrual	 as	 scr-transfected	 cells	 revealed	 equal	 amounts	 of	 lipid	 accumulation	 as	non-transfected	cells.		From	 these	 results,	 we	 conclude	 that	 loss	 of	 2500002B13Rik	 and	 H19	 gene	expression	leads	to	a	defect	in	BAT,	yet	not	scWAT	or	vWAT	differentiation.																	
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Figure	6:	Loss	of	2500002B13Rik	and	H19	results	in	a	decrease	of	lipid	accrual	Photomicrograph	of	 (A)	BAT,	 (B)	scWAT,	and	(C)	vWAT	derived	1°	adipocytes	after	no	 transfection	(no	TFX),	 transfection	with	25	nM	scrambled	(scr),	1700007L15Rik,	2500002B13Rik,	Gm12319	or	H19	LNAs.	Pictures	are	representative	of	n=6	(1°	BAT)	or	n=3	(1°	scWAT	and	1°	vWAT)	 independent	experiments,	performed	in	n=3	technical	replicates	each.	Scale	bar	=	100	µm.	Modified	after	Schmidt	et	al.	(2018)204.				
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Next,	 we	 tested	 which	 effect	 RNAi	 of	 the	 candidate	 genes	 has	 on	 gene	 expression	 of	browning/’beiging’	or	common	AT	markers	in	1°	SVF	adipocyte	precursor	cells	isolated	from	 BAT,	 scWAT,	 and	 vWAT.	 RNAi	 of	 1700007L15Rik	 did	 not	 result	 in	 changes	 in	adipogenesis	markers	 in	all	 three	adipose	tissues	except	 from	the	common	AT	marker	
Peroxisome	 Proliferator	 Activated	 Receptor	 Gamma	 (Pparg)	 which	 was	 significantly	decreased	 in	 scWAT	 (Figure	7A).	RNAi	 of	2500002B13Rik	 did	 not	 show	differences	 in	gene	 expression	 in	 scWAT	 or	 vWAT	 whereas	 BAT	 markers	 like	 Cell	 Death-Inducing	
DFFA-Like	Effector	A	 (Cidea)	and	Ucp1	were	 significantly	decreased	 in	BAT.	Moreover,	
CCAAT/Enhancer	Binding	Protein	Alpha	(Cebpa),	Iodothyronine	Deiodinase	2	(Dio2),	and	
Fatty	Acid	Binding	Protein	 4	 (Fabp4)	 showed	 a	 tendency	 to	 be	 decreased	 (Figure	7B).	RNAi	 of	Gm12319	 resulted	 in	no	difference	of	 gene	 expression	 in	 all	 three	AT	 (Figure	7C).	RNAi	of	H19	 led	 to	a	significant	decrease	of	BAT	markers	such	as	Cidea	 and	Ucp1	along	with	Elovl3	which	showed	a	tendency	to	be	decreased	in	1°	BAT.	In	scWAT	RNAi	of	
H19	 resulted	 in	 a	 significant	 decrease	 of	 common	 adipogenesis	 markers	 Fabp4	 and	
Pparg	 and	 BAT-specific	 marker	 PPARG	 Coactivator	 1	 Alpha	 (Pgc1a).	 In	 vWAT	
Adiponectin	(AdipoQ),	Cebpa,	and	Fabp4	showed	a	tendency	to	be	reduced	upon	RNAi	of	
H19	(Figure	7D).			 These	results	show	that	the	knockdown	of	both	2500002B13Rik	and	H19	leads	to	a	 decrease	 in	 lipid	 accumulation	 (Figure	 6)	 and	 gene	 expression	 of	 adipogenesis	markers	 (Figure	 7)	 in	 primary	 adipocytes	 of	 BAT	 whereas	 the	 loss	 of	 Gm12319	 and	
1700007L15Rik	did	not	have	an	effect	on	adipogenesis.	Although	H19	loss	also	resulted	in	 a	 decrease	 of	 adipogenesis	 markers	 in	 primary	 scWAT	 and	 vWAT,	 the	 effect	 was	weaker	compared	to	BAT.															
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Figure	7:	2500002B13Rik	and	H19	RNAi	results	in	decreased	expression	of	browning	markers	in	1°	
BAT	Relative	 expression	 of	 indicated	 mRNAs	 in	 BAT,	 scWAT,	 and	 vWAT	 derived	 from	 1°	 adipocytes	 after	transfection	 with	 25	 nM	 scr,	 (A)	 1700007L15Rik	 LNAs	 (n=2	 for	 1700007L15Rik	 in	 BAT,	 n=1	 for	
1700007L15Rik	 in	 scWAT	 and	 vWAT,	 and	 n=3	 for	 other	 genes	 in	 1°	 BAT,	 scWAT,	 and	 vWAT),	 (B)	
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2500002B13Rik	LNAs		(n=2	for	2500002B13Rik	in	BAT,	n=1	for	2500002B13Rik	in	scWAT	and	vWAT,	and	n=3	for	other	genes	in	1°	BAT,	scWAT,	and	vWAT),	(C)	Gm12319	LNAs	(n=2	for	Gm12319	in	BAT,	n=1	for	
Gm12319	 in	scWAT	and	vWAT,	and	n=3	for	other	genes	in	1°	BAT,	scWAT,	and	vWAT)	or	(D)	H19	LNAs	(n=4	 for	H19	 in	BAT,	n=3	 for	other	genes	 in	BAT,	 scWAT	and	vWAT).	Transcript	 levels	of	mRNAs	were	normalized	 to	Hprt1	 expression.	Graphs	 show	 floating	bars	with	a	 line	at	 the	mean	with	all	data	points	plotted.	 A	 paired,	 two-tailed	 Student´s	 t-test	 was	 used	 to	 assess	 statistical	 significance	 across	 n=3	independent	 experiments	 performed	 in	 n=3	 technical	 replicates.	 *p<0,05,	 **p<0,01,	 ***p<0,001.	 If	applicable,	p-values	are	indicated	within	the	panel.		Modified	after	Schmidt	et	al.	(2018)204.			We	 henceforth	 only	 focussed	 on	 the	 lncRNA	H19,	which	was	 induced	 in	 cold-exposed	and	 decreased	 in	 obese	 BAT	 due	 to	 its	 BAT-selective	 expression,	 strong	 sequence	conservation	 among	 eutherians,	 and	 stronger	 impact	 on	 gene	 expression	 upon	 RNAi	(compared	to	2500002B13Rik).	Notably,	H19	expression	was	not	altered	accordingly	in	scWAT	or	vWAT	depots	in	contrast	to	browning/’beiging’	markers	like	Ucp1,	pointing	to	a	 selective	 involvement	 of	H19	 in	 brown	 but	 not	 white	 adipocyte	 differentiation	 and	function.	 For	 further	 characterisation	of	 the	 effects	 of	H19	 on	 adipogenesis,	Oil	Red	O	(ORO)	staining	was	performed	for	quantification	of	 lipid	accrual.	ORO	staining	showed	that	upon	RNAi	of	H19	significantly	less	lipid	droplets	were	formed	resulting	in	impaired	adipogenesis	(Figure	8).		
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Figure	8:	LncRNA	H19	controls	brown	but	not	white	adipocyte	differentiation	Macroscopic	view	of	ORO	stained	24-well	plates	(left),	photomicrographs	of	ORO	stainings	of	(A)	BAT,	(B)	scWAT,	and	(C)	vWAT	derived	1°	adipocytes	and	densitometric	quantification	ORO	dye	incorporation	in	(A)	1°	BAT	after	transfection	with	25nM	scr	versus	H19	LNA.	An	unpaired,	two-tailed	Student´s	t-test	was	applied	to	assess	statistical	significance	across	n=3	independent	experiments	performed	in	n=3	technical	replicates	each.	***p<0,001.	Scale	bar	=	100	µm.	Modified	after	Schmidt	et	al.	(2018)204.			To	support	the	findings	of	alterations	in	gene	expression	in	H19	deficient	1°	BAT	and	the	substantial	 morphological	 defect	 seen	 during	 brown	 adipocyte	 differentiation,	 we	conducted	immunoblot	analyses	and	observed	a	significant	reduction	of	terminal	brown	adipocyte	marker	proteins	such	as	UCP1	and	PGC1a	in	H19-deficient	1°	BAT	(Figure	9).		These	results	show	that	lncRNA	H19	is	required	for	the	commitment	of	BAT	but	not	 scWAT	or	vWAT-derived	progenitors	and	argue	 for	a	 selective	 involvement	of	 the	lncRNAs	in	brown	but	not	‘beige’	adipocyte	differentiation	and	function.			 	 	
0
0.2
0.4
0.6
0.8
1
O
il 
R
ed
 O
***
scr LNA
H19 LNA
scr LNA 
scr LNA scr LNA 
H19 LNA 
H19 LNA H19 LNA 
	 	 3	Results	
	 74	
	
	
	 	
Figure	9:	Loss	of	H19	results	in	decreased	PGC1a	and	UCP1	protein	expression	in	1°	BAT		PGC1a	 and	 UCP1	 immunoblot	 analysis	 (left)	 and	 quantification	 (right)	 of	 1°	 BAT	 adipocytes	 after	transfection	 with	 25	 nM	 scr	 or	 H19	 LNA.	 Image	 is	 representative	 of	 three	 independent	 experiments.	Graphs	 show	 floating	bars	with	 a	 line	 at	 the	mean	with	 all	 data	points	plotted.	An	unpaired,	 two-tailed	Student´s	 t-test	 was	 applied	 to	 assess	 statistical	 significance	 across	 n=3	 independent	 experiments	performed	in	n=3	technical	replicates	each.	*p<0,05,	**p<0,01.	Modified	after	Schmidt	et	al.	(2018)204.	
	
	
3.3	Second	LNA	GapmeR	(LNA	H19_2)	confirms	H19	effect	on	adipogenesis	
and	excludes	off-target	effects		Although	 novel	 technologies	 like	 LNA	 GapmeRs	 are	 continuously	 improved,	 off-target	effects	are	still	a	problem	which	have	to	be	addressed	when	using	these	inhibitors.	Off-target	 effects	most	often	arise	 from	partial	 complementarity	of	 the	 sense	or	 antisense	strand	to	an	unintended	gene	sequence	due	to	the	single	sequence	of	LNA	GapmeRs.	To	exclude	 off-target	 effects,	 we	 used	 another	 LNA	 GapmeR	 for	 H19	 (LNA	 H19_2)	 to	confirm	former	results.	Knockdown	experiments	with	LNA	H19_2	confirmed	the	results	by	showing	a	decrease	in	the	accumulation	of	lipid	droplets	as	well	as	a	tendency	for	a	decrease	in	the	expression	of	Cebpa,	Cidea,	and	Ucp1	in	1°	BAT	whereas	no	difference	in	gene	 expression	 of	 adipogenesis	 genes	 could	 be	 shown	 in	 1°	 scWAT	 and	 1°	 vWAT	(Figure	10).		These	 data	 confirm	 that	 the	 use	 of	 two	 LNA	 GapmeR	 inhibitors	 for	H19	 with	different	sequences	leads	to	the	same	effects,	although	RNAi	with	LNA	H19_2	was	not	as	strong	as	the	first	inhibitor.	Thus,	the	second	inhibitor	showed	less	pronounced	effects.			
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A   
1° BAT 1° scWAT 1° vWAT 
   
   								
Figure	10:	LNA	H19_2	confirms	H19	effect	on	adipogenesis	and	excludes	off-target	effects	(A)	Photomicrographs	and	(B)	gene	expression	of	the	indicated	mRNAs	in	BAT,	scWAT,	and	vWAT	derived	1°	 adipocytes	 after	 transfection	with	25	nM	 scr	 versus	H19_2	LNAs.	 Pictures	 are	 representative	 of	 n=3	independent	 experiments.	 Scale	 bar	 =	 100	 µm.	 Transcript	 levels	 of	 mRNAs	 were	 normalized	 to	 Hprt1	expression.	Graphs	show	floating	bars	with	a	line	at	the	mean	with	all	data	points	plotted.	A	paired,	two-tailed	 Student´s	 t-test	 was	 used	 to	 assess	 statistical	 significance	 across	 n=3	 independent	 experiments	performed	in	n=3	technical	replicates	each.	*p<0,05,	**p<0,01.	If	applicable,	p-values	are	indicated	within	the	panel.	Modified	after	Schmidt	et	al.	(2018)204.			
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3.4	 Gene	 expression	 of	 early	 progenitors	 remains	 high	 in	 H19-ablated	
differentiated	primary	brown	adipocytes		
Protein	delta	homolog	1	(Dlk1),	also	termed	adipocyte	differentiation	inhibitor	protein	or	
preadipocyte	 factor	 1	 is	 known	 to	 be	mostly	 expressed	 in	 preadipocytes	 and	 declines	with	brown	adipocyte	differentiation211.	To	analyse	whether	the	expression	of	Dlk1	and	other	 preadipocyte	markers	 remained	 high	 in	 the	H19-ablated	 cells	 and	 whether	 the	defect	of	adipogenesis	resulted	from	a	failure	in	the	repression	of	preadipocyte	markers,	we	 checked	 the	 expression	 of	 genes	 relevant	 to	 adipocyte	 progenitor	 function	 in	 SVF	adipocyte	precursor	cells	isolated	from	1°	BAT	and	treated	with	RNAi	H19.	In	1°	BAT	the	expression	 of	 all	 adipocyte	 precursor	 genes	 remained	 high,	 whereas	 Runt	 Related	
Transcription	 Factor	 2	 (Runx2)	 and	 Platelet	 Derived	 Growth	 Factor	 Receptor	 Alpha	(Pdgfra)	 were	 significantly	 upregulated	 (Figure	 11A).	 This	 result	 demonstrates	incomplete	differentiation	of	1°	BAT	cells.	In	scWAT	and	vWAT	no	gene	was	significantly	changed	upon	H19	loss	(Figure	11B,	C).		From	 these	 results,	 we	 conclude	 that	 H19-ablation	 leads	 to	 a	 defect	 in	 the	transcriptional	cascade	of	genes	required	for	terminal	brown	adipocyte	differentiation.			
A            1° BAT B          1° scWAT C             1° vWAT 
   
	
Figure	11:	Failed	repression	of	early	progenitor	genes	in	committed	1°	BAT	upon	H19	ablation		Relative	expression	of	indicated	mRNAs	in	(A)	BAT,	(B)	scWAT,	and	(C)	vWAT	derived	1°	adipocytes	after	transfection	 with	 25	 nM	 scr	 versus	 H19	 LNAs.	 Transcript	 levels	 of	 mRNAs	 were	 normalized	 to	Hprt1	expression.	Graphs	show	floating	bars	with	a	line	at	the	mean	with	all	data	points	plotted.	A	paired,	two-tailed	 Student´s	 t-test	 was	 used	 to	 assess	 statistical	 significance	 across	 n=3	 independent	 experiments	performed	in	n=3	technical	replicates	each.	*p<0,05.	Modified	after	Schmidt	et	al.	(2018)204.		
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3.5	The	imprinted	lncRNA	H19	controls	oxidative	metabolism	in	BAT	
	To	investigate	the	cell-intrinsic	and	metaboregulatory	properties	of	H19	we	performed	
in	vitro	loss-of-function	approaches.	For	this	SVFs	were	isolated	from	BAT,	scWAT,	and	vWAT	 from	 C57BL/6	 N	mice	 and	H19	 RNAi	 was	 performed	 to	 analyse	H19-deficient	adipocytes.	 Cellular	 analyses	 using	 Seahorse	 technology	 indicated	 and	 calculation	 of	coupling	 efficiencies	 (CEs)	 confirmed	 that	 H19	 RNAi	 impaired	 oxidative	 metabolism	(Figure	 12A,	 B)	 and	 impaired	 uncoupling	 (Figure	 12C)	 in	 fully	 differentiated	 brown	adipocytes.	Calculations	of	CEs	are	important	for	determining	brown	adipocyte	function	under	conditions	where	too	few	brown	fat	cells	are	formed.	We	observed	increased	CEs	(reduced	 uncoupling),	 suggesting	 that	 not	 only	 less	 brown	 adipocytes	 are	 formed	but	also	that	the	individual	brown	adipocyte	is	less	proficient	in	uncoupled	respiration.	No	alterations	in	CE	were	seen	for	1°	scWAT	and	1°	vWAT	(Figure	12C)	which	stresses	the	specificity	of	H19	effects	in	1°	BAT.		Thus,	 we	 conclude	 that	H19	 supports	 oxidative	metabolism	 and	mitochondrial	dynamics	in	mature	adipocytes	in	a	BAT-specific	manner.		
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Figure	12:	Loss	of	H19	in	1°	BAT	impairs	oxidative	metabolism	and	uncoupling	(A)	Oxygen	consumption	rates	(OCR)	in	1°	adipocytes	derived	from	indicated	depots	transfected	with	25	nM	 scr	 versus	 H19	 LNA	 using	 Seahorse	 technology.	 Alternating	 white	 and	 grey	 backgrounds	 depict	injections	 of	 oligomycin,	 FCCP,	 and	 rotenone	 plus	 antimycin	 A.	 The	 number	 of	 wells	 measured	 are	indicated	in	each	panel.	A	two-way	analysis	of	variance	(ANOVA)	test	with	repeated	measurements	(2WA-RM)	was	 applied	 to	 assess	 statistical	 significance.	 (B)	Relative	OCRs	 in	BAT	 (left),	 scWAT	 (middle),	 and	vWAT	 (right)	derived	1°	 adipocytes	under	basal	 conditions	and	after	 addition	of	 oligomycin,	 FCCP,	 and	rotenone	 plus	 antimycin	 A	 after	 transfection	 with	 25	 nM	 scr	 versus	H19	 LNAs.	 The	 number	 of	 wells	measured	are	indicated	in	each	panel.	Graphs	represent	floating	bars	with	a	line	at	the	mean	with	all	data	points	 plotted.	 Unpaired,	 two-tailed	 Student´s	 t-test	 was	 applied	 to	 assess	 statistical	 significance.	 (C)	Coupling	 efficiencies	 (CEs)	 calculated	 from	absolute	OCRs	 from	 (A)	 according	 to	Brand	 et	 al.	 (2011)212.	Unpaired,	 two-tailed	 Student´s	 t-test	was	 applied	 to	 assess	 statistical	 significance.	 *p<0.05,	 **p<0.01.	 If	applicable,	p-values	are	indicated	within	the	panel.	Modified	after	Schmidt	et	al.	(2018)204.			
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3.6	H19	is	located	in	nuclear	and	cytoplasmic	compartments	in	1°	BAT		
H19	was	reported	to	reside	in	nuclear,	but	also	cytoplasmic	and	ribosomal	fractions	in	other	 cell	 types213,214.	 To	 determine	 localization	 of	 H19	 in	 1°	 BAT,	 subcellular	fractionation	 experiments	 were	 performed	 upon	 knockdown	 of	H19	 with	 either	 H19	LNA	(acts	mainly	in	the	nuclei)	or	H19	siRNA	(acts	preferentially	(predominantly)	in	the	cytoplasm).	When	analysing	H19	 gene	expression	 in	scr-transfected	cells	we	could	see	that	H19	was	equally	expressed	 in	the	nuclear	and	cytoplasmic	 fractions	(Figure	13A).	Furthermore,	H19	expression	was	significantly	decreased	upon	RNAi	LNA	knockdown	in	both	 compartments	 when	 normalized	 to	 Hprt	 or	 the	 unspliced	 heteronuclear	 RNA	(hnNctc1)	 (Figure	 13A).	 Thus,	 H19	 ablation	 was	 observed	 across	 subcellular	compartments	using	H19	LNA.			 	To	 show	 that	 the	 subcellular	 fraction	 was	 free	 of	 contamination	 from	 other	fractions,	a	 standard	procedure215,216	was	used	 to	compare	 the	expression	of	 	hnNctc1	and	 the	 nuclear	 RNA	 RNU6	 in	 the	 cytoplasmic	 and	 nuclear	 fractions.	 Analysing	 the	localization	of	hnNctc1	and	RNU6	RNA,	they	were	found	to	be	highly	enriched	in	nuclear	as	 appose	 to	 cytosolic	 fractions,	 which	 was	 shown	 for	 both	 knockdown	 techniques	(Figure	13B).			 Thus,	 we	 conclude	 that	 H19	 is	 located	 equally	 in	 nuclear	 and	 cytoplasmic	fractions	 and	 LNA	 knockdown	 leads	 to	 efficient	 silencing	 of	 both	 cytosolic	 as	well	 as	nuclear	H19	 pools.	 Moreover,	 fractions	were	 free	 of	 contaminations	 as	 shown	 by	 the	precedence	of	nuclear	RNA	transcripts	solely	in	the	nucleus.		
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Figure	13:	H19	is	located	in	nuclear	and	cytoplasmic	compartments	in	1°	BAT	(A)	 H19	 and	 (B)	 nuclear	 transcripts	 HnNctc1	 and	 RNU6	 expression	 in	 nuclear	 and	 cytoplasmic	compartments	 of	 1°	 BAT	 transfected	 with	 H19	 LNA	 or	 siH19	 inhibitors	 followed	 by	 subcellular	fractionation	using	PARIS	kits.	Transcript	levels	of	mRNAs	were	normalized	to	(A,	left)	and	(B)	Hprt1	and	(A,	 right)	 hnNctc1	 expression.	 Graphs	 show	 floating	 bars	 with	 a	 line	 at	 the	 mean	 with	 all	 data	 points	plotted.	An	unpaired,	 two-tailed	Student´s	 t-test	was	applied	to	assess	statistical	significance	across	n=3	independent	experiments	performed	in	n=3	technical	replicates	each.	*p<0.05,	**p<0.01.	Experiment	was	performed	with	kind	help	by	Dr.	M.	Bilban.	Modified	after	Schmidt	et	al.	(2018)204.	
	
	
3.7	 Cold/diet-induced	 obesity	 (DIO)-evoked	 alterations	 in	 H19	 are	
independent	of	H19-Igf2	imprinting	regulation		Historically,	 H19	 was	 discovered	 as	 monoallelically	 expressed,	 maternal	 gene.	 The	expression	 of	 a	 gene	 from	 only	 one	 parental	 strand	 is	 an	 epigenetic	 process	 called	‘genomic	imprinting’	(see	1.4).	Here,	the	reciprocally	expressed	H19-Igf2	imprinted	gene	cluster	 is	 regulated	 by	 the	 enhancer-blocking	 properties	 of	 CCCTC-Binding	 Factor	(CTCF)	 proteins155,169.	 To	 investigate	 whether	 H19-Igf2	 imprinting	 is	 altered	 we	performed	RNAi	of	Ctcf	in	primary	brown	adipocytes	and	analysed	the	gene	expression	of	Ctcf	and	Igf2	in	BAT	of	mice	exposed	to	either	4°C	or	22°C	and	mice	which	have	been	fed	either	a	HFD	or	a	CD.	No	defects	 in	BAT	adipogenesis	were	visible	after	Ctcf	RNAi	(Figure	14A,	B).	 Furthermore,	BAT	Ctcf	 and	 Igf2	 levels	were	unaltered	by	 cold	or	DIO	conditions	(Figure	14C).	Thus,	we	conclude	that	cold/DIO-evoked	alterations	in	H19	are	not	based	on	altered	H19-Igf2	imprinting.		The	first	exon	of	H19	encodes	the	miR-675	gene.	To	exclude	that	the	H19-encoded	
miR-675	 controls	BAT	differentiation	and	 function	we	analysed	 the	expression	of	miR-
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675-3p	 and	miR-675-5p	 in	BAT	of	mice	exposed	 to	either	4°C	or	22°C	and	mice	which	have	 been	 exposed	 to	 either	 HFD	 or	 CD.	 Both	 isoforms	 were	 not	 expressed	 in	 BAT	(Figure	14D,	E).	Therefore,	we	conclude	that	miR-675	is	not	involved	in	brown	adipocyte	differentiation.	
	
D  E 
  
 
	
Figure	14:	H19/Igf2	cluster	and	miR-675	are	not	affected	by	alterations	of	H19	upon	cold	or	DIO	(A)	Photomicrographs	and	(B)	expression	of	indicated	mRNAs	in	1°	BAT	after	transfection	with	25	nM	scr	versus	Ctcf	LNAs.	Pictures	are	representative	of	n=2	independent	experiments.	Scale	bar	=	250	µm.	Gene	expression	 analysis	 was	 performed	 twice	 in	 n=3	 technical	 replicates	 each.	 Transcript	 levels	 of	mRNAs	were	 normalized	 to	Hprt1	 expression.	 Graphs	 show	 floating	 bars	with	 a	 line	 at	 the	mean	with	 all	 data	points	plotted.	(C)	Relative	BAT	Ctcf	expression	(left	and	middle	left)	in	lean	C57BL/6	N	male	mice	housed	at	22°C	(n=4)	versus	24h	of	4°C	(n=4)	or	exposed	to	chronic	HFD	(n=10)	versus	CD	(n=8)	feeding.	Relative	BAT	 Igf2	 (right	and	middle	right)	expression	 in	 lean	C57BL/6	N	male	mice	housed	at	22°C	(n=4)	versus	24h	of	4°C	(n=4)	or	exposed	to	chronic	HFD	(n=5)	versus	CD	(n=7)	feeding.	Transcript	 levels	of	mRNAs	were	 normalized	 to	Hprt1	 expression.	 Graphs	 show	 floating	 bars	with	 a	 line	 at	 the	mean	with	 all	 data	points	plotted.	An	unpaired,	 two-tailed	Student´s	 t-test	was	applied	 to	assess	statistical	significance.	 (D)	Relative	miR-675-3p	and	miR-675-5p	abundance	(CT	cycle)	in	lean	C57BL/6	N	male	mice	housed	at	22°C	(n=4)	versus	24h	of	4°C	(n=4)	or	exposed	to	HFD	(n=6)	versus	CD	(n=7)	feeding.	(C)	and	(D)	blue	=	4°C,	red	=	HFD.	Graphs	show	floating	bars	with	a	line	at	the	mean	with	all	data	points	plotted.	(E)	Illustration	of	H19	(top)	and	miR-675	(bottom)	abundances	in	indicated	ATs	determined	by	total	(top)	or	small	RNA-Seq	(bottom,	UCSC	Genome	Browser).	*p<0,05.	Modified	after	Schmidt	et	al.	(2018)204.	DIO	=	diet	induced	obesity.		
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3.8	H19	overexpression	prevents	DIO	and	results	 in	 increased	BAT	energy	
expenditure	in	vivo		Impairments	 in	 EE	 because	 of	 defects	 in	 brown	 fat	 differentiation	 and	 function	make	mice	more	susceptible	to	DIO-induced	weight	gains.	Additionally,	they	have	an	increased	probability	to	develop	metabolic	diseases217–219.	To	investigate	the	role	of	H19	in	energy	metabolism	and	EE	in	vivo	we	exposed	H19	gain-of-function210	and	Control	mice	to	HFD	or	CD.	The	mouse	model	Tg(Igf2/LacZ,H19)YZ15Aco	contains	a	130	kb	YAC	transgene,	YZ,	 which	 harbours	 the	 Igf2	 and	H19	 genomic	 regions.	 In	 this	 mouse	model	 the	 Igf2	coding	 sequence	 is	 interrupted	with	 the	LacZ	 reporter	 gene.	The	YZ15	 line	 carries	10	copies	of	the	transgene.	When	adjusted	for	transgene	copy	number,	the	level	of	activity	in	the	ten	copy	mouse	line	was	suggested	to	be	approximately	20%	as	transgenic	YZ15	embryos	 express	 H19	 at	 two	 times	 more	 compared	 to	 non-transgenic	 littermates,	instead	of	eleven	times	as	would	be	assumed	if	the	transgene	copy	was	fully	active210.		 Metabolic	phenotyping	of	these	mice	showed	that	H19	expression	is	ubiquitously	induced	 (Figure	 15A)	 without	 changes	 in	 Ctcf	 (Figure	 15B)	 and	 Igf2	 (Figure	 15C)	expression	or	body	 length	 (Figure	15D).	H19	 overexpression	prevented	DIO-mediated	weight	 gains	 (Figure	15E)	 and	 improved	 insulin	 sensitivity	 (Figure	15F).	 Surprisingly,	glucose	 tolerance	 was	 decreased	 (Figure	 15G)	 in	 H19	 gain-of-function	 mice220.	 The	beneficial	effect	of	H19	overexpression	in	DIO	was	presumably	linked	to	an	increase	in	energy	 expenditure	 (EE)	 (Figure	 15I),	 a	 trend	 towards	 increased	 lipid	mobilisation	 at	22°C	(Figure	15J)	and	oxygen	consumption	at	22°C,	4°C,	and	after	norepinephrine	(NE)	administration	at	4°C	for	24	h	(Figure	15K).	Furthermore,	the	H19-dependent	induction	of	EE	 in	obese	mice	 co-occurred	with	 increased	 scWAT	 ‘beiging’	 (Figure	15N)	despite	little	 alterations	 in	 BAT	 thermogenesis	 (Figure	 15M).	 The	 observed	 rise	 in	 EE	 tended	towards	 prevention	 of	 DIO-evoked	 increases	 in	 scWAT	 and	 vWAT	 adiposity	 (Figure	15H)	 and	 precluded	 DIO-associated	 elevations	 in	 serum	 cholesterol	 (Figure	 15O)	 but	not	triglycerides	(Figure	15P).	Overall	these	results	indicate	an	improved	BAT	function	in	H19	TG	mice.		
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Figure	15:	H19	overexpression	protects	from	obesity	by	increasing	energy	expenditure	and	scWAT	
‘beiging’	(A)	Relative	H19	expression	in	indicated	tissues	from	male,	HFD-fed	Control	(n=4)	versus	H19	TG	(n=3	for	Bat,	 n=5	 for	 other	 tissues)	 mice.	 (B)	 Relative	 Ctcf	 expression	 in	 indicated	 tissues	 from	 male,	 HFD-fed	Control	 (n=4)	 versus	 H19	 TG	 (n=3	 BAT,	 n=5	 for	 other	 tissues)	 mice.	 (C)	 Relative	 Igf2	 expression	 in	indicated	tissues	from	male,	HFD-fed	Control	(n=4)	versus	H19	TG	(n=2	for	vWAT,	n=3	BAT	and	n=5	for	other	 tissues)	mice.	 (A),	 (B),	 and	 (C)	Transcript	 levels	 of	mRNAs	were	normalized	 to	Hprt1	 expression.	
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Graphs	 represent	 floating	bars	with	a	 line	at	 the	mean	and	all	data	points	plotted.	Unpaired,	 two-tailed	Student´s	 t-test	were	 used	 to	 assess	 statistical	 significance.	 (D)	 Nose-anus	 body	 length	 in	male,	 CD-fed	Control	 (n=5)	 versus	 H19	 TG	 (n=6)	 and	 HFD-fed	 Control	 (n=4)	 versus	 H19	 TG	 (n=5)	 mice.	 Graphs	represent	 floating	 bars	 with	 a	 line	 at	 the	 mean	 and	 all	 data	 points	 plotted.	 One-Way	 ANOVAs	 with	Bonferroni	post	hoc	 tests	 (1WA-B)	were	used	 to	assess	statistical	 significance.	 (E)	Body	weight	of	male,	HFD-fed	Control	(n=4-5)	versus	H19	TG	(n=4-5)	mice.	A	2WA-RM	with	Bonferroni	post	hoc	correction	for	multiple	comparisons	(2WA-B)	was	applied	to	assess	statistical	significance.	(F)	Insulin	tolerance	test	of	male,	 HFD-fed	 Control	 (n=4)	 versus	 H19	 TG	 (n=6)	 mice.	 (G)	 Glucose	 tolerance	 test	 of	 male,	 HFD-fed	Control	(n=5)	versus	H19	TG	(n=5)	mice.	For	ITT	and	GTT,	a	2WA-RM	with	Bonferroni	post	hoc	correction	for	multiple	comparisons	(2WA-B)	was	applied	to	assess	statistical	significance.	(H)	Tissue/body	weight	(BW)	 ratios	 in	male,	 HFD-fed	 Control	 (n=4)	 versus	H19	TG	 (n=5)	mice.	 Graphs	 represent	 floating	 bars	with	a	line	at	the	mean	and	all	data	points	plotted.	An	unpaired,	two-tailed	Student´s	t-test	was	applied	to	assess	 statistical	 significance	between	 genotypes.	 (I)	EE	 in	male,	HFD-fed	Control	 (n=4)	 versus	H19	TG	(n=5)	 mice.	 A	 2WA-RM	with	 Bonferroni	 post	 hoc	 correction	 (2WA-B)	 was	 applied	 to	 assess	 statistical	significance.	(J)	Respiratory	Exchange	Rations	(RER)	in	male,	HFD-fed	Control	(n=4)	versus	H19	TG	(n=5)	mice.	(K)	Oxygen	consumption	in	male,	HFD-fed	Control	(n=4)	versus	H19	TG	(n=5)	mice.	A	2WA-RM	with	repeated	 measures	 plus	 Bonferroni	 post	 hoc	 test	 was	 applied	 to	 assess	 statistical	 significance.	 (L)	Representative	photomicrograph	of	liver	sections	from	HFD-fed	Control	versus	H19	TG	mice.	Scale	bar	=	100	µm.	(M)	Relative	BAT	expression	of	indicated	mRNAs	from	male,	HFD	fed	Control	(n=4)	versus	H19	TG	 (n=3)	mice.	 (N)	 Relative	 scWAT	 expression	 of	 indicated	mRNAs	 from	male,	 HFD-fed	 Control	 (n=4)	versus	 H19	 TG	 (n=5)	 mice.	 (M,	 N)	 Transcript	 levels	 of	 mRNAs	 were	 normalized	 to	Hprt1	 expression.	Graphs	represent	floating	bars	with	a	line	at	the	mean	and	all	data	points	plotted.	An	unpaired,	two	tailed	Student´s	t-test	was	used	to	assess	statistical	significance.	(O)	Serum	cholesterol	levels	in	HFD-fed	Control	(n=4)	versus	H19	TG	mice	(n=5).	 (P)	Serum	triglyceride	 levels	 in	HFD-fed	Control	(n=4)	versus	H19	TG	(n=5)	mice.	 For	 (O)	 and	 (P),	 graphs	 represent	 floating	bars	with	 a	 line	 at	 the	mean	 and	 all	 data	points	plotted.	 Unpaired,	 two-tailed	 Student´s	 t-test	 were	 applied	 to	 assess	 statistical	 significance	 between	genotypes.	*p<0,05,	**p<0,01,	***p<0,001.	If	applicable	p-values	are	indicated	within	the	panel.	Modified	after	Schmidt	et	al.	(2018)204.			
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When	 analysing	 adipocyte	 and	 liver	 morphologies	 microscopically,	 we	 observed	 that	
H19	 overexpression	 prevented	 ‘whitening’	 of	 BAT	 (Figure	 16,	 left),	 reduced	 vWAT	(Figure	16,	right)	but	not	scWAT	(Figure	16,	middle)	hypertrophy	and	the	development	of	steatosis	in	obese	animals	(Figure	15L).			
A          BAT B         scWAT C         vWAT 
   
   
   
	
Figure	16:	H19	prevents	whitening	of	BAT	and	reduces	vWAT	hypertrophy		Representative	photomicrograph	of	(A,	top)	BAT,	(B,	top)	scWAT	and	(C,	top)	vWAT	from	HFD-fed	Control	versus	H19	TG	mice	 (A,	B,	C;	middle).	 Scale	bar	=	100	µm.	Automated	quantification	of	 adipocyte	mean	area	per	 field	 in	H&E	stained	(A,	bottom)	BAT	sections	 from	male,	HFD-fed	Control	(n=12	fields)	versus	H19	TG	 (n=9	 fields)	mice,	 (B,	bottom)	 scWAT	sections	 from	male,	HFD-fed	Control	 (n=12	 fields)	versus	H19	TG	(n=16	fields)	mice,	and	(C,	bottom)	vWAT	sections	from	male,	HFD-fed	Control	(n=8	fields)	versus	H19	 TG	 (n=10	 fields)	mice.	 Graphs	 represent	 floating	 bars	with	 a	 line	 at	 the	mean	 and	 all	 data	 points	plotted.	 An	 unpaired,	 two-tailed	 Student´s	 t-test	 was	 applied	 to	 assess	 statistical	 significance	 between	genotypes.	 **p<0.01.	 If	 applicable	 p-values	 are	 indicated	within	 the	panel.	Modified	 after	 Schmidt	 et	 al.	(2018)204.		
	
H19	 overexpression	 in	 lean	 mice	 led	 to	 little	 changes	 in	 body	 weight	 (Figure	 17A),	insulin	sensitivity	(Figure	17B),	glucose	clearance	(Figure	17C),	EE	(Figure	17D),	and	did	not	 affect	 lipid	 mobilisation	 (Figure	 17	 E),	 oxygen	 consumption	 (Figure	 17	 F),	 BAT	thermogenesis	 (Figure	 17G),	 adiposity	 (Figure	 17I)	 or	 scWAT	 ‘beiging’	 (Figure	 17H).	
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Furthermore,	food	and	water	intake	as	well	as	locomotion	was	unchanged	between	H19	TG	and	Control	mice	on	both	diets	(Figure	18).		Here,	 we	 conclude	 that	 H19	 is	 beneficial	 during	 DIO,	 but	 does	 not	 cause	detrimental	effects	in	lean	mice.		
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Figure	17:	H19	overexpression	causes	minor	increases	of	energy	expenditure	in	lean	mice	(A)	Body	weight	of	CD-fed	Control	(n=5)	versus	H19	TG	(n=6)	mice.	A	2WA-RM	with	repeated	measures	plus	 Bonferroni	post	 hoc	 test	was	 applied	 to	 assess	 statistical	 significance.	 (B)	 Insulin	 tolerance	 test	 of	male,	CD-fed	Control	(n=6)	versus	H19	TG	(n=5)	mice.	(C)	Glucose	tolerance	test	of	male,	CD-fed	Control	(n=5)	 versus	 H19	 TG	 (n=5)	 mice.	 For	 the	 ITT	 and	 the	 GTT	 a	 2WA-RM	 with	 repeated	 measures	 plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance.	(D)	EE	and	(E)	RER	in	male,	CD-fed	Control	(n=4)	versus	H19	TG	(n=6)	mice.	(F)	Oxygen	consumption	in	male,	HFD-fed	Control	versus	H19	TG	mice.	(G)	Relative	BAT	expression	of	indicated	mRNAs	from	male,	CD-fed	Control	(n=5)	versus	H19	TG	(n=6)	mice.	(H)	Relative	scWAT	expression	of	 indicated	mRNAs	from	male,	CD-fed	Control	(n=5)	versus	H19	 TG	 (n=6)	 mice.	 (G,	 H)	 Transcript	 levels	 of	 mRNAs	 were	 normalized	 to	 Hprt1	 expression.	 (I)	Tissue/body	 weight	 ratio	 in	 male,	 CD-fed	 Control	 (n=5)	 versus	 H19	 TG	 (n=6)	 mice.	 (G,	 H,	 I)	 Graphs	represent	 floating	 bars	 with	 a	 line	 at	 the	 mean	 with	 all	 data	 points	 plotted	 and	 unpaired,	 two-tailed	Student´s	 t-test	were	used	 to	assess	statistical	 significance.	 *p<0,05,	 **p<0,01.	 If	applicable	p-values	are	indicated	within	the	panel.	Modified	after	Schmidt	et	al.	(2018)204.	
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Figure	18:	Systemic	overexpression	of	H19	does	not	influence	food	intake,	water	intake,	and	
locomotion	(A)	Food	intake	of	HFD-fed	(left)	Control	(n=5)	versus	H19	TG	(n=5)	mice	and	of	CD-fed	(right)	Control	(n=5	at	22°C	and	n=4	at	4°C)	versus	H19	TG	(n=5)	mice.	(B)	Water	intake	of	HFD-fed	(left)	Control	(n=5)	versus	H19	TG	(n=5)	mice	and	of	CD-fed	(right)	Control	(n=4)	versus	H19	TG	(n=6)	mice.	(C)	Locomotion	of	HFD-fed	(left)	Control	(n=5)	versus	H19	TG	(n=5)	mice	and	of	CD-fed	(right)	Control	(n=4)	versus	H19	TG	 (n=6)	mice.	 (D)	 Distance	 of	 HFD-fed	 (left)	 Control	 (n=5)	 versus	 H19	 TG	 (n=5)	mice	 and	 of	 CD-fed	(right)	Control	(n=4)	versus	H19	TG	(n=6)	mice.	Graphs	represent	floating	bars	with	a	line	at	the	mean.			
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3.9	H19	loss	in	fat	impairs	energy	expenditure	(EE)	and	sensitizes	towards	
DIO-induced	weight	gain	
	To	 investigate	 the	 fat-intrinsic	 effects	 of	 H19	 in	 an	 adipocyte-intrinsic	 manner,	 we	conditionally	 deleted	 H19-DMR	 (an	 epigenetic	 regulator	 that	 controls	 expression	 of	
H19)	 by	 crossing	 female	 H19flDMR/flDMR	 mice	 with	 male	 Adipoq-cre	 expressing	 mice	(H19∆AT)	 (Figure	19A).	H19∆AT	mice	 showed	decreased	H19	expression	 in	BAT	 (Figure	19B)	and	1°	BAT	cells	(Figure	19C)	whereas	no	decrease	in	expression	was	observed	in	other	tissues	(Figure	19B).	H19∆AT	mice	gained	more	body	weight	compared	to	Control	mice	 upon	 HFD	 (Figure	 19D)	 but	 not	 on	 CD	 feeding	 (Figure	 20A).	 The	 alterations	 in	insulin	 sensitivity	 (Figure	 19E,	 Figure	 20B)	 and	 glucose	 tolerance	 (Figure	 19F,	 Figure	20C)	 were	 negligible	 on	 both	 diets.	 Importantly,	 BAT-specific	H19	 loss	 decreased	 EE	(Figure	 19H,	 Figure	 20E)	 and	 oxygen	 consumption	 (Figure	 19J,	 Figure	 20G)	 on	 both	diets,	 tended	 towards	 decreased	 lipid	 oxidation	 (Figure	 19I)	 at	 4°C,	 and	 increased	scWAT	 adiposity	 (Figure	 19G)	 in	 obese,	 but	 not	 lean	 knockout	mice	 (Figure	 20D,	 F).	Food	 and	 water	 intake	 as	 well	 as	 locomotion	 was	 unchanged	 between	 H19∆AT	 and	Control	mice	on	both	diets	(Figure	21).		From	these	results,	we	conclude	that	BAT	function	is	decreased	in	H19∆AT	mice,	especially	under	DIO	condition.																	
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Figure	19:	Fat-specific	deletion	of	H19	sensitizes	towards	DIO-associated	weight	gains	and	
impairments	in	energy	expenditure	(A)	 Mating	 strategy	 for	 parental	 allele-of-origin	 specific	 deletion	 of	 the	 H19	 differentially	 methylated	domain	(DMD)	in	adipose	tissue.	(B)	H19	expression	in	indicated	tissues	from	male	Control	(n=3)	versus	H19∆AT	 (n=3)	mice.	Transcript	 levels	of	mRNAs	were	normalized	 to	Hprt1	 expression.	Graphs	represent	floating	 bars	 with	 a	 line	 at	 the	 mean.	 An	 unpaired,	 two-tailed	 Student´s	 t-test	 was	 applied	 to	 asses	statistical	significance.	(C)	H19	expression	in	BAT	derived	1°	adipocytes	from	male	Control	versus	H19∆AT	mice.	 Transcript	 levels	 of	mRNAs	were	normalized	 to	Hprt1	 expression.	Graphs	 represent	 floating	bars	with	a	line	at	the	mean.		A	paired,	two-tailed	Student´s	t-test	was	applied	to	assess	statistical	significance	across	n=4	independent	experiments	performed	in	n=3	technical	replicates	each.	(D)	Body	weight	of	male,	HFD-fed	 Control	 (n=5)	 versus	 H19∆AT	 (n=4)	 mice.	 A	 2WA-RM	 with	 plus	 Bonferroni	 post	 hoc	 test	 was	applied	to	assess	statistical	significance.	(E)	Insulin	tolerance	test	of	male,	HFD-fed	Control	(n=5)	versus	H19∆AT	 (n=4)	mice.	 (F)	Glucose	 tolerance	 test	of	male,	HFD-fed	Control	 (n=5)	versus	H19∆AT	 (n=4)	mice.	For	(E)	and	(F),	a	2WA-RM	plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance.	(G)	Tissue/body	weight	 ratio	 in	male,	 HFD-fed	 Control	 (n=5)	 versus	 H19∆AT	 (n=4)	mice.	 Graphs	 represent	floating	 bars	 with	 a	 line	 at	 the	 mean.	 An	 unpaired,	 two-tailed	 Student´s	 t-test	 was	 applied	 to	 assess	statistical	significance.	(H)	EE	in	male,	HFD-fed	Control	(n=5)	versus	H19∆AT	(n=4)	mice.	A	2WA-RM	test	was	applied	to	assess	statistical	significance.	(I)	RER	in	male,	HFD-fed	Control	(n=5)	versus	H19∆AT	(n=4)	mice.	(J)	Oxygen	consumption	in	male,	HFD-fed	Control	(n=5)	versus	H19∆AT	(n=4)	mice.	A	2WA-RM	test	was	 applied	 to	 assess	 statistical	 significance.	 If	 applicable	 p-values	 are	 indicated	 within	 the	 panel.	Modified	after	Schmidt	et	al.	(2018)204.		
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Figure	20:	Fat-specific	deletion	of	H19	causes	minor	decreases	in	energy	expenditure	in	lean	mice	Body	weight	of	male,	CD-fed	Control	 (n=5)	versus	H19∆AT	 (n=5)	mice.	 (B)	 Insulin	 tolerance	 test	of	male,	CD-fed	Control	(n=5)	versus	H19∆AT	(n=5)	mice.	(C)	Glucose	tolerance	test	of	male,	CD-fed	Control	(n=5)	versus	H19∆AT	(n=5)	mice.	A	2WA-RM	with	repeated	measures	plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance.	(D)	Tissue/body	weight	ratio	 in	male,	CD-fed	Control	(n=5)	versus	H19∆AT	(n=5)	mice.	Graphs	represent	floating	bars	with	a	line	at	the	mean.	(E)	EE	in	male,	CD-fed	Control	(n=5)	versus	H19∆AT	(n=5)	mice.	A	2WA-RM	with	repeated	measures	plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance.	(F)	RER	in	male,	CD-fed	Control	(n=5)	versus	H19∆AT	(n=5)	mice.	A	2WA-RM	with	repeated	measures	plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance.	(G)	Oxygen	consumption	in	male,	CD-fed	Control	(n=5)	versus	H19∆AT	(n=5)	mice.	A	2WA-RM	with	repeated	measures	plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance.	If	applicable	p-values	are	indicated	within	the	panel.	Modified	after	Schmidt	et	al.	(2018)204.		
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Figure	21:	Fat-specific	deletion	of	H19	does	not	influence	food	intake,	water	intake,	and	
locomotion	(A)	Food	 intake	of	HFD-fed	 (left)	Control	 (n=5)	versus	H19∆AT	 (n=5)	mice	and	of	CD-fed	 (right)	Control	(n=5)	 versus	H19∆AT	 (n=5)	mice.	 (B)	Water	 intake	 of	 HFD-fed	 (left)	 Control	 (n=5)	 versus	H19∆AT	 (n=5)	mice	and	of	CD-fed	(right)	Control	(n=5)	versus	H19∆AT	(n=5	at	22°C	and	n=4	at	4°C)	mice.	(C)	Locomotion	of	 HFD-fed	 (left)	 Control	 (n=5)	 versus	 H19∆AT	 (n=5)	 mice	 and	 of	 CD-fed	 (right)	 Control	 (n=5)	 versus	H19∆AT	(n=5)	mice.	(D)	Distance	of	HFD-fed	(left)	Control	(n=5)	versus	H19∆AT	(n=5)	mice	and	of	CD-fed	(right)	Control	(n=4)	versus	H19∆AT	(n=5)	mice.	Graphs	represent	floating	bars	with	a	line	at	the	mean.		
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3.10	H19	regulates	brown	adipose	mitochondrial	biogenesis	in	vitro	and	in	
vivo			Chronic	 induction	 of	 thermogenesis	 through	 cold	 temperature	 requires	mitochondrial	biogenesis	 and	 rearrangements	 of	 mitochondrial	 network	 via	 fission	 and	 fusion	 in	BAT221,222.	 As	 we	 observed	 cell-intrinsic	 differences	 in	 oxidative	 metabolism	 of	 H19-deficient	 (Chapter	 3.5)	 adipocytes,	 we	 wanted	 to	 investigate	 whether	 mitochondrial	morphology	in	BAT	was	changed	using	electron	microscopy	(EM).	Global	factors	such	as	mitochondrial	perimeter	(Figure	22G)	and	area	(Figure	22H)	were	unchanged.	However,	we	observed	defects	in	mitochondrial	architecture.	Cristae	formation	was	perturbed	in	obese	 BAT	 of	 Control	 mice	 (Figure	 22B,	 C)	 but	 not	H19	 TG	 mice	 (Figure	 22E,	 F).	 In	addition,	we	analysed	the	gene	expression	of	mitochondrial	biogenesis	as	well	as	fission	and	fusion	markers.	The	expression	of	genes	involved	in	mitochondrial	biogenesis	was	decreased	in	BAT	and	scWAT	of	obese	mice	(Figure	22I).	H19	overexpression	was	able	to	 reverse	 the	DIO-evoked	 defects	 in	 gene	 expression	 in	 BAT	 (Figure	 22I),	 but	 not	 in	scWAT	(Figure	22J).	Mitochondrial	fission	and	fusion	marker	dynamin-related	protein	1	(Drp1)	 and	mitochondrial	 fission	 factor	 (Mff)	were	 significantly	 decreased	 along	 with	other	markers	 of	 the	 panel	which	 showed	 a	 tendency	 to	 be	 downregulated	 in	BAT	 of	Control	mice	on	HFD.	When	analysing	the	same	panel	of	genes	in	H19	TG	mice	on	HFD,	expression	 of	 markers	 tended	 to	 be	 slightly	 increased	 compared	 to	 Control	 mice,	although	this	effect	was	not	significant	(Figure	22K).	 In	scWAT	of	H19	TG	and	Control	mice	on	HFD,	mitochondrial	 fission	and	 fusion	markers	were	not	altered	compared	 to	Control	mice	on	CD	(Figure	22L).		These	results	 lead	to	the	conclusion	that	H19	reverses	detrimental	DIO-induced	defects	on	mitochondrial	morphology	and	biogenesis	in	BAT	whereas	effects	of	H19	on	fission	and	fusion	is	weaker.			
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Figure	22:	H19	overexpression	promotes	brown	adipose	mitochondrial	biogenesis	in	vitro	and	in	
vivo	(A-F)	Representative	EM	images	from	BAT	mitochondria	across	diets	and	genotypes.	White	arrows	depict	cristae	 structures.	 Scale	 bar	 (A,	 B,	 D,	 E)	 =	 2	 µm,	 (C,	 F)	 =	 500	 nM.	 (G)	 Quantification	 of	 mitochondrial	perimeters	 (total	 mitochondria	 numbers	 in	 brackets)	 in	 BAT	 of	 indicated	 diets	 and	 genotypes.	 (H)	Quantification	of	mitochondrial	 area	 (total	mitochondria	number	 in	brackets)	 in	BAT	of	 indicated	diets	and	 genotypes.	 (G,	H)	 Graphs	 represent	 floating	 bars	with	 a	 line	 at	 the	mean.	 	 An	 unpaired,	 two-tailed	Student´s	 t-test	 was	 applied	 to	 assess	 statistical	 significance	 between	 genotypes.	 (I)	 Relative	 BAT	expression	of	indicated	mRNAs	in	age-matched	HFD-fed	H19	TG	(n=3),	HFD-fed	Control	(n=4)	and	CD-fed	Control	(n=5)	male	mice.	(J)	Relative	scWAT	expression	of	indicated	mRNAs	in	age-matched	HFD-fed	H19	TG	(n=3),	HFD-fed	Control	(n=4),	and	CD-fed	Control	(n=5)	male	mice.	 (I,	 J)	Transcript	 levels	of	mRNAs	were	normalized	to	Hprt1	expression.	Graphs	represent	floating	bars	with	a	line	at	the	mean.	A	One-Way	ANOVA	plus	Bonferroni	post	hoc	test	was	applied	to	assess	statistical	significance;	(a)=	Significance	versus	CD-fed	Control,	(b)=	Significance	versus	HFD-fed	Control.	(K)	Relative	BAT	expression	of	indicated	mRNAs	in	HFD-fed	H19	TG	(n=3),	HFD-fed	Control	(n=4),	and	CD-fed	Control	(n=5)	male	mice.	Transcript	levels	of	mRNAs	were	normalized	to	Hprt1	expression.	Graphs	represent	 floating	bars	with	a	 line	at	 the	mean.	A	One-Way	 ANOVA	 test	 with	 Bonferroni	 post	 hoc	 test	 was	 applied	 to	 assess	 statistical	 significance;	 (a)=	Significance	versus	CD-fed	Control.	 	 (L)	Relative	scWAT	expression	of	 indicated	mRNAs	 in	HFD-fed	H19	TG	(n=3),	HFD-fed	Control	(n=4),	and	CD-fed	Control	(n=5)	male	mice.	Transcript	levels	of	mRNAs	were	normalized	 to	 Hprt1	 expression.	 Graphs	 represent	 floating	 bars	 with	 a	 line	 at	 the	 mean.	 	 *p<0.05,	**p<0.01,	***p<0.001.	Modified	after	Schmidt	et	al.	(2018)204.	Figure	continued	on	the	next	page.									
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The	protective	effects	of	H19	overexpression	on	BAT	mitochondria	spurred	 interest	 in	analysing	 its	 effect	 on	 mitochondria	 in	 more	 detail.	 Consequently,	 we	 wanted	 to	investigate	whether	H19	ablation	leads	to	an	opposite	effect	on	mitochondria	in	BAT	of	H19∆AT	mice	and	performed	EM	imaging	and	gene	expression	analyses.		The	experiments	revealed	pathological	alterations	in	mitochondrial	morphology,	specifically	 cristae	shape,	of	BAT	 in	H19∆AT	mice	coupled	with	DIO	 (Figure	23A-D).	To	support	 these	 morphological	 findings,	 we	 analysed	 genes	 involved	 in	 mitochondrial	biogenesis	in	BAT	of	H19∆AT	mice	and	observed	that	NADH	dehydrogenase	[ubiquinone]	
flavoprotein	2	(Ndufv2)	was	significantly	decreased	and	other	genes	of	the	investigated	panel	were	also	reduced	compared	to	BAT	of	Control	mice	(Figure	23E).	In	scWAT	gene	expression	 of	 mitochondrial	 biogenesis	 markers	 was	 unaltered	 (Figure	 23F).	 The	expression	of	 fission	and	 fusion	parameters	 in	BAT	showed	a	decreased	expression	of	
mitochondrial	fission	1	protein	(Fis1)	and	Mitofusin-1	(Mfn1)	in	H19∆AT	mice	compared	to	Control	mice	(Figure	23G).	In	scWAT	of	H19∆AT	mice	fission	and	fusion	markers	tended	to	 be	 increased	 compared	 to	 Control	 mice,	 although	 this	 effect	 was	 not	 significant	(Figure	23H).		Interestingly,	 cell-intrinsic	 defects	 in	 mitochondriogenesis	 occurred	 also	 in	mature	 adipocytes	 from	de	novo	 differentiated	SVFs	of	H19	 RNAi	 treated	1°	BAT	 cells	(Figure	23I)	and	H19∆AT	mice	(Figure	23J).	These	observations	in	1°	BAT	adipocytes	are	in	 accordance	with	 the	 expression	defects	 observed	 in	 the	 same	gene	 set	 seen	 in	 vivo	with	 H19∆AT	 BAT.	 In	 addition,	 we	 used	 SVF	 isolated	 BAT	 from	 H19∆AT	 mice	 and	differentiated	 them	 into	 mature	 adipocytes	 to	 perform	 Seahorse	 experiments.	 We	observed	a	tendency	towards	reduced	basal	OCRs,	which	we	take	as	measure	of	general	mitochondrial	 function	 of	 brown	 adipocytes	 selective	 lacking	 H19	 in	 mature	 cells	(Figure	23K).		From	 these	 results,	 we	 conclude	 that	H19	 loss	 in	 AT	 causes	 mice	 to	 be	 more	susceptible	 to	 DIO	 weight	 gains	 and	 leads	 to	 impairments	 in	 EE,	 possibly	 due	 to	 the	control	of	mitochondrial	dynamics	by	the	lncRNA	H19.							
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Figure	23:	H19	ablation	exacerbates	HFD-induced	detrimental	effects	on	mitochondrial	biogenesis		(A-D)	Representative	EM	images	from	BAT	mitochondria	across	diets	and	genotypes.	White	arrows	depict	cristae	structures.	Scale	bar	=	2	µm.	(E)	Relative	BAT	expression	of	indicated	mRNAs	in	HFD-fed	Control	(n=4)	versus	HFD-fed	H19∆AT	(n=3)	male	mice.	(F)	Relative	scWAT	expression	of	indicated	mRNAs	HFD-fed	Control	 (n=4)	 versus	HFD-fed	H19∆AT	 (n=3)	male	mice.	 For	 (E)	 and	 (F),	 transcript	 levels	 of	mRNAs	were	normalized	to	Hprt1	expression.	Graphs	represent	floating	bars	with	a	line	at	the	mean.	An	unpaired,	two-tailed	Student´s	 t-test	was	applied	 to	assess	statistical	 significance	between	genotypes.	 (G)	Relative	BAT	expression	of	 indicated	mRNAs	 in	HFD-fed	Control	 (n=4)	versus	HFD-fed	H19∆AT	 (n=3)	male	mice.	(H)	 Relative	 scWAT	 expression	 of	 indicated	 mRNAs	 in	 HFD-fed	 Control	 (n=4)	 versus	 HFD-fed	 H19∆AT	(n=3)	 male	 mice.	 For	 (G)	 and	 (H),	 transcript	 levels	 of	 mRNAs	 were	 normalized	 to	 Hprt1	 expression.	Graphs	 represent	 floating	 bars	 with	 a	 line	 at	 the	 mean.	 An	 unpaired,	 two-tailed	 Student´s	 t-test	 was	applied	to	assess	statistical	significance	between	genotypes.	(I)	Relative	expression	of	indicated	mRNAs	in	BAT	derived	1°	adipocytes	after	 transfection	with	25	nM	scr	versus	H19	LNA.	(J)	Relative	expression	of	indicated	mRNAs	in	BAT	1°	adipocytes	from	Control	versus	H19∆AT	mice.	For	(I)	and	(J),	transcript	levels	of	mRNAs	were	normalized	to	Hprt1	expression.	Graphs	represent	floating	bars	with	a	line	at	the	mean.		A	paired,	 two-tailed	 Student´s	 t-test	was	 applied	 to	 assess	 statistical	 significance	 across	 n=3	 independent	experiments	performed	in	n=3	technical	replicates	each.	(K)	OCRs	in	1°	BAT	from	Control	or	H19∆AT	mice.	Alternating	backgrounds	depict	 injections	of	medium,	oligomycin,	FCCP	and	rotenone	plus	antimycin	A.	Numbers	 of	 measured	 wells	 per	 genotype	 are	 indicated.	 *p<0.05,	 **p<0.01.	 If	 applicable	 p-values	 are	indicated	within	the	panel.	Modified	after	Schmidt	et	al.	(2018)204.	Figure	continued	on	the	next	page.																
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3.11	 BAT	 represents	 a	 unique	 case	 of	 tissue-specific	 imprinting	 and	 PEG	
loss		Mechanistically,	 the	 lncRNA	 H19	 is	 a	 rather	 well	 understood	 example	 of	 imprinted	genes,	 which	 are	 exclusively	 transcribed	 from	 one	 parental	 allele169,223.	 Research	 has	shown	 that	 H19	 belongs	 to	 an	 imprinted	 gene	 network	 (IGN)	 and	 regulates	 the	expression	of	eight	 imprinted	genes,	both	maternally	and	paternally	expressed,	within	this	cluster224.		Based	on	the	BAT-selectivity	of	H19	and	its	novel	role	in	the	regulation	of	brown	adipocyte	 differentiation	 and	 function,	 we	were	 interested	 in	 the	 transcriptome-wide	expression	 of	 paternally	 expressed	 genes	 (PEGs)	 and	 maternally	 expressed	 genes	(MEGs)	 across	 fat	 depots.	 RNA-Seq	 from	 C57BL/6	 N	mice	 revealed	 no	 differences	 in	MEGs	abundances	between	BAT,	scWAT	or	vWAT	(Figure	24A,	B).	However,	seven	fat-abundant	protein-coding	genes	(such	as	G	Protein	Coupled	Receptor	1	(Gpr1),	Insulin	Like	
Growth	 factor	 2	 (Igf2),	 Mesoderm	 Specific	 Transcript	 (Mest),	 Neuronatin	 (Nnat),	
Paternally	Expressed	3	and	10	 (Peg3,	Peg10)	and	Plagl1	Like	Zinc	Finger	1	 (Plagl1)	and	three	microRNA	PEGs	(miR-184,	miR-298	and	miR-335))	and	many	others	were	absent	from	BAT	yet	robustly	expressed	in	scWAT	and	vWAT	(Figure	24C-E).		From	this	result,	we	conclude	that	MEGs	are	equally	distributed	between	adipose	tissues,	whereas	PEGs	are	mainly	absent	from	BAT	but	enriched	in	WAT.		
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Figure	24:	Repression	of	paternal	monoallelic	gene	expression	in	BAT	(A,	B)	Plot	of	expression	fold-changes	of	maternally	expressed	genes	(MEGs)	in	BAT	versus	(A)	scWAT	and	(B)	 vWAT.	 (C,	 D)	 Plot	 of	 expression	 fold-changes	 of	 paternally	 expressed	 genes	 (PEGs)	 between	 BAT	versus	(C)	scWAT	and	(D)	vWAT.	A	Wilcoxon	matched-pairs	signed	rank	test	was	used	to	assess	statistical	significance	 for	 up-	 or	 downregulation	 of	 PEGs/MEGs.	 (E)	 UCSC	 Genome	 Browser	 illustration	 of	 PEG	abundances	 in	 BAT,	 scWAT,	 and	 vWAT.	 If	 applicable	 p-values	 are	 indicated	within	 the	 panel.	Modified	after	Schmidt	et	al.	(2018)204.			
-1 0 1 2 3 4 5 6
-8
-6
-4
-2
0
2
4
6
8
Cumulative FPKM (log10)
fo
ld
-c
ha
ng
e 
(B
AT
/s
cW
AT
, l
og
2) miRNA mRNA
Cdkn1c
H19
Slc22a3
Igf2r
Dcn
p=0.01, median(scWAT=1.409) 
(Wilcoxon signed rank test)
-1 0 1 2 3 4 5 6
-8
-6
-4
-2
0
2
4
6
8
Cumulative FPKM (log10)
fo
ld
-c
ha
ng
e 
(B
AT
/v
W
AT
, l
og
2) miRNA mRNA
H19
Dcn
Slc22a3
Igf2r
p=0.067, median(vWAT=0.784) 
(Wilcoxon signed rank test)
-1 0 1 2 3 4 5
-8
-6
-4
-2
0
2
4
6
8
Cumulative FPKM (log10)
fo
ld
-c
ha
ng
e 
(B
AT
/s
cW
AT
, l
og
2)
Nnat
Mest
Peg10
Plagl1
Igf2
Peg3
p=0.002, median(scWAT=0.26) 
(Wilcoxon signed rank test)
-1 0 1 2 3 4 5
-8
-6
-4
-2
0
2
4
6
8
Cumulative FPKM (log10)
fo
ld
-c
ha
ng
e 
(B
AT
/v
W
AT
, l
og
2)
Peg10 Mest
Nnat
Plagl1
Igf2
Peg3
p=0.0001, median(scWAT=0.326) 
(Wilcoxon signed rank test)
	 	 3	Results	
	 100	
3.12	H19	recruits	MBD1	chromatin	modifier	in	mature	BAT			As	 expression	 of	H19	 was	 not	 altered	 during	 BAT,	 scWAT,	 and	 vWAT	 differentiation	(Figure	25),	we	next	wanted	to	discern	if	H19	interacts	with	specific	protein	interactors	to	repress	PEGs	in	brown	adipocytes.		
1° BAT 1° scWAT 1° vWAT 
   
	
Figure	25:	Timecourse	of	AdipoQ,	H19	and	Ucp1	expression	in	1°	adipocytes	during	differentiation	Relative	 expression	 of	 indicated	mRNAs	 in	 1°	 BAT,	 scWAT,	 and	 vWAT	 adipocytes	 during	 the	 course	 of	differentiation.	 Transcript	 levels	 of	 mRNAs	 were	 normalized	 to	 Hprt1	 expression.	 Data	 represent	 one	experiment,	performed	in	n=3	technical	replicates.	Modified	after	Schmidt	et	al.	(2018)204.		To	 investigate	 this,	 we	 performed	 Capture	Hybridisation	 Analysis	 of	RNA	 Targets225	coupled	to	mass	spectrometry	(CHART-MS)	from	confluent	and	differentiated	PIBA	cells.	ChART	is	a	technique	that	uses	complementary	oligonucleotides	to	purify	an	RNA	with	its	associated	proteins	from	formaldehyde	cross-linked	chromatin	(more	details	on	this	technique	can	be	found	in	chapter	2.8).	In	total	3,590	proteins	that	were	associated	with	
H19	were	detected	by	MS.	Of	 those	proteins,	168	were	enriched	 in	H19	antisense,	not	sense,	oligonucleotide	co-immunoprecipitation	samples.	76	proteins	were	bound	to	H19	in	confluent	and	54	proteins	in	differentiated	cells,	whereas	38	proteins	were	bound	to	
H19	 in	 both	 conditions	 (Figure	26A).	Next,	we	performed	 Ingenuity	Pathway	Analysis	(IPA)	to	construct	a	H19-protein	interactome	comprised	of	61	proteins	(Figure	26C).	IPA	is	 an	 analysis	 and	 search	 tool	 with	 which	 interaction	 network	 analyses	 can	 be	performed	 to	 explore,	 among	other	 options,	RNA-protein	networks.	When	performing	gene	 ontology	 (GO)	 analyses	 using	 Ami	 Gene	 Ontology	 2	 (AMIGO2),	 a	 multiplatform	software	 tool	 for	 browsing	 the	 Gene	 Ontology	 database226,	 we	 could	 see	 that	 in	immature	 BAT	 H19	 mainly	 recruited	 proteins	 annotated	 as	 ‘RNA-binding	 proteins’	(RBPs,	e.g.	H19	interactors	like	Insulin	Like	Growth	Factor	2	Binding	Protein	3	(IGFBP3))	
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whereas	in	differentiated	cells	H19	primarily	recruited	proteins	classified	as	‘chromatin	binders’	 or	 ‘chromatin	 modifiers’	 (Figure	 26B).	 The	 protein	 DNA	 methyltransferase	MBD1	(and	its	homologue	MECP2)	was	found	to	only	bind	to	H19	in	differentiated	PIBA	cells.		 From	this	result,	we	conclude	that	H19	interacts	with	proteins	to	fulfil	its	function	in	BAT	and	might	even	recruit	the	chromatin	modifier	MBD1	during	BAT	differentiation	to	suppress	PEGs	in	BAT.			
A 
 
 
 
 
 
 
 
 
 
confluent PIBA cells 
differentiated PIBA cells 
 
B 
	
C
 
D
 
Figure	26:	ChART-MS	reveals	H19-associated	proteins	in	confluent	and	differentiated	PIBA	cells	(A)	 Quantification	 and	 overlap	 of	H19-associated	 proteins	 in	 confluent	 (red)	 and	 differentiated	 (blue)	PIBA	cells	determined	by	ChART-MS.	Pulldown	of	H19-interacting	proteins	was	performed	using	pools	of	six	H19-specific	antisense/sense	oligonucleotides	in	n=3	replicates.	(B)	AMIGO2	GO	classification	of	H19	interactors	across	cellular	states.	(C,	D)	Illustration	of	H19	protein	interaction	network	comprising	n=61	proteins	 generated	 using	 Ingenuity	 Pathway	 Analysis	 (IPA).	 Red	 and	 blue	 nodes	 depict	 proteins	 co-immunoprecipitating	 in	 confluent	 and	 differentiated	 cells,	 respectively.	 Modified	 after	 Schmidt	 et	 al.	(2018)204.	
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3.13	 Fat	 tissue	 human	 H19	 (hH19)	 is	 reduced	 in	 obese	 humans	 and	
correlates	positively	with	browning	markers		
H19	 is	 strongly	 conserved	 at	 the	 transcript	 level227.	 Therefore,	 we	 next	 wanted	 to	decipher	 if	 hH19	 is	 also	 affected	 by	 obesity	 and	 T2DM	 in	 humans.	 We	 henceforth	quantified	hH19	abundances	in	scWAT	(Table	6)	and	vWAT	(Table	7)	biopsies	from	169	lean	and	obese	patients	and	observed	that	hH19	expression	decreased	with	 increasing	BMIs	 in	 both	 adipose	 depots.	 Moreover,	 hH19	 correlated	 positively	 with	 markers	 of	adipose	‘beiging’	like	UCP1	mRNA	levels.		Therefore,	 we	 conclude	 that	 hH19	 can	 support	 EE	 and	 acquisition	 of	 catabolic	expression	profiles	in	human	fat.			
Table	6:	Correlation	of	human	scWAT	H19	with	obesity	cohort	patient	characteristics,	serum	
parameters	and	gene	markers	of	adipose	tissue	browning.		
Data	were	obtained	from	a	human	study	and	provided	by	Prof.	Matthias	Blüher.	
	
	
	
Table	7:	Correlation	of	human	vWAT	H19	with	obesity	cohort	patient	characteristics,	serum	
parameters	and	gene	markers	of	adipose	tissue	browning.		
Data	were	obtained	from	a	human	study	and	provided	by	Prof.	Matthias	Blüher.	
sc_H19 [AU] vs All n Mean (95% CI) Rho p-Value w/o T2D n Mean (95% CI) Rho p-Value
CIDEA [AU] 163 2.438 (2.026-2.85) 0.01288 0.8704 80 3.161 (2.481-3.841) 0.1873 0.0963#
PRDM16 AU] 164 2.254 (1.917-2.592) -0.04605 0.5582 80 2.415 (1.876-2.953) 0.07682 0.4982
UCP1 [AU] 61 1.486 (0.9696-2.002) 0.4615 0.0002C 33 1.831 (1.003-2.659) 0.535 0.0013
BMI 169 44.14 (42.21-46.07) -0.1359 0.0781# 82 38.9 (36.02-41.97) -0.2745 0.0126
Creatinin [µmol/l] 168 76.17 (72.01-80.32) -0.02076 0.7894 81 70.88 (67.33-74.43) -0.09806 0.3838
CrP [mg/l] 168 11.84 (9.376-14.31) -0.02313 0.766 81 11.53 (7.551-15.5) -0.06706 0.5519
FPG [mmol/l] 158 6.725 (6.266-7.183) -0.06038 0.451 74 5.395 (5.161-5.629) -0.2118 0.0701#
Leucocyte 166 7.957 (7.469-8.445) 0.06575 0.4 80 8.044 (7.183-8.905) 0.04563 0.6877
ALAT [µkat/l] 164 0.5891 (0.5306-0.6476) -0.07846 0.318 79 0.562 (0.49-0.633) -0.1768 0.119
ASAT [µkat/l] 158 0.4839 (0.4535-0.7074) 0.01569 0.8449 77 0.459 (0.414-0.505) -0.01391 0.9045
gGT [µkat/l] 163 0.8485 (0.7074-0.9896) 0.04341 0.5822 78 0.826 (0.595-1.056) -0.004883 0.9662
TSH [mU/l] 144 1.554 (1.387-1.721) -0.1279 0.1267 71 1.523 (1.27-1.775) -0.2558 0.0313A
visc_H19[AU] vs All n Mean (95% CI) Rho p-Value w/o T2D n Mean (95% CI) Rho p-Value
CIDEA [AU] 165 2.429 (2.004-2.854) -0.01972 0.8015 80 3.09 (2.355-3.825) 0.05031 0.6576
PRDM16 AU] 165 2.951 (2.419-3.484) -0.0285 0.7163 81 3.899 (2.936-4.863) -0.0172 0.8789
UCP1 [AU] 113 2.925 (1.683-4.167) 0.1075 0.2571 57 4.172 (1.834-6.509) 0.2804 0.0347A
BMI 169 44.14 (42.21-46.07) -0.2549 0.0008C 82 38.9 (36.02-41.97) -0.3144 0.004B
Creatinin [µmol/l] 168 76.17 (72.01-80.32) 0.01963 0.8006 81 70.88 (67.33-74.43) 0.02555 0.8209
CrP [mg/l] 168 11.84 (9.376-14.31) -0.05255 0.4988 81 11.53 (7.551-15.5) -0.08711 0.4394
FPG [mmol/l] 158 6.725 (6.266-7.183) -0.1038 0.1945 74 5.395 (5.161-5.629) -0.08031 0.4964
Leucocyte 166 7.957 (7.469-8.445) 0.02613 0.7383 80 8.044 (7.183-8.905) -0.01946 0.864
ALAT [µkat/l] 164 0.5891 (0.5306-0.6476) -0.1263 0.1071 79 0.562 (0.49-0.633) -0.1552 0.1721
ASAT [µkat/l] 158 0.4839 (0.4535-0.7074) 0.0002603 0.9974 77 0.459 (0.414-0.505) 0.06409 0.5798
gGT [µkat/l] 163 0.8485 (0.7074-0.9896) -0.1104 0.1606 78 0.826 (0.595-1.056) -0.09666 0.3999
TSH [mU/l] 144 1.554 (1.387-1.721) -0.08148 0.3316 71 1.523 (1.27-1.775) -0.09212 0.4448
sc_H19 [AU] vs All n Mean ( 5% CI) Rho p-Value w/o T2D n Mean (9 % CI) Rho p-Value
CIDEA [AU] 63 2.438 2.02 -2.85) . 128 .8704 80 3.161 (2.481-3.841) .1873 0.0963#
PRDM16 AU] 4 2.2 4 1.917-2.592) -0.04605 .5582 80 2.415 (1.876-2.953) 0.07682 0.4982
UCP1 [AU] 61 1.4 6 (0.9696-2.002) .4615 .0002C 33 1.831 (1.003-2.659) .535 0.0013
BMI 69 4 .14 (42.21-46.0 ) -0. 35 .0781# 82 38.9 (36.02-41.97) -0.2745 0.0126
Creatinin [µmol/l] 8 76.17 (72.01-80.32) -0.02076 .7 94 81 70.88 (67.33-74.43) -0.09806 0.3838
CrP [ g/l] 68 1.8  (9. 76- 4.3 ) - .0 313 .76 81 11.53 (7.55 -15.5) -0.06706 0.5519
FPG [mmol/l] 158 6.725 (6.266-7.183) -0.06038 0.451 74 5.395 (5.161-5.629) -0.2118 0.0701#
Leucocyte 166 7.957 7.469-8.445) 0.06575 0.4 80 8.044 (7.183-8.905) 0.04563 0.6877
ALAT [µkat/l] 164 0.5891 (0.5306-0.6476) -0.07846 0.318 79 0.562 (0.49-0.633) -0.1768 0.119
ASAT [µkat/l] 158 0.4839 (0.4535-0.7074) 0.01569 0.8449 77 0.459 (0.414-0.505) -0.01391 0.9045
gGT [µkat/l] 163 0.8485 (0.7074-0.9896) 0.04341 0.5822 78 0.826 (0.595-1.056) -0.004883 0.9662
TSH [mU/l] 144 1.554 (1.387-1.721) -0.1279 0.1267 71 1.523 (1.27-1.775) -0.2558 0.0313A
visc_H19[AU] vs All n Mean 5% CI) Rho p-Value w/o T2D n Mean (9 % CI) Rho p-Value
CIDEA [AU] 65 2.4 9 (2.004-2.854) - .01972 .801 80 3.09 (2.355-3.825) . 5 0.6576
PRDM16 AU] 165 2.951 (2.419-3.484) -0.0285 0.7163 81 3.899 (2.936-4.863) -0.0172 0.8789
UCP1 [AU] 113 2.925 (1.683-4.167) 0.1075 0.2571 57 4.172 (1.834-6.509) 0.2804 0.0347A
BMI 169 44.14 (42.21-46.07) -0.2549 0.0008C 82 38.9 (36.02-41.97) -0.3144 0.004B
Creatinin [µmol/l] 168 76.17 (72.01-80.32) 0.01963 0.8006 81 70.88 (67.33-74.43) 0.02555 0.8209
CrP [ g/l] 168 11.84 (9.376-14.31) -0.05255 0.4988 81 11.53 (7.551-15.5) -0.08711 0.4394
FPG [mmol/l] 158 6.725 (6.266-7.183) -0.1038 0.1945 74 5.395 (5.161-5.629) -0.08031 0.4964
Leucocyte 166 7.957 (7.469-8.445) 0.02613 0.7383 80 8.044 (7.183-8.905) -0.01946 0.864
ALAT [µkat/l] 164 0.5891 (0.5306-0.6476) -0.1263 0.1071 79 0.562 (0.49-0.633) -0.1552 0.1721
ASAT [µkat/l] 158 0.4839 (0.4535-0.7074) 0.0002603 0.9974 77 0.459 (0.414-0.505) 0.06409 0.5798
gGT [µkat/l] 163 0.8485 (0.7074-0.9896) -0.1104 0.1606 78 0.826 (0.595-1.056) -0.09666 0.3999
TSH [mU/l] 144 1.554 (1.387-1.721) -0.08148 0.3316 71 1.523 (1.27-1.775) -0.09212 0.4448
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4	Discussion	Obesity	 is	 a	 serious	 medical	 and	 social	 problem	 all	 over	 the	 world	 that	 results	 from	chronic	 imbalances	 between	 energy	 intake	 and	 expenditure.	 If	 untreated	 obesity	 can	lead	 to	 life-threatening	 diseases	 such	 as	 type	 2	 diabetes	 mellitus.	 For	 counteracting	obesity	 and	 related	metabolic	 disorders,	 activation	 of	 BAT	 thermogenesis	 has	moved	into	focus	for	therapeutic	purposes	due	to	its	unique	capacity	for	dissipating	energy	as	heat	 through	 the	 unique	 action	 of	 UCP1-mediated	 chemical	 uncoupling.	 Because	 of	BAT´s	 beneficial	 effects	 on	 body	 metabolism,	 understanding	 and	 harnessing	 the	molecular	 circuits	 activating	 BAT	 function	 is	 of	 great	 interest.	 Several	 protein-coding	genes,	 mRNAs,	 and	 miRNAs	 have	 been	 identified	 that	 play	 a	 role	 in	 adipocyte	development.	LncRNAs,	however,	a	class	of	RNAs	that	have	been	identified	only	recently,	are	 not	 well	 understood	 but	 have	 received	 a	 lot	 of	 attention	 due	 to	 their	 broad	involvement	 in	 different	 physiological	 processes	 and	 their	 tissue-specific	 character	which	stresses	their	high	potential	as	drug	target.		In	 this	 study,	 we	 identified	 the	 maternally	 expressed	 lncRNA	 H19	 as	 a	 novel	regulator	 of	 BAT	 differentiation	 and	 function.	 H19	 protects	 from	 dietary	 obesity	 by	controlling	 mitochondrial	 biogenesis	 in	 mature	 adipocytes	 and	 interacts	 with	 MBD1	which	potentially	results	in	maintenance	of	quiescence	of	obesity-predisposing	PEGs	in	BAT.	The	findings	discussed	in	this	thesis	have	implications	both	for	the	understanding	of	 how	monoallelic	 gene	 expression	 affects	metabolism	 in	 rodents	 and,	 potentially,	 in	humans	 but	 also	 for	 finding	 new	 treatment	 possibilities	 via	 the	 manipulation	 of	H19	expression	in	BAT.			
4.1	 Maternally	 expressed	 lncRNA	 H19	 regulates	 BAT	 differentiation	 and	
function	independent	of	imprinting	gene	cluster	in	vitro		For	 the	 identification	of	 lncRNAs	correlating	with	BAT	 function,	 total	RNA-Seq	 in	BAT	(as	 well	 as	 in	 cold-evoked	 subcutaneous	 white	 adipose	 tissue)	 was	 conducted.	 This	screening	 approach	 is	 in	 accordance	with	 several	 recently	 published	 studies	 in	which	different	 whole	 genome	 sequencing	 techniques	 were	 applied	 and	 resulted	 in	 the	identification	 of	 regulators	 of	 adipogenesis108,120,228.	 Whilst	 some	 of	 them	 focused	 on	adipogenesis	 in	 general,	 including	 WAT,	 in	 our	 study,	 we	 exclusively	 searched	 for	lncRNAs	 regulating	 BAT	 homeostasis.	 At	 the	 moment,	 a	 variety	 of	 sequencing	
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approaches	 to	 identify	 lncRNAs	 are	 available	 and	 applied	 by	 the	 experimenter’s	demands229.	In	our	study,	we	performed	total	RNA-Seq	as	it	broadly	identifies	not	only	coding	 but	 also	 multiple	 forms	 of	 noncoding	 RNAs230.	 Additionally,	 the	 sequencing	technique	 can	 accurately	 measure	 the	 abundance	 of	 genes	 and	 transcripts	 based	 on	which	known	and	novel	features	of	the	transcriptome	can	be	defined.	This	gave	us	the	possibility	to	 find	and	finally	characterize	novel	 lncRNA	candidates	that	are	associated	with	BAT.	After	applying	a	stringent	filter	to	the	found	candidates,	we	decided	to	begin	with	the	 characterization	 of	 the	 following	 lncRNA	 candidates:	 1700007L15Rik,	
2500002B13Rik,	Gm12319,	 and	H19.	All	 candidates	showed	 increased	expression	upon	cold-mediated	 BAT	 activation	 and	were	 decreased	 upon	 chronic	 diet-induced	 obesity	(DIO)	 BAT	 dysfunction.	 While	 1700007L15Rik,	 2500002B13Rik	 and	 Gm12319	 are	 all	transcripts	with	 unknown	 function,	 the	 lncRNA	H19	 is	widely	 studied	 and	 one	 of	 the	best	researched	imprinting	genes.		For	 further	 functional	 characterization,	 we	 investigated	 the	 effect	 of	 lncRNA	candidate	ablation	on	adipogenesis	by	performing	 locked	nucleic	acid	(LNA)-mediated	RNA	 interference	 (RNAi)	 in	 SVF	 adipocyte	 precursor	 cells	 isolated	 from	 three	 major	adipose	depots	(BAT,	scWAT,	and	vWAT).	With	this,	we	could	show	that	the	lack	of	both	
2500002B13Rik	 and	 H19	 expression	 led	 to	 a	 decrease	 in	 lipid	 accrual	 and	 a	 proper	expression	 of	 browning	 markers,	 whereas	 we	 did	 not	 observe	 these	 differences	 for	lncRNAs	1700007L15Rik	or	Gm12319.	Antisense	oligonucleotides	(ASOs)	or	LNA	GapmeRs,	used	for	RNAi	experiments	in	 this	 study,	 have	 gained	 recognition	 as	 therapeutic	 tools231.	 Many	 are	 in	 advanced	clinical	trials	as	oligonucleotide	drug	candidates	or	even	approved	by	the	FDA,	such	as	mipomersen	(trade	name	Kynamro)	which	targets	apolipoprotein	B	(apoB)	and	is	used	for	homozygous	 familial	 hypercholesterolemia	 (HoFH)232.	With	 the	use	of	ASOs	 in	 the	laboratory	there	are	still	safety	and	technical	limitations	such	as	affinity	to	unintended	targets	 with	 partial	 sequence	 complementarity	 which	 might	 lead	 to	 hybridization-dependent	off-target	effects	(OTEs)233.	The	risks	for	OTEs	are	not	yet	fully	investigated,	and	thus	RNAi	experiments	ex	vivo	were	performed	with	two	different	LNA	GapmeRs	to	exclude	that	effects	seen	stem	from	OTEs.		Of	 all	 four	 candidates,	 H19	 revealed	 the	 most	 pronounced	 effects	 on	adipogenesis.	This	outcome	and	its	BAT-selective	expression	and	sequence	conservation	among	eutherians	led	to	the	decision	to	only	focus	on	the	characterization	of	H19	in	BAT	
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homeostasis.	 The	 current	 research	 has	 shown	 that	 H19	 is	 abundantly	 expressed	maternally	in	embryonic	tissues,	decreases	after	birth,	and	its	transcription	persists	only	in	skeletal	muscle173	and	liver234.	Additionally,	 in	our	study,	we	could	for	the	first	time	show	 that	 H19	 expression	 also	 remained	 high	 in	 BAT	 after	 birth.	 BAT	 and	 skeletal	muscle	 both	 originate	 from	a	mesodermal	 progenitor	 population	 in	 the	 somites.	With	that,	 they	 are	 sharing	 the	 same	 origins,	 and	 thus	 are	 closely	 related	 in	 their	development66.	 Different	 studies	 have	 investigated	 the	 involvement	 of	 H19	 and	 its	encoded	 miR-675	 in	 muscle	 differentiation	 and	 regeneration173,235	 and	 have	demonstrated	 that	H19	 contributes	 to	glucose	metabolism	 in	muscle	 cells197.	Yet,	 how	
H19	affects	BAT	homeostasis	after	birth	has	not	been	studied	until	now.	To	 find	 out	 more	 about	 what	 led	 to	 the	 defect	 in	 proper	 adipogenesis	 we	analysed	 BAT	 progenitor	 expression	 to	 see	 whether	 cells	 that	 lacked	H19	 expression	stayed	in	a	progenitor-like	state,	and	thus	were	unable	to	continue	in	the	differentiation	process.	One	example	of	a		preadipocyte	marker	that	is	known	to	be	mostly	expressed	in	preadipocytes	 and	 declines	 with	 brown	 adipocyte	 differentiation	 is	 Delta	 Like	 Non-
Canonical	 Notch	 Ligand	 1	 (Dlk1)211.	 When	 analyzing	 the	 expression	 of	 Dlk1	 and	additional	preadipocyte	markers	after	H19	ablation	we	observed	that	only	 in	BAT	and	not	in	scWAT	and	vWAT	the	expression	of	various	progenitors	remained	high,	showing	that	H19	is	indeed	required	for	the	commitment	of	BAT	but	not	scWAT	or	vWAT-derived	progenitors.		Two	 early	 progenitor	 genes	 we	 found	 significantly	 expressed	 in	 BAT	 cells	 are	
Runx2	 and	 Pdgfra.	 Runx2	 is	 an	 osteogenic	 transcription	 factor	 that	 is	 required	 for	osteogenic	differentiation236.	Adipocytes	and	osteoblasts	both	stem	from	mesenchymal	stem	cells,	a	non-hematopoietic	stem	cell	population	which	was	first	discovered	in	bone	marrow.	 The	 differentiation	 commitment	 for	 both	 cell	 types	 is	 tightly	 regulated	 and	several	in	vitro	studies	have	demonstrated	that	fat-induction	factors	inhibit	osteogenesis	and	at	the	same	time	bone-induction	factors	prevent	adipogenesis237.	Thus,	the	failure	in	repression	of	Runx2	in	mature	brown	adipocytes	upon	H19	loss	might	hint	to	a	defect	in	the	adipo-osteogenic	balance	as	shown	recently237–239.	
Pdgfra	is	a	receptor	located	on	the	surface	of	different	cell	types	and	is	involved	in	cell	signaling	pathways	leading	to	cellular	growth	and	differentiation.	Normally,	 it	 is	used	 as	 a	 marker	 for	 fibroblasts	 and	 undifferentiated	 mesenchymal	 cells	 and	 not	expressed	 in	mature	 adipocytes240.	Moreover,	Pdgfra	 has	 been	 shown	 to	 regulate	 the	balance	of	stromal	and	adipogenic	cells	during	AT	organogenesis.	An	increased	activity	
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of	Pdgfra	has	been	shown	to	cause	AT	fibrosis	in	adult	mice240.	This	shows	that	proper	functioning	 of	 H19	 expression	 is	 necessary	 to	 prevent	 the	 development	 of	 diseased	tissue.		Next,	we	aimed	 to	dissect	 the	 cell	 intrinsic	 and	metaboregulatory	properties	of	
H19	 using	 Seahorse	 technology.	 H19	 RNAi	 impaired	 oxidative	 metabolism	 and	uncoupling	 in	 differentiated	 brown	 adipocytes.	 Experiments	 with	 1°	 BAT	 of	 H19	overexpression	mice,	performed	by	a	Master	student	 from	the	 lab	and	not	 included	 in	this	PhD	 thesis,	 showed	 improved	oxidative	metabolism,	uncoupling,	and	extracellular	acidification	 rates	 (ECAR)	 in	 differentiated	 brown	 adipocytes.	 These	 experiments	demonstrated	 that	 H19	 supports	 adipocyte	 differentiation	 and	 thermogenic	 gene	expression,	oxidative	metabolism,	and	mitochondrial	dynamics	in	mature	adipocytes	in	a	BAT-specific	manner	and	gave	a	first	hint	that	H19	is	not	only	involved	in	the	process	of	adipogenesis	but	also	in	the	function	of	BAT.		
H19	has	been	reported	to	reside	in	nuclear,	but	also	cytoplasmic	and	ribosomal	fractions	in	various	cell	types186,213,214.	In	the	nucleus,	it	has	been	shown	to	interact	with	chromatin-modifying	complexes	such	as	methyl-CpG-binding	domain	protein	1	(MBD1)	to	 control	 gene	 expression	 of	 the	 imprinting	 gene	 network	 (IGN)190	 or	 serve	 as	 a	microRNA	 precursor	 for	 miR-675-3p	 and	 miR-675-5p241,242.	 In	 the	 cytoplasm	 it	 can	control	myogenic	differentiation	by	binding	to	RNA	binding	proteins243	or	it	can	act	as	a	molecular	sponge	for	miRNA	let-7127,197.	When	analyzing	H19	localization	in	1°	BAT	cells,	we	could	show	that	H19	 is	 located	in	nuclear	and	cytoplasmic	compartments	of	brown	adipocytes	 pointing	 to	 the	 fact	 that	 H19	 fulfills	 different	 actions	 in	 different	compartments	of	the	cell.	As	LNA-mediated	RNAi	acts	via	RNAse	H-mediated	transcript	decay	 predominantly	 in	 nuclei,	 we	 also	 targeted	 H19	 using	 siRNAs,	 which	 act	preferentially	 in	 the	 cytoplasm.	 H19	 loss	 was	 observed	 across	 all	 subcellular	compartments	using	both	techniques	and	led	to	equal	results.		Historically,	 H19	 was	 discovered	 as	 monoallelically	 expressed	 gene	 in	 which	solely	 maternal	 alleles	 express	 H19	 in	 an	 epigenetic	 process	 termed	 ‘genomic	imprinting’.	In	the	H19-Igf2	imprinted	gene	cluster	the	reciprocally	regulation	critically	depends	 on	 the	 enhancer-blocking	 properties	 of	 CCCTC-Binding	 Factor	 (Ctcf)	proteins155,169.	As	no	effects	on	BAT	adipogenesis	occurred	after	Ctcf	RNAi	and	as	Ctcf	and	Igf2	BAT	levels	were	unchanged	by	DIO	or	cold,	we	concluded	that	cold/DIO-evoked	alterations	 in	 H19	 are	 not	 secondary	 to	 altered	 H19-Igf2	 imprinting.	 This	 is	 in	
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accordance	 with	 earlier	 reports	 on	 reduced	 H19	 expression	 independent	 from	traditional	H19-Igf2	imprinting	control244.			Moreover,	 the	 H19-encoded	 microRNA	 miR-675	 was	 not	 expressed	 in	 BAT,	arguing	 against	 the	 involvement	 of	 miR-675	 in	 brown	 adipocyte	 differentiation	 as	observed	for	myogenic	lineage	determination173.		Collectively,	 we	 showed	 that	 the	 conserved	 lncRNA	 H19	 promoted	 brown	adipocyte	 differentiation	 and	 function	 in	 vitro	 and	 in	 vivo	 independently	 of	 the	imprinting	gene	cluster.		
	
4.2	H19	regulates	BAT	function	via	regulating	mitochondrial	biogenesis		Defects	 in	BAT	differentiation	and	 function	as	well	 as	 concomitant	 impairments	 in	EE	render	mice	susceptible	to	DIO-induced	weight	gain	and	the	development	of	metabolic	diseases217–219.		In	a	study	by	Ellis	et	al.	(2013)	it	has	been	shown	that	gene	expression	of	lncRNA	CRNDE	was	 affected	 by	 the	 anabolic	master	 regulator	 insulin	 and	 insulin-like	growth	 factor	 1	 (IGF1)	 signaling,	 pointing	 for	 the	 first	 time	 to	 the	 fact	 that	 lncRNAs	might	be	 implicated	 in	 the	metabolic	effects	of	 insulin	and	 the	development	of	 insulin	resistance138.		To	analyze	whether	H19	is	involved	in	glucose	metabolism	in	mice,	we	performed	gain-and	 loss-of	 function	 studies	 of	 H19	 in	 mice.	 We	 exposed	 H19	 gain-of-function	mice210	 and	 Controls	 to	 HFD	 and	 CD.	 H19	 overexpression	 strongly	 prevented	 DIO-mediated	weight	gains	and	improved	insulin	sensitivity	whereas	glucose	tolerance	was	decreased.	This	unexpected	result	 is	 in	accordance	with	a	study	by	Zhang	et	al.	(2018)	who	 showed	 that	 elevated	 hepatic	 expression	 of	 H19	 promoted	 hepatic	 glucose	production	and	insulin	resistance220.	Furthermore,	we	observed	an	increase	in	EE.	This	rise	in	energy	catabolism	tended	towards	prevention	of	DIO-induced	increases	in	scWAT	and	 vWAT	 adiposity	 and	 prevented	 the	 ‘whitening’	 of	 BAT.	 In	 lean	 mice	 H19	overexpression	elicited	little	changes	showing	that	counteracting	the	HFD-induced	H19	decline	is	beneficial	during	DIO,	but	does	not	cause	detrimental	effects	in	lean	mice.		To	show	that	the	effects	of	H19	overexpression	on	energy	metabolism	are	due	to	
H19	 induced	 alteration	 in	 BAT	 function	 and	 not	 due	 to	 other	 tissues,	 experiments	 at	thermoneutrality	could	be	performed	to	assess	changes	upon	conditions	 in	which	BAT	activity	is	low.	In	general,	thermoneutrality	is	important	because	people	tend	to	live	at	thermoneutral	conditions	with	the	aid	of	clothing	and	heating	whereas	for	mice	Rtemp	
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is	 not	 thermoneutral	 and	 they	 need	 to	 spend	 extra	 energy	 to	 uphold	 their	 body	temperature49.	 However,	 in	 our	 experiments	 the	 exposure	 to	 thermal	 stress	 was	 a	performed	 experimental	 approach	 for	 physiologically	 relevant	 BAT	 activation.	 We	housed	H19	TG	and	H19∆AT	mice	 at	 4°C	 for	4	days,	 a	 condition	 in	which	mice	 expend	60%	 of	 their	 energy	 for	 thermoregulation	 through	 BAT	 non-shivering	 thermogenesis	(NST)245,246.	Muscle	shivering	thermogenesis	(ST)	can	be	seen	only	in	the	early	phases,	for	 several	 hours,	 of	 cold	 adaptation247	 and	 should	 not	 significantly	 contribute	 to	 EE	afterwards.	As	we	observed	elevated	Ees	in	cold-exposed	H19	TG	mice	beyond	the	point	of	muscle	ST	but	also,	crucially,	in	H19∆AT	where	H19	is	ablated	only	in	mature	adipose	tissue,	we	could	demonstrate	an	(B)AT-specific	effect	of	altered	H19	levels	in	vivo.		
H19	TG	mice	ubiquitously	overexpress	H19.	To	ablate	H19	specifically	in	AT,	we	crossed	female	mice	harbouring	loxP-flanked	H19	methylation-sensitive	ICRs	with	male	
Adipoq-cre	 expressing	animals.	Adipoq-cre	mice	harbour	 the	Adipoq-cre	BAC	 transgene	and	 express	 Cre	 recombinase	 under	 control	 of	 the	 mouse	 adiponectin	 (Adipoq)	promoter/enhancer	regions	within	the	BAC	transgene.	Thus,	Adipoq-cre	transgenic	mice	delete	floxed	sequences	in	WAT	and	BAT.	Since	H19	remains	expressed	in	adult	BAT,	the	H19∆AT	knockout	mice	provide	an	interesting	model	to	study	the	role	of	this	gene	in	the	adult.	Surprisingly,	we	did	not	observe	a	knockdown	or	deletion	of	H19	in	other	AT	like	scWAT	or	vWAT	which	could	come	from	undetectable	expression	levels	of	H19	 in	both	tissues.	 This	 made	 the	 H19∆AT	 mouse	 model	 interesting	 to	 exclusively	 analyse	 H19	function	in	BAT.		H19∆AT	knockout	mice	gained	more	weight	compared	to	Control	mice	on	a	HFD,	whereas	 alterations	 in	 insulin	 sensitivity	 and	 glucose	 tolerance	were	 negligible.	 BAT-specific	 H19	 loss	 decreased	 EE	 and	 oxygen	 consumption	 on	 both	 diets	 suggesting	 a	decrease	 in	 BAT	 function.	Adipoq-cre	 is	 not	 active	 in	 adipocyte	 progenitors,	 and	 thus	results	 can	 only	 be	 ascribed	 to	mature	 adipocytes.	 To	 specifically	 ask	 whether	H19`s	effect	on	metabolism/EE	runs	via	alteration	of	brown	adipogenesis,	one	would	need	to	ablate	H19	 or	 the	H19	DMD	 using	 adipocyte	 progenitor	 recombinases,	 examples	 are	
Pdgfra-Cre	or	Prx1-Cre.	Unfortunately,	both	recombinases	are	not	useful	 for	 studies	of	brown	 preadipocytes	 as	 Pdgfra-Cre	 deletes	 also	 in	 muscle	 stem	 cell	 progenitors	 and	liver248	 and	Prx1-Cre	 expression	 is	 confined	 to	 subcutaneous	 adipocyte	 precursors249.	Apart	 from	 adipocyte	 progenitor	 recombinases,	 one	 could	 also	 use	 Ucp1-Cre	 to	specifically	ablate	H19	in	interscapular	BAT	at	ambient	temperatures	and	after	6	days	of	cold	 exposure	 in	 inguinal	 and	 epidedymal	 WAT.	 The	 results	 from	 this	 mouse	 model	
4	Discussion	
	 109	
would	give	more	insight	about	the	function	of	H19	 in	beige	adipocytes	about	which	we	received	only	little	information	in	our	study.		The	difference	in	EE	spurred	the	analysis	of	mitochondrial	constitution	in	BAT	of	
H19	 gain-	 and	 loss-of-function	 mice.	 Cold-induced	 adaptive	 thermogenesis	 and	 the	turnover	 of	 nutrients	 require	 active	 mitochondrial	 biogenesis	 and	 rearrangements	 of	mitochondrial	 networks	 via	 fission	 and	 fusion.	 While	 studying	 mitochondrial	morphologies	 using	 EM	we	 observed	 perturbed	 cristae	 formation	 in	 Control	mice	 on	HFD.	This	effect	was	diminished	in	H19	TG	mice	on	HFD.	When	we	analysed	the	cristae	formation	in	H19∆AT	mice	compared	with	Control	mice,	both	fed	a	HFD,	we	observed	that	the	 deformation	 of	 cristae	 structure	 was	 worsened	 in	 mice	 lacking	 H19	 in	 BAT	compared	to	Control	mice.		Cristae	are	functional	dynamic	compartments	whose	shape	is	maintained	by	the	cooperation	 of	 mitochondrial-shaping	 proteins	 such	 as	 Mfn1	 and	 2,	 Optic	 Atrophy	 1	(Opa1),	 as	 well	 as	 the	 cytosolic	 Drp1	 and	 its	 receptor	 which	 is	 located	 on	 the	 outer	mitochondrial	 membrane	 Fis1250.	 Perturbations	 of	 mitochondrial-shaping	 proteins	disrupt	 cristae	 shape	 and	 influence	 the	 structure	 of	 the	 oxidative	 phosphorylation	system,	 thereby	 impairing	 cellular	 metabolism	 and	 growth251.	 When	 analysing	mitochondrial	 fission	and	fusion	markers	 in	H19	TG	BAT,	we	observed	a	trend	that	all	markers	 in	 Control	 mice	 on	 HFD	 compared	 to	 Control	 mice	 on	 CD	 were	 decreased	among	which	Drp1	and	Mff	were	significantly	decreased.	When	analysing	the	same	set	of	genes	in	H19	TG	mice	fed	a	HFD	markers	showed	a	tendency	to	be	increased	compared	to	Control	mice	fed	a	HFD	pointing	to	a	rescue	of	diminished	gene	expression	of	fission	and	fusion	markers	upon	gain	of	H19	expression.	The	expression	of	this	set	of	markers	in	BAT	of	H19∆AT	mice	revealed	 that,	 specifically	upon	H19	 loss,	markers	decreased	 in	expression	 and	 for	 Fis1	 the	 effect	 was	 significant.	 Thus,	 the	 gene	 expression	 of	mitochondrial-shaping	proteins	reflected	cristae	morphology.	 In	scWAT	of	both	mouse	lines	the	expression	of	fission	and	fusions	markers	was	unchanged.		The	 expression	 of	 genes	 involved	 in	 mitochondrial	 biogenesis	 was	 blunted	 in	obese	 BAT,	 but	 H19	 overexpression	 reversed	 these	 DIO-evoked	 defects	 in	 gene	expression	 in	BAT	but	not	scWAT.	H19∆AT	mice	showed	less	pronounced	reductions	of	the	 same	 gene	 set	 in	 BAT	 yet	 not	 scWAT.	 The	 rescue	 in	 H19	 TG	mice	was	 especially	strong	 for	mitochondrial	 ribosomal	 protein	MRPL12	 (Mrpl12),	 DNA	 polymerase	 subunit	
gamma	 (Polg),	 succinate	 dehydrogenase	 (Sdha),	 and	Ubiquinol-cytochrome	 c	 reductase	
complex	 (Uqcr10).	 When	 analysing	 mitochondrial	 biogenesis	 markers	 in	 1°	 BAT	 cells	
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treated	with	H19	 RNAi	we	 observed	 a	 significant	 downregulation	 of	 various	markers	whereas	Mrpl12,	 Polg	 and	 Sdha	 were	 significantly	 decreased	 and	 Pgc1a	 and	 nuclear	
respiratory	factor	1	 (Nrf1)	showed	a	tendency	to	be	decreased.	When	investigating	the	same	 set	 of	 genes	 in	 1°	 BAT	 cells	 isolated	 from	 H19∆AT	 we	 could	 see	 that	 the	 genes	
NADH:Ubiquinone	 Oxidoreductase	 Complex	 Assembly	 Factor	 7	 (Ndufaf7),	 Uqcr10,	 and	
Nrf1	 as	well	 as	 Sdha,	 already	 observed	 partly	 in	 isolated	 BAT	 tissue	 and	 in	 H19	 LNA	treated	cells,	were	significantly	downregulated.		The	product	of	Mrpl12	 is	 a	protein	of	 the	mitochondrial	 ribosome	and	helps	 in	protein	 synthesis252,253.	 POLG	 is	 a	 catalytic	 subunit	 of	 the	 mitochondrial	 DNA	polymerase254.	 SDHA	 is	 the	 major	 catalytic	 subunit	 of	 succinate-ubiquinone	oxidoreductase	 of	 complex	 II	 and	 participates	 in	 both	 the	 citric	 acid	 cycle	 and	 the	respiratory	 chain255.	 NRF1	 is	 a	 transcription	 factor	 that	 activates	 the	 transcription	 of	some	key	metabolic	genes	required	for	respiration	and	mitochondrial	DNA	transcription	and	replication256.	NDUFAF7	is	an	assembly	factor	protein	and	methyltransferase	which	helps	in	the	assembly	and	stabilization	of	complex	I257	and	the	gene	product	of	Uqcr10	is	a	subunit	of	 the	respiratory	chain	protein	ubiquinol	cytochrome	c	reductase	(Complex	III)258.		The	 above-described	 deregulation	 of	 genes	 involved	 in	 oxidative	phosphorylation	 shows	 that	 H19	 loss	 leads	 to	 a	 global	 defect	 in	 the	 functions	 of	mitochondria	 in	BAT	whereas	gain	of	H19	 function	was	partially	 able	 to	diminish	 this	effect.	 This	 defect	 in	 oxidative	 phosphorylation	 could	 result	 also	 in	 defects	 in	 EE	 and	explain	why	the	mice	are	more	susceptible	to	DIO	weight	gains.		
4.3	 H19	 interacts	 with	 MBD1	 to	 repress	 genes	 of	 the	 imprinting	 gene	
network			Expression	levels	of	H19	were	not	altered	during	BAT,	scWAT,	and	vWAT	differentiation.	Therefore,	 we	 asked	 whether	 specific	 protein	 interactors	 of	H19	 control	 its	 function	selectively	 in	brown	adipocytes.	 	The	 interaction	of	H19	with	different	 factors	 such	as	transcriptional	repressors	(MBD1)259,	RNA	binding	proteins	(K	homology-type	splicing	regulatory	protein	(KSPR))243,	miRNAs	(miR-17-5p)	260,	chromatin	modifiers	(MBD1)190,	and	enzymes	(S-adenosylhomocysteine	hydrolase	(SAHH))261	has	been	shown	recently.		In	order	 to	address	our	question,	we	conducted	Capture	Hybridization	Analysis	of	 RNA	 Targets	 coupled	 to	 mass	 spectrometry	 (CHART-MS)	 with	 confluent	 and	
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differentiated	 PIBA	 cells.	 The	 construction	 of	 an	 interconnected	H19	 binding	 protein	network	 using	 Ingenuity	 Pathway	 Analysis	 (IPA)	 led	 to	 the	 identification	 of	 61	interesting	proteins.	Gene	ontology	analysis	showed	that	in	immature	brown	adipocytes	
H19	mostly	recruited	proteins	annotated	as	‘RNA-binding	proteins’	and,	in	differentiated	cells,	H19	 preferentially	 associated	 with	 proteins	 classified	 as	 ‘chromatin	 binders’	 or	‘chromatin	modifiers’.	We	specifically	searched	for	a	protein	which	was	only	bound	by	
H19	 in	 differentiated	 cells	 and	 found	 the	 DNA	 methyltransferase	 MBD1	 (and	 its	homologue	MECP2).	MBD1	 belongs	 to	 a	 group	 of	 methyl-CpG-binding	 proteins	 that	 are	 epigenetic	‘readers’	 by	 connecting	 DNA	methylation	 to	 the	 regulation	 of	 transcription262.	H19	 is	part	 of	 an	 IGN	and	 controls	 the	 expression	of	 other	 eight	 imprinted	 genes	within	 this	network:	 IGF2,	 SLC38A4,	 DCN,	 DLK1,	 PEG1,	 GTL2,	 CDKN1C	 and	 IGF2R.	 All	 genes	 are	known	regulators	of	embryonic	growth	in	mouse	and	human224.	The	interaction	of	H19	with	MBD1	as	a	physical	and	functional	partner	has	already	been	shown	previously	in	a	paper	 by	 Monnier	 et	 al.	 (2013)	 which	 demonstrated	 that	 the	 H19-MBD1	 complex	 is	required	 for	 the	 control	 of	 several	 genes	 of	 the	 IGN190.	 Specifically,	 they	 showed	 that	
H19-MBD1	 complexes	 affect	 histone	 3	 lysine	 methyltransferases	 (KMT)	 dependent	deposition	of	repressive	H3K27	trimethylation	marks.	H19	or	MBD1	loss	both	resulted	in	reduced	H3K9me3,	and	thus	de-repression	at	PEG	loci	like	Igf2,	Solute	Carrier	Family	
38	 Member	 4	 (Slc38a4),	 and	Mest/Paternally	 Expressed	 1	 (Peg1)190.	 In	 light	 of	 these	results,	 we	 suggest	 that	 H19-mediated	 alterations	 of	 IGNs	 constitute	 an	 important	regulatory	 layer	of	BAT	development	and	function,	by	 influencing	cell-intrinsic	control	of	mitochondrial	biogenesis	in	mature	brown	adipocytes,	according	to	which	PEGs	have	a	 negative	 effect	 on	 brown	 fat	 (Dlk1,	 Peg1,	 Ndn,	 paternally	 expressed	 GNAS	 isoform	
XLas)	 whereas	 MEGs	 (Gas)	 have	 a	 positive	 effect	 on	 BAT148.	 Furthermore,	 H19	maintains	 quiescence	 of	 obesity-predisposing	 PEGs	 in	 BAT.	 These	 hypotheses	 are	supported	 by	 the	 finding	 that	 PEGs,	 such	 as	Mest,	 regulate	WAT-associated	 processes	like	 adipogenesis	 and	 adipocyte	 cell	 size	 and	 number	 regulation263	 whereas	 the	MEG	
Ndn	 has	 been	 shown	 to	 suppress	 adipocyte	 cell	 proliferation.	 Loss	 of	Ndn	 expression	resulted	in	increased	adiposity	due	to	hyperplasia	of	WAT	cells264.	Moreover,	data	have	shown	that	DIO-induced	‘whitening’	of	BAT	leads	to	brown	adipocyte	death265,	a	process	which	is	suppressed	by	H19.		These	overall	results	are	 is	 in	accordance	with	the	kinship	theory	of	 imprinting	(see	 1.4)	 that	 predicts	 that	 PEGs	 should	 act	 to	 reduce	 energy-costly	 thermogenic	
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output266	whilst	MEGs	are	predicted	to	support	higher	levels	of	thermogenesis167.	Data	of	a	Master´s	student	of	our	lab,	not	included	in	this	PhD	thesis,	were	broadly	consistent	with	 this	 prediction	 as	 a	 loss	 of	 H19	 in	 brown	 preadipocytes	 led	 to	 a	 coordinated	transcriptional	 upregulation	 of	 PEGs	 (Igf2,	Mest,	Nnat,	 Peg3,	 Peg10,	 Plagl1	 and	 Gpr1)	whereas	 MEGs	 (Cdkn1c,	 Dcn,	 Igf2r,	 Slc22a3)	 were	 not	 affected.	 Accordingly,	 after	conducting	siH19	and	or	siMBD1	RNAi	in	1°	BAT,	performed	by	a	collaborator	and	not	included	 in	 this	 thesis,	 we	 observed	 that	 BAT-abundant	 PEGs	 were	 increased	 with	similar	 tendencies	 supporting	 the	 claim	 of	 functional	H19/MBD1	 complexes	 in	 these	cells.		 A	 publication	 by	Ripoche	 et	 al.	 (1997)	 showed	 that	 a	 deletion	 of	 the	H19	gene	resulted	 in	an	upregulation	of	 the	 IGN	and	culminated	 in	an	overgrowth	phenotype	 in	mice	and	human194.	This	overgrowth	phenotype	has	as	well	been	associated	with	IDs,	a	group	 of	 rare	 congenital	 diseases	 affecting	 growth,	 development,	 and	 metabolism267.	One	 of	 these	 diseases	 associated	 with	 the	 human	 H19-Igf2	 locus	 is	 the	 Beckwith-Wiedemann	 syndrome	 (BWS),	 (also	 called	 ‘overgrowth	 disorder’)	 in	 which	 affected	children	possess	among	other	symptoms	of	macrosomnia.	In	this	syndrome,	a	mutation	in	a	specific	region	of	the	short	arm	of	chromosome	11	referred	to	as	11p15	results	in	an	over-activity	of	 the	 IGF-2	gene,	which	 is	a	growth	 factor268.	However,	different	genetic	defects	 have	 been	 identified	 in	 BWS	 patients	 such	 as	 maternal	 chromosomal	rearrangements	 of	 11p15,	 paternal	 uniparental	 disomy	 (UPD)	 of	 chromosome	 11,	abnormal	DNA	methylation,	or	that	a	single	gene	copy	is	located	within	11p15	instead	of	two	copies269.		Another	 developmental	 growth	 restriction	 disorder	 characterised	 by	 low	 birth	weight	and	neonatal	hypoglycemia	is	Silver-Russell	syndrome	(SRS).	Several	epigenetic	and	genetic	mutations	have	been	linked	to	SRS,	mainly	involving	imprinted	genes270.	In	a	study	by	Van	de	Pette	et	al.	(2016),	a	mouse	model	was	described	which	displayed	a	rare	microduplication	 and	 with	 this,	 a	 double	 dose	 of	 the	 MEG	 Cdkn1c,	 often	 reported	 in	some	SRS	patients271.	These	mice	possessed	substantially	more	BAT,	something	which	is	in	accordance	with	our	H19	overexpression	mouse	model	as	that	both	MEGs	Cdkn1c	and	
H19	supported	either	growth	(Cdkn1c)	or	function	(H19)	of	BAT.	These	observations	are	also	 supported	 by	 the	 kinship	 theory.	 A	 two-fold	 Cdkn1c	 expression	 resulted	 in	 fetal	growth	 restriction	with	 characteristics	 of	 SRS	whereas	 the	 loss	 of	Cdkn1c	 led	 to	 fetal	overgrowth	and	characteristics	of	BWS270.	This	result	was	in	accordance	with	both	our	gain-	 and	 loss-of-function	mouse	models	 as	H19	 overexpression	 resulted	 in	 a	 smaller	
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and	 slimmer	 body	 shape	 on	 both	 diets,	 whereas	 H19	 loss	 resulted	 in	 an	 opposite	phenotype.	These	results	show	that	H19	functions	as	a	key	player	in	the	strict	regulation	of	 the	 IGN	by	 inhibiting	 other	 imprinting	 genes	 and	 that	 the	dysregulation	 of	 the	 IGN	may	result	in	serious	diseases.		To	 investigate	 whether	 H19	 recruits	 specific	 BAT	 differentiation	 interaction	partners	 that	 are	 not	 relevant	 for	 vWAT	 adipocyte	 formation	 or	whether	 it	 is	 simply	more	 abundant	 in	 BAT,	 it	 would	 be	 interesting	 to	 use	 depot-specific	 immortalized	adipocytes	and	perform	H19	ChART	experiments	in	these	depot-specific	cell	systems	as	we	 already	 did	 with	 immortalized	 PIBA	 cells.	 Moreover,	 to	 uncover	more	 interaction	partners	 of	 H19	 one	 could	 also	 perform	 other	 techniques	 such	 as,	 e.g.,	 chromatin	isolation	by	RNA	purification	(ChIRP)	and	its	applications	to	capture	and	purifiy	specific	lncRNA	 –chromatin	 complexes	 from	 the	 cell	 or	 also	 RNA-RNA	 interactions272.	 These	experiments	would	further	reveal	the	molecular	mechanism	through	which	H19	affects	and	controls	its	targets.			
4.4	Difficulties	in	obtaining	human	BAT	biopsies	justify	the	need	for	mouse	
studies		
H19	is	strongly	conserved227.	Therefore,	we	were	curious	to	investigate	whether	human	
H19	 (hH19)	could	also	be	affected	by	obesity	 in	humans.	We	quantified	hH19	 levels	 in	scWAT	and	vWAT	biopsies	from	169	lean	and	obese	patients.	hH19	expression	declined	with	increasing	BMIs	in	both	depots	and	correlated	positively	with	markers	of	adipose	‘beiging’	 like	 UCP1	 mRNA	 levels.	 Unfortunately,	 gene	 expression	 levels	 could	 not	 be	determined	 in	 human	 BAT	 tissue	 due	 to	 the	 difficulties	 that	 still	 exist	 in	 obtaining	human	BAT	biopsies	for	ex	vivo	studies.		Although	 human	 and	 mouse	 BAT	 mitochondria	 have	 comparable	 functions	 of	UCP1273,	several	intrinsic	differences	between	human	and	mouse	adipocytes	such	as	the	response	to	adrenocorticotropic	hormone274	have	been	observed.	This	stresses	that	not	all	 findings	 in	 mouse	 models	 can	 be	 applied	 to	 the	 human	 context	 and	 that	 proper	human-derived	 cell	 models	 are	 necessary	 to	 study	 human	 physiology	 and	pathophysiology.	The	availability	of	those	cell	lines,	however,	is	still	difficult	as	primary	human	brown	adipocytes	are	mainly	available	by	surgical	procedures,	where	cancer	 is	suspected,	 in	 cervical	 and	 supraclavicular	 regions.	 As	 expected,	 the	 amount	 of	 the	obtained	material	in	these	regions	is	most	often	limited275.	Moreover,	it	is	likely	that	the	
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metabolism	of	BAT	cells	obtained	from	those	patients	is	changed	as	it	is	known	from	the	‘emerging	hallmark	of	cancer:	reprogramming	energy	metabolism’	that	cancer	is	capable	to	modify,	or	reprogram	cellular	metabolism	in	order	to	fuel	cell	growth	and	division276–278.	Thus,	it	has	been	shown	that	head	and	neck	squamous	cell	carcinoma	(HNSCC)	used	glycolytic	and	oxidative	metabolism	to	support	tumorigenesis279.	Furthermore,	Curry	et	al.	 (2014)	 demonstrated	 that	 genetic	 changes	 in	 HNSCC	 cells	 can	 affect	 the	 tumour	microenvironment,	 and	 with	 this	 probably	 the	 adjacent	 BAT,	 by	 increasing	 reactive	oxygen	 species	 (ROS),	 the	 production	 of	 cytokines	 and	 epithelial	 to	 mesenchymal	transition	(EMT)279.		Only	recently,	Ding	et	al.	(2018)	have	published	the	first	comprehensive	de	novo-reconstructed	human	lncRNA	catalog	with	909	lncRNAs	specifically	detected	in	BAT	by	performing	RNA-Seq	on	adult	subcutaneous,	omental	WAT	and	fetal	BAT228.	Fetal	BAT,	however,	was	obtained	from	deceased	donors,	questioning	which	effect	the	death	of	the	donor	had	on	tissue	conservation	and	gene	expression280.		Until	 proper	 methods	 are	 established	 to	 obtain	 primary	 human	 brown	adipocytes,	mouse	 studies	 are	 the	most	 suitable	 resource	 to	 provide	 insights	 into	 the	regulation	of	brown	fat,	especially	for	follow-up	studies	such	as	the	characterization	of	candidate	 genes	 via	 gain-	 and	 loss-of-function	 experiments.	 Here	 the	 strong	conservation	of	H19	between	mouse	and	human,	the	exciting	results	we	obtained	with	the	 human	 cohort	 as	 well	 as	 the	 broad	 involvement	 of	 hH19	 in	 different	 biological	processes,	as	presented	earlier	in	this	thesis,	give	reasons	to	specifically	pursue	further	
H19	studies	in	mice.		
4.5	First-line	medication	for	T2DM	Metformin	influences	H19	expression	in	
liver			When	 analysing	H19,	 we	 could	 show	 that	 it	 has	 a	 supportive	 function	 in	 BAT	 and	 a	positive	 influence	 on	 whole	 body	metabolism	 in	mice	 and,	 potentially,	 in	 humans.	 In	contrast	 to	 that,	 when	 elevated	 in	 the	 liver	 H19	 has	 been	 shown	 to	 favour	 diabetic	hyperglycemia220.	The	biological	significance	of	these	tissue-specific,	and	even	opposing,	effects	is	highlighted	by	the	observation	of	similar	findings	in	parallel	studies,	showing	that	lncRNAs	can	have	varying	biological	functions	within	the	individual	tissue	they	are	expressed281.		
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Metformin	is	a	biguanide	compound	and	one	of	the	most	commonly	used	drugs	for	the	treatment	of	T2DM	worldwide	due	to	its	high	efficacy	and	minimal	side	effects.	Although	 its	 target	 has	 proved	 elusive,	 a	 recent	 study	 by	 Madiraju	 et	 al.	 (2014)	 has	shown	 that	 Metformin	 suppresses	 hepatic	 gluconeogenesis282.	 Additionally,	 a	 recent	study	by	Breining	et	al.	(2018)	identified	BAT	as	putative	metformin	target	as	 injected	[11C]-metformin	 was	 avidly	 taken	 up	 in	 the	 murine	 interscapular	 BAT	 depot283.	 One	mechanism	 of	 how	 Metformin	 acts	 is	 by	 inducing	 genome-wide	 alterations	 in	 DNA	methylation.	 More	 specifically,	 it	 modulates	 the	 activity	 of	 S-adenosylhomocysteine	hydrolase	 (SAHH),	 the	 only	 mammalian	 enzyme	 capable	 of	 hydrolysing	 S-adenosylhomocysteine	 (SAH),	 to	homocysteine	and	adenosine.	 SAH	acts	 as	 a	 feedback	inhibitor	of	S-adenosylmethionine	(SAM)-dependent	methyltransferases	that	methylate	various	cellular	components,	such	as	DNA,	RNA,	proteins,	lipids,	neurotransmitters	and	histones.	 Interestingly,	 during	 that	 process,	 microRNA	 let-7	 is	 up-regulated	 through	AMPK	activation,	which	leads	to	H19	degradation284.	The	outcome	of	that	process	is	the	hypermethylation	of	genes.		Similar	to	these	results,	a	study	by	Zhou	et	al.	(2015),	demonstrated	that	H19	was	able	 to	 influence	 genome-wide	 methylation	 by	 binding	 and	 subsequently	 inhibiting	SAHH261	 opposite	 to	 the	 actions	 of	 Metformin.	 H19	 knockdown	 activated	 SAHH,	resulting	 in	 active	 DNA	 methylation	 by	 DNMT3B.	 When	 H19	 was	 present,	 SAH	accumulated	 and	 decreased	 DNMT3B-mediated	 methylation261	 resulting	 in	hypomethylation	 of	 genes.	 Metformin	 and	 H19	 are	 therefore	 involved	 in	 a	 similar	mechanism	 and	 are	 both	 able	 to	 influence	 genome-wide	 methylation	 patterns.	 One	mechanism	 of	 how	 H19	 leads	 to	 differences	 in	 global	 methylation	 is	 via	 forming	complexes	with	MBD1	and	acting	through	a	trans	signalling	mechanism.		Other	human	and	animal	studies	that	show	a	connection	of	Metformin	and	H19	have	 demonstrated	 that	 prenatal	 metformin	 exposure	 may	 lead	 to	 increased	 risk	 for	metabolic	 disorders	 in	 adult	 offspring285,286.	 Fetuses	 exposed	 to	 metformin	 exhibited	increased	H19	expression,	which	resulted	 in	hypomethylation	and	elevated	expression	of	hepatocyte	nuclear	factor	4a	(HNF4a),	a	key	factor	for	liver	development	and	function.	A	 perturbation	 of	 this	 pathway	 may	 contribute	 to	 the	 fetal	 origin	 of	 metabolic	abnormalities	in	the	adult286.		From	these	studies,	we	learn	that	metformin	targets	both	liver	and	BAT	and	that	
H19	expression	supports	diabetes	development	in	the	liver	whereas	we	could	show	that	it	has	protective	functions	in	BAT.	Although	the	overall	results	of	Metformin	are	without	
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a	doubt	promising,	 it	would	be	interesting	to	explore	the	connection	of	Metformin	and	
H19	in	more	detail,	especially	the	effect	of	Metformin-induced	H19	degradation	in	BAT.			
4.6	Conclusions	and	future	perspectives		Collectively,	 the	 data	 presented	 in	 this	 work	 revealed	 a	 novel	 crucial	 role	 for	 the	conserved	lncRNA	H19	in	regulating	BAT	differentiation	and	function.		We	 demonstrated	 that	 the	 maternally	 expressed	 imprinted	 lncRNA	 H19	increased	upon	cold-activation	and	decreased	in	obesity	in	BAT,	which	is	in	accordance	with	our	human	data	that	also	showed	an	inverse	correlation	of	H19	with	BMI.	By	using	two	 genetic	 mouse	 models	 for	 gain-	 and	 loss-of-function,	 we	 demonstrated	 that	H19	overexpression	 promoted	 adipogenesis,	 oxidative	 metabolism,	 and	 mitochondrial	respiration	in	brown	but	not	white	adipocytes	ex	vivo	whereas	silencing	of	H19	resulted	in	 impairment	 of	 these	 processes.	 In	 vivo,	H19	 overexpression	 protected	 against	 DIO,	increased	energy	dissipation,	improved	insulin	sensitivity,	and	mitochondrial	biogenesis	whereas	H19	loss	in	AT	sensitized	towards	HFD	weight	gains.	Additionally,	we	observed	that	PEGs	were	 largely	absent	 from	BAT	and	we	demonstrated	 that	H19	 recruits	PEG-inactivating	 H19-MBD1	 complexes,	 and	 thus	 acts	 possibly	 as	 a	 BAT-selective	 ‘PEG	gatekeeper’.	These	results	have	implications	for	our	understanding	of	how	monoallelic	gene	expression	affects	metabolism	in	rodents	and,	potentially,	in	humans.		In	the	future,	it	would	be	interesting	to	investigate	whether	H19	is	located	in	the	mitochondrion	and	exhibits	a	specific	interactome,	in	addition	to	MBD1	in	the	nucleus.	This	 information,	 especially	 the	 molecular	 mechanisms,	 could	 be	 useful	 to	 develop	therapeutic	 strategies	 to	 counteract	 obesity-associated	 pathologies.	 Although	we	 have	reasons	 to	 assume	 that	H19	 regulates	 BAT	 homeostasis	 by	 its	 cell-intrinsic	 control	 of	mitochondrial	 biogenesis	 in	 mature	 adipocytes	 and	 by	 maintaining	 quiescence	 of	obesity-predisposing	PEGs	 in	BAT,	 the	molecular	effects	 through	which	H19	 affects	 its	targets	should	be	 the	object	of	 further	studies	 in	order	 to	develop	specific	 therapeutic	strategies	for	obesity	associated	diseases	targeting	H19	or	its	interaction	partners.	
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5	Summary	In	light	of	the	continuously	rising	number	of	patients	suffering	from	obesity	or	its	closely	related,	 often	 life-threatening,	 diseases	 such	 as	 type	 2	 diabetes	 mellitus,	 the	development	 of	 novel	 preventative	 or	 therapeutic	measures	 is	 of	 utmost	 importance.	Increasing	 brown	 adipose	 tissue	 (BAT)	 thermogenesis	 in	mice	 and	 humans	 improves	metabolic	 health.	 Therefore,	 understanding	 and	 controlling	 BAT	 function	 is	 of	 great	interest	 for	 novel	 approaches	 to	 counteract	 obesity.	 Long	 noncoding	 RNAs	 (lncRNAs)	emerged	 as	 potential	 targets	 for	 novel	 therapies	 due	 to	 their	 diverse	 functions,	 and	tissue-specific	 effects,	 in	 the	 regulation	 of	 metabolic	 processes.	 However,	 the	 role	 of	lncRNAs	during	BAT	differentiation	and	function	is	not	yet	understood.		To	 explore	 this,	 we	 performed	 RNA-Sequencing	 and	 identified	 the	 maternally	expressed	 lncRNA	H19	which	 was	 increased	 upon	 cold-mediated	 BAT	 activation	 and	decreased	upon	 chronic	 diet-induced	obesity	BAT	dysfunction.	 Inverse	 correlations	 of	
hH19	 with	 Body-Mass-Index	were	 also	 observed	 in	 a	 human	 cohort.	We	 showed	 that	
H19	 overexpression	 promoted	 adipogenesis,	 oxidative	metabolism,	 and	mitochondrial	respiration	in	brown	but	not	white	adipocytes	whilst	the	silencing	of	H19	impaired	these	processes.	In	vivo,	H19	overexpression	protected	against	diet-induced-obesity,	improved	energy	 expenditure,	 insulin	 sensitivity,	 and	 mitochondrial	 biogenesis	 whereas	 the	ablation	 of	H19	 in	 fat	 sensitized	 towards	 high-fat	 diet	 (HFD)	weight	 gains.	 Strikingly,	paternally	expressed	genes	(PEGs)	were	largely	absent	from	BAT	and	we	demonstrated,	by	 performing	 Capture	 hybridization	 analysis	 of	 RNA	 targets	 coupled	 to	 Mass	Spectrometry,	that	H19	recruits	PEG-inactivating	H19-MBD1	complexes	and	potentially	acts	as	BAT-selective	‘PEG	gatekeeper’.		Taken	together,	the	results	presented	in	this	work	reveal	a	novel	function	for	the	maternally	 expressed	 lncRNA	 H19	 as	 a	 BAT-regulatory	 lncRNA	 regulating	 BAT	differentiation	 and	 function,	 thereby	 protecting	 from	 diet-induced	 obesity.	 Moreover,	the	results	show	how	monoallelic	gene	expression	affects	metabolic	homeostasis	in	both	rodent	 models	 and,	 potentially,	 in	 human	 patients.	 Future	 studies	 will	 uncover	 the	molecular	mechanisms	of	how	H19	affects	its	molecular	targets	in	more	detail.			
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6	Zusammenfassung	Angesichts	 der	 stetig	 steigenden	 Anzahl	 an	 Patienten,	 welche	 mit	 Übergewicht	 oder	damit	 assoziierten,	 oftmals	 lebensbedrohlichen	 Krankheiten,	 wie	 Typ	 2	 Diabetes	Mellitus	 diagnostiziert	 werden,	 steigt	 die	 Notwendigkeit	 der	 Entwicklung	 präventiver	und	 neuartiger	 Behandlungsmöglichkeiten.	 Vermehrte	 Thermogenese	 des	 braunen	Fettgewebes	(BAT)	verbessert	den	Stoffwechsel	in	Mäusen	und	Menschen.	Deshalb	ist	es	wichtig	die	Funktion	des	braunen	Fettgewebes	zu	analysieren	und	besser	zu	verstehen,	damit	 neue	 Ansätze	 gefunden	werden	 können,	 die	 dem	Übergewicht	 entgegenwirken.	Lange	nicht-kodierende	RNAs	(lncRNAs)	haben	aufgrund	ihrer	diversen	Funktionen	und	gewebespezifischen	Effekte	in	der	Regulation	von	Stoffwechselprozessen,	als	potentielle	Kandidaten	 für	 neue	 Behandlungstherapien	 an	 Bedeutung	 gewonnen.	 Die	 Rolle	 von	lncRNAs	 in	 der	 Differenzierung	 und	 Funktion	 von	 braunem	 Fettgewebe	 ist	 jedoch	weiterhin	unklar.	Um	 dies	 zu	 untersuchen	 haben	wir	 eine	 RNA-Sequenzierung	 durchgeführt	 und	die	 maternal	 exprimierte	 lncRNA	 H19	 identifiziert.	 H19	 zeigte	 eine	 erhöhte	Genexpression	 während	 kälteinduzierter	 Aktivierung	 des	 braunen	 Fettgewebes,	wohingegen	 die	 Expression	 durch	 ernährungsbedingtes	 Übergewicht	 und	 daraus	resultierender	Dysfunktion	des	braunen	Fettgewebes	verringert	war.	Zudem	wurde	eine	inverse	 Korrelation	 von	 humanem	 H19	 (hH19)	 mit	 dem	 Body-Mass-Index	 einer	humanen	Kohorte	beobachtet.	Wir	konnten	zeigen,	dass	die	Überexpression	von	H19	die	Fettbildung,	 den	 oxidativen	 Stoffwechsel	 und	 die	mitochondriale	 Atmung	 in	 braunen,	aber	nicht	in	weißen	Adipozyten	verbesserte,	wohingegen	das	Stilllegen	von	H19	diese	Prozesse	negativ	beeinträchtigte.	Im	lebenden	Organismus,	schützte	die	Überexpression	von	H19	 vor	 ernährungsbedingtem	 Übergewicht,	 verbesserte	 den	 Energieumsatz,	 die	Insulin-Sensitivität	 und	 die	 mitochondriale	 Biogenese.	 Eine	 Entfernung	 von	 H19	 im	Fettgewebe	führte	zu	einem	gegenteiligen	Effekt	und	begünstigte	die	Gewichtszunahme	durch	Ernährung	mit	hohem	Fettanteil.	Eindrucksvoll	konnten	wir	zeigen,	dass	paternal	exprimierte	Gene	 (PEG)	 im	braunen	Fettgewebe	vorwiegend	abwesend	waren.	Zudem	haben	wir	entdeckt,	dass	H19	PEG-inaktivierende	H19-MBD1	Komplexe	rekrutiert	und	als	„PEG-Torwächter“	im	braunen	Fettgewebe	fungiert.		Zusammenfassend	zeigen	die	Ergebnisse	dieser	Arbeit	eine	neue	Funktion	für	die	maternal	 exprimierte	 lncRNA	 H19	 als	 eine	 BAT-regulatorische	 lncRNA,	 die	 die	Differenzierung	 und	 die	 Funktion	 von	 braunem	 Fettgewebe	 reguliert	 und	 somit	 vor	
6	Zusammenfassung	
	 119	
ernährungsbedingtem	 Übergewicht	 schützt.	 Zudem	 zeigen	 die	 Ergebnisse,	 wie	monoallelische	 Genexpression	 das	 metabolische	 Gleichgewicht	 in	 Nagetieren	 und	möglicherweise	 auch	 in	 Menschen	 beeinflusst.	 Zukünftige	 Studien	 werden	 die	molekularen	 Mechanismen,	 durch	 welche	 H19	 seine	 molekularen	 Zielmoleküle	beeinflusst,	detaillierter	entschlüsseln.		
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